<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2026-02-02 09:38:22 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>101</td>
          <td>48</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="Sepsis is a life-threatening condition arising from a dysregulated host response to infection, characterized by a complex interplay between pro-inflammatory and anti-inflammatory immune mechanisms. B cells, that are key components of humoral immunity, are essential for antibody production, antigen presentation, and immune modulation. Sepsis is commonly associated with B cell lymphopenia, particularly in severe cases, as evidenced by a marked reduction in circulating B cells in both adult and pediatric patients. However, the mechanisms driving this depletion have not been completely understood, particularly in pediatric sepsis. In this study, we employed single-cell RNA sequencing (scRNA-seq) to profile peripheral blood leukocytes from pediatric patients with sepsis (three with mild and three with severe condition) alongside four healthy controls. Our analysis revealed a broad depletion of immune cells in sepsis, with B cells showing the most pronounced reduction and the strongest capacity to discriminate between mild and severe disease states. Subset-level analysis identified significant loss and transcriptional reprogramming of natural killer-like B cells (ΝΚΒ), MHC IIhighnaïve, and MHC IIlownaïve B cells in severe sepsis, accompanied by signatures indicative of intrinsic and extrinsic apoptosis, disrupted differentiation, and enhanced migratory potential. Importantly, we identified and validated the population of NKB cells in both pediatric and adult cohorts, broadening the known landscape of B cell phenotypes in human sepsis. We also explored intercellular communications, focusing on B cell-neutrophil interactions, given the notable neutrophilia observed, revealing potential crosstalk that may contribute to the overall immune dysregulation in sepsis. Collectively, these findings offer new insights into the cellular and molecular drivers of immune dysfunction in pediatric sepsis, shedding light on B cell depletion as a central feature of disease severity. This work lays the foundation for future diagnostic and therapeutic strategies targeting B cell-mediated immunity in septic children. The study was registered on ClinicalTrials.gov (NCT04103268), with registration date on 2019-09-23, before the first patient was enrolled.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bce54efd110fde03077139b1afa9c1f4e6856c6b" target='_blank'>
              Single-cell analysis of B cell dysregulation in pediatric sepsis stratified by disease severity
              </a>
            </td>
          <td>
            Fahd Alhamdan, Stefano Gianoli, Koichi Yuki, S. Koutsogiannaki
          </td>
          <td>2025-12-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/046a4759f61fd2ed00479ddd2426526fb3c7aa64" target='_blank'>
              Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade
              </a>
            </td>
          <td>
            Valeria Manriquez, Sofia Cavada-Silva, Kévin Beccaria, L. L. Niborski, Amaury Leruste, W. Richer, Mathias Vandenbogaert, Zhi-Yan Han, C. Sedlik, Jordan Denizeau, Jeremy Mesple, Zoé Fusilier, L. Laëtitia Lesage, Jérémie Goldstein, Yohan Gerber-Ferder, Stéphanie Fitte-Duval, Federico Marziali, R. Mena-Osuna, Jimena Tosello-Boari, Rachida Bouarich-Bourimi, Maria Florencia Pacini, Y. Missolo-Koussou, Mylène Bohec, Sylvain Baulande, Philippe Benaroch, J. Helft, Hélène D Moreau, J. Waterfall, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5984ff16cfe613f763f0430e61d72c3b4c0bbf01" target='_blank'>
              The breast tumor microenvironment exploits eosinophil plasticity to suppress their anti-tumor activity
              </a>
            </td>
          <td>
            Zofia Varyova, M. Pohin, Gracie J. Mead, Libby K. Jennings, Valeria da Costa, Sarah Spear, I. McNeish, A. Schwenzer, Adrian L. Harris, Audrey Gérard, Kim S. Midwood
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e10756da93e249564dafc2b41fce10c7b1ebac2e" target='_blank'>
              Dual PD-L1/TIGIT blockade induces PNAd⁺ HEV-like vessels and CD62L⁺ lymphocyte recruitment, driving rhabdoid tumor rejection
              </a>
            </td>
          <td>
            Stéphanie Fitte-Duval, Sofia Cavada Silva, R. Mena-Osuna, Owen Hoare, L. L. Niborski, Jordan Denizeau, Laëtitia Lesage, W. Richer, C. Sedlik, Kévin Beccaria, Maëva Veyssière, Rachida Bouarich-Bourimi, Jérémie Goldstein, Federico Marziali, Jimena Tosello Boari, J. Masliah-Planchon, Zhi-Yan Han, Dario Rocha, Mylène Bohec, Sylvain Baulande, J. Waterfall, Valeria Manriquez, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4⁺ T-cells, and CD8⁺ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS–ICOSL pathway, and are enriched for ICOS⁺ Th1-like CD4⁺ T cells and ICOSLhigh cDC1s. CD8⁺ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon-γ–responsive program that sustains CD8⁺ T-cell function and prevents dysfunction. Functionally, ICOSL⁺ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6a060eabfcbbb0a36b483e2912054f711b0272" target='_blank'>
              Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
              </a>
            </td>
          <td>
            Mehdi Chaib, M. Aminu, Shelley M Herbrich, Mahshid Arabi, Yue Xuan, Akshay V. Basi, Anna Casasent, Marc D. Macaluso, Kenneth H. Hu, Matthew M. Gubin, Xi Chen, James J. Mancuso, Sreyashi Basu, Sonali Jindal, Jared K. Burks, S. Watowich, Jia Wu, James P. Allison, Padmanee Sharma
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="The CD4+ cytotoxic T lymphocytes (CD4-CTLs) with cytotoxic potential are reported to be the components of protective immune response in many diseases. However, the lack of understanding about their lineage, molecular character, and cytolytic potential in comparison to CD8+(CD8)-CTLs has restricted their utility. Thus, here, by parallelly analyzing the human peripheral CD4-CTLs and CD8-CTLs, we demonstrate that they are indistinguishable for the cytotoxic program. Furthermore, using an integrative multiomics approach combining the transcriptome, T cell antigen-receptor repertoire, and open chromatin profile of CD4+ T cell memory subsets, we found a stem-cell memory subset that is precommitted to the cytotoxicity program. Through an in vitro differentiation model, we developed CD4+ T cells with cytolytic potential coexpressing and exhibiting progressive chromatin accessibility for cytotoxicity- and longevity-associated genes, hence generating long-lived CD4-CTL effectors of varying cytotoxic capacity. Together, our study advocates for exploring both CD4-CTLs and CD8-CTLs for vaccine development, vaccine efficacy testing, and immunotherapies and cell-based therapies for precision medicine.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9990f503fa88e6b76658f17909059f434731f60e" target='_blank'>
              A distinct subset of stem-cell memory is poised for the cytotoxicity program in CD4+ T cells in humans
              </a>
            </td>
          <td>
            Raunak Kar, Shreya Sinha, Zainab Khatun, Anjali Sharma, Veena S. Patil
          </td>
          <td>2026-01-07</td>
          <td>Science Advances</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Glioblastoma (GBM), the most frequent and aggressive primary brain tumor, remains refractory to all current therapies including surgical resection, chemotherapy, radiotherapy and immunotherapy. Immunosuppressive mechanisms in the GBM tumor microenvironment contribute to the lack of anti-tumor adaptive immunity. We found that a subset of tumor associated macrophages (TAMs) can be repolarized into an anti-tumor phenotype via agonist stimulation of the retinoic acid-inducible gene I (RIGI), a cytosolic double-stranded RNA pattern recognition receptor (PRR). In silico analysis of adult GBM datasets available in the public domain revealed that RIGI expression by a subset of activated TAMs positively correlated with patient survival. Studies in syngeneic mouse models of GBM showed that intratumoral delivery of stem-loop RNA 14 (SLR14), a RIG-I agonist, improved the efficacy of chemotherapy, radiotherapy and immunotherapy treatments, beyond the effects of other nuclei acid sensor agonists. We found that RIGI+ macrophages are the main drivers of SLR14 effect, combining activation of TAMs and priming of functional cytotoxic CD8+ T lymphocytes and NK cells. The anti-GBM effect of SLR14 is opening a significant new avenue for adult GBM treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1342f808c2fd345588c30c0266370e6a04636995" target='_blank'>
              RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Han Xu, Sungwoon Lee, Felipe Leser, Olga Fedorova, Peiwen Lu, Eric Song, Mehdi Touat, Anne Eichmann, Akiko Iwasaki, A. Pyle, Jean-Leon Thomas
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8+ T cell responses. Constitutive Tmem33-/- mice exhibited delayed melanoma tumor growth and increased CD8+ T cell infiltration. Antigen-specific CD8+ compartments in tumors of Tmem33-/- mice showed TCF-1+PD-1+ progenitor-exhausted cell (Tpex) enrichment, elevated effector function and reduced exhaustion, alongside improved effector memory expansion and T-bet expression in draining lymph nodes. We highlight that TMEM33 functions intrinsically within the T cell compartment, as TMEM33 deletion (1) enhanced polyclonal activation of naive CD8+ T cells ex vivo, (2) promoted preferential Tpex accumulation among adoptively transferred naive OT-I cells in B16F10-OVA tumors and draining lymph nodes, and (3) improved the potency of ex vivo-expanded OT-I cells in controlling tumor growth during adoptive cell therapy. Finally, in a large, prospectively recruited metastatic melanoma cohort, lower TMEM33 expression in patient CD8+ T cells significantly correlated with improved survival and elevated TCF-7 (encoding TCF-1). Collectively, our findings define TMEM33 as a formerly unrecognized intrinsic determinant of tumor-directed CD8+ T cell fate that limits Tpex maintenance, and restrains cell therapy responses, suggesting that its modulation may strengthen immunotherapeutic efficacy. One sentence summary TMEM33 intrinsically limits progenitor exhausted CD8+ T cells, scales anti-tumor responses and predicts melanoma patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b5c85fa3ccdffaf374a3f09dd7d217b43c30d4c" target='_blank'>
              TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity
              </a>
            </td>
          <td>
            M. T. Jackson, Tianming Zhao, G. Milotay, I. Pedroza-Pacheco, Yanshu Cai, Claire Willis, S. Phyu, Bruno Beernaert, Jamie TW Kwon, Hala Estephan, Vinnycius Pereira Almeida, Maria Aggelakopoulou, Silvia Panetti, Christian Zierhut, Tim Elliott, Eleni Adamopoulou, J. Rehwinkel, Malcolm JW Sim, Amit Grover, Dmitry I. Gabrilovich, Benjamin P. Fairfax, E. Honoré, D. Withers, John C. Christianson, Eileen E. Parkes
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival. Pilcher et al. present a single-cell transcriptomics-based immune atlas of participants with newly diagnosed multiple myeloma, reporting on the association of cell types, gene expression and intercellular interactions with disease progression phenotypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f88dd8011aa8686433c4d02b3a0e4dfd59a9255" target='_blank'>
              A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
              </a>
            </td>
          <td>
            William C. Pilcher, Lijun Yao, Edgar Gonzalez-Kozlova, Yered H. Pita-Juárez, Dimitra Karagkouni, Chaitanya R. Acharya, Marina E. Michaud, Mark Hamilton, Shivani Nanda, Yizhe Song, Kazuhito Sato, Julia Wang, Sarthak Satpathy, Yuling Ma, Jessica Schulman, D. D’souza, R. Jayasinghe, Denis J Ohlstrom, Katherine E. Ferguson, Giulia Cheloni, Mojtaba Bakhtiari, Nick Pabustan, K. Nie, J. Foltz, Isabella Saldarriaga, Rania Alaaeldin, Eva Lepisto, Rachel Chen, M. Fiala, , April Cook, Junia Vieira Dos Santos, Chiang I-ling, Igor Figueiredo, J. Fortier, Michael Slade, Stephen T. Oh, Michael P. Rettig, Emilie I. Anderson, Ying Li, Surendra Dasari, Michael A. Strausbauch, Vernadette A. Simon, , I-ling Chiang, N. Kalavros, Jennifer Rogers, T. Dawson, Brian H. Lee, G. Kelly, Laura A Walker, Nicolas F. Fernandez, John Leech, Jarod Morgenroth-Rebin, K. Angeliadis, Matthew A. Wyczalkowski, Song Cao, Omar Ibrahim, Roderick Lin, T. Fehniger, Andrew J. Houston, E. Radkevich, , Zhihong Chen, A. Laganà, John F. DiPersio, J. Rosenblatt, S. Kim-Schulze, S. Lonial, Shaji Kumar, Swati S. Bhasin, T. Kourelis, M. Dhodapkar, Ravi Vij, D. Avigan, H. Cho, George Mulligan, Li Ding, Sacha Gnjatic, Ioannis S. Vlachos, Manoj K. Bhasin
          </td>
          <td>2026-01-01</td>
          <td>Nature Cancer</td>
          <td>0</td>
          <td>113</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Natural killer (NK) cells are integral to the innate immune system, playing a crucial role in immune surveillance and the rapid response to virally infected and tumor cells. Epigenetic gene expression regulation significantly influences NK cell function and differentiation. Using a high-throughput small-molecule drug screening approach, we identified bromodomain and extra-terminal domain (BET) inhibitors (BETi) as potent modulators of NK cell function, reducing proinflammatory cytokine secretion while increasing markers of NK cell maturation and cytotoxicity. During NK lineage specification from hematopoietic stem cells, we demonstrated that BETi reduced NK cell fate and promoted increased myeloid cell differentiation. Moreover, differentiated NK cell types had more functionally differentiated gene expression programs. Thus, BET proteins are crucial for both mature NK cell functions and controlling NK cell lineage development from progenitors in the bone marrow. These findings suggest that BETi can fine-tune NK cell responses, offering promising therapeutic potential for cancer immunotherapy and the treatment of inflammatory and autoimmune diseases. Our study underscores the critical role of BET inhibitors in regulating NK cell function and opens new avenues for targeted immune modulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1b914c2c6315017334ad728068ea592de3c5137" target='_blank'>
              Bromodomain and extra-terminal protein inhibitors modulate natural killer cell function and differentiation
              </a>
            </td>
          <td>
            Eric S. Geanes, Gage Greening, Maria Aggelakopoulou, Linh-Huyen Truong, Santosh Khanal, C. LeMaster, Marc Herman, Rebecca McLennan, P. Borrow, Todd Bradley
          </td>
          <td>2026-01-03</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="Dogs play a major role in sustaining transmission of Leishmania infantum to people, thus prevention and treatment of canine leishmaniosis (CanL) to reduce transmission represents an unmet public health need. Although advances have been made in understanding how immunopathology correlates to infectiousness as CanL progresses, the immune mechanisms underlying transition between disease stages and terminal decline remain ill-defined. To address this knowledge gap, we generated a comprehensive atlas of peripheral immune cells from control dogs and naturally-infected dogs using single-cell RNA sequencing. The LeishDog Atlas captures the cellular and transcriptional complexity underlying CanL, tracing shifts in immune composition and gene expression across progressive, well-defined disease stages. Notably, we identified distinct myeloid, CD4+ and CD8+ T cell phenotypes and transcriptional states associated with disease progression. This resource provides a valuable framework for understanding systemic immune dysregulation in CanL, including determinants of T cell exhaustion and myeloid cell activation, and establishes a foundation for comparative, translational, and mechanistic studies of CanL immunopathology and transmissibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8412687f28e64e4d6b2558529c494e2ee4440eca" target='_blank'>
              A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis
              </a>
            </td>
          <td>
            Danielle P. Uhl, Daniel J. Holbrook, Max C Waugh, S. Dey, Najmeeyah Brown, Karen I. Cyndari, Jacob J. Oleson, Paul M. Kaye, Christine A. Petersen
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/59359ad678fb5970076eddf100c364fea7a28f75" target='_blank'>
              Adrenergic signaling induces a pro-tumorigenic B cell state in colorectal cancer
              </a>
            </td>
          <td>
            Meike S. Thijssen, Simone L. Schonkeren, Linde Coolkens, Yuchi Zou, Lieve Temmerman, Joëlle de Vaan, M. Idris, Jorunn Vrancken, Kim Wouters, Nathalie Vaes, Marion J. Gijbels, Sharon Scardellato, Erwin Wijnands, Willine J. van de Wetering, F. Verhaegen, L. J. Dubois, Erik Biessen, Carmen López Iglesias, Kim M Smits, A. Bardelli, Stefano Casola, W. Boesmans, V. Melotte
          </td>
          <td>2026-01-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a82efc5b2c9cc4922bf6d2b205d9310648f4f84" target='_blank'>
              Single-cell multiomics reveals epigenetic rewiring of splenic memory B cells in murine malaria reinfection
              </a>
            </td>
          <td>
            Montserrat Coronado, Á. Vincelle-Nieto, Isabel G. Azcárate, S. Pérez-Benavente, A. Puyet, Amalia Díez, José M. Bautista, A. Reyes-Palomares
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/457d4de587553b09db9c04406c900e3b240f5c8f" target='_blank'>
              CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migration
              </a>
            </td>
          <td>
            Eleftheria Maranou, Gayoung Park, Pauline Weinzettl, Jonna Alanko, Otto I. Pulkkinen, Sarah E. Coupland, Marko Salmi, Carlos R. Figueiredo
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab0829fa668d3f68087f51374ae0be2ba943151" target='_blank'>
              Perturbational single-cell profiling of patient tumors defines lineage- and context-specific programs of innate immune resistance
              </a>
            </td>
          <td>
            C. Perry, A. Frey, Y. Fei, J. Wang, P. Costa, H. N. Amin, S. Ghadermarzi, D. Levine, W. Tong, A. Koda, M. Mackie, M. He, Y. Nie, K. Clulo, F. Ouerghi, J. Wei, T. Cordero Dumit, M. Yaskolko, M. Ding, A. Caldera, O. Kyrysyuk, L. Lum, J. W. Allen, W. Guo, A. Naqash, A. Elliot, A. Vanderwalde, M. Capelletti, T. Adeyelu, S. Barry, M. Hugaboom, A. Bacchiocchi, H. Kluger, M. Bosenberg, A. Iwasaki, D. Braun, J. Clune, D. van Dijk, K. Olino, J. Ishizuka
          </td>
          <td>2025-12-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Type 2 diabetes mellitus (T2DM) worsens stroke outcomes, but the underlying mechanisms linking T2DM to systemic immune dysfunction remain unclear. We investigated whether T2DM alters bone marrow (BM) hematopoiesis and dysregulate immune signaling following ischemic stroke in mice. Single-cell RNA sequencing, GeoMx digital spatial profiling (DSP), nCounter, and flow cytometry were used to analyze BM cells from control (db/+, Ctrl) and diabetic (db/db, T2DM) mice underwent experimental stroke or sham surgery. Diabetes caused marked structural remodeling of BM, with reduced cellularity and imbalance of hematopoietic lineages. Pseudotime trajectory analysis revealed impaired differentiation and maturation signatures of hematopoietic progenitor cells (HPC1) and granulocytes, and overactivation toward monocytes in diabetes after stroke. CellChat analysis demonstrated reorganization of intercellular communication, with hematopoietic progenitor cells (HPC1) and monocytes emerging as dominant signaling hubs through upregulated MIF, SIRP, and THBS pathways. AUCell enrichment indicated increased glycolysis and oxidative phosphorylation but reduced interferon-γ (IFN-γ) signaling, reflecting metabolic activation coupled with immune dysregulation. DSP and nCounter further confirmed upregulation of genes in the MIF, SIRP and THBS pathways in CD115⁺ monocytes and Ly6G⁺ neutrophils, indicating proinflammatory and migratory activation in diabetic bone marrow. Our data suggest that T2DM reprograms hematopoiesis and signaling networks, leading to maladaptive myeloid responses and impaired immune regulation after stroke. This maladaptive BM environment amplifies inflammation and limits repair, linking diabetic metabolic stress to worsened ischemic outcomes. Targeting bone marrow immune dysfunction may offer a therapeutic strategy to improve stroke recovery in diabetic patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ab79f630ee108b9ad79cdd23cb73d99a2673e4d" target='_blank'>
              Type 2 diabetes Reprograms Bone Marrow Hematopoiesis and Dysregulates Immune Signaling in Response to Stroke
              </a>
            </td>
          <td>
            Hongxia Zhang, Wanjun Gu, Kailin Yu, Chia-Ling Tu, Wenhan Chang, Jialing Liu
          </td>
          <td>2025-12-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of B-cell malignancies, but its success in acute myeloid leukemia (AML) remains limited. Durable responses depend on the formation of long-lived memory T cells, whereas T cell exhaustion contributes to non-response and relapse. In patients with AML who achieved remission after cord blood transplantation, we here first observe enrichment of memory T cells with high expression of the chemokine receptor CXCR4. Next, we show that engineering CAR-T cells to co-express CXCR4 enhances their persistence and anti-leukemic activity in patient-derived xenograft models. Using single-cell profiling and metabolic analysis, we find that CXCR4 promotes memory-associated transcriptional programs, reduces exhaustion, and supports oxidative metabolism. These effects are observed with CAR-T cells targeting CD25 or CD96 as AML-associated targets. Our results indicate that CXCR4 strengthens CAR-T cell memory and durability, offering a strategy to improve immunotherapy outcomes in AML and beyond. CAR-T cell efficacy is often limited by the inability to maintain a memory T cell program. Here, the authors show that intrinsic CXCR4 expression enhances CAR-T cell persistence and memory differentiation in acute myeloid leukemia.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2a1a8fac6df24e06173a348494a1e7d9ae0ffe6" target='_blank'>
              CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting
              </a>
            </td>
          <td>
            Ari Itoh-Nakadai, Minggao Liang, Michiho Shindo, Chen Bibi, Mariko Tomizawa-Murasawa, Saera Fujiki, Akiko Kaneko, Emi Kanamaru, Mari Hashimoto, Hiroshi Kajita, Yoshinari Ando, Miki Kojima, Jonathan Moody, Makoto Iwasaki, S. Takagi, Ryo Nakagawa, Saumya Agrawal, Hanae Amitani-Iijima, Kaori Sato, Yuriko Sorimachi, Nahoko Suzuki, Takehiro Fukami, Kazuharu Hanada, Satoshi Morita, Kazushige Katsura, Takehisa Matsumoto, Maiko Kobayashi, Masahiko Kato, Yasuyuki Negishi, Mikako Shirouzu, Y. Najima, K. Takubo, C. Hon, N. Uchida, Shuichi Taniguchi, Y. Momozawa, P. Carninci, Leonard D. Shultz, Yoriko Saito, Michiel J. L. de Hoon, Jay W. Shin, Fumihiko Ishikawa
          </td>
          <td>2026-01-26</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9ae85bd79cada9f97140c874baf065a8524c49a" target='_blank'>
              NF1 Loss Remodels Tumor Niches for Immune Evasion
              </a>
            </td>
          <td>
            Milad Ibrahim, Irineu Illa-Bochaca, Tara Muijlwijk, Ines Delclaux, K. S. Ventre, G. Jour, Paola Angulo Salgado, Shi Qiu, Agrima Dutt, Amanda W. Lund, Iman Osman, Markus Schober
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Immune rejection poses a major challenge in organ transplantation, with tissue-resident memory T (TRM) cells playing a critical role in graft rejection. This study investigated the impact of CCR8 on TRM cells using single-cell RNA sequencing (scRNA-seq), flow cytometry, and immunohistochemistry. The results show that CCR8 expression was upregulated on CD8⁺ TRM cells after transplantation, peaking on day 7. Blocking or knocking out CCR8, as well as neutralizing CCL1 and CCL8, significantly reduced CD8⁺ TRM cell accumulation in the graft and their cytokine production. These treatments prolonged graft survival, alleviated rejection severity, and impaired the ability of CD8⁺ TRM cells to produce GZMB, IFN-γ, and IL-2. Single-cell analysis of skin transplantation revealed that loss of CCR8 disrupted macrophage–T cell interactions, particularly CD8⁺ TRM–macrophage crosstalk, while enhancing CD40, PD-L1, and NRG signaling. These findings suggest that targeting CCR8 to limit the accumulation and function of CD8⁺ TRM cells may be an effective strategy to alleviate transplant rejection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90971d5b49b0f0a4e21364a3098badc63c73195f" target='_blank'>
              Single-cell analysis indicating CCR8 modulates CD8+ tissue-resident memory T cells to attenuates rejection in transplantation
              </a>
            </td>
          <td>
            Xueteng Wang, Xinqiang Li, Hailun Cai, Zhuoyu Jia, Xin Zhou, Ruidong Ding, Meiying Song, Huan Liu, Feng Wang, Bin Wu, Kai Zhao, Shipeng Li, Bei Zhang, Dahong Teng, Jinzhen Cai
          </td>
          <td>2025-12-16</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bd9aca00aac6bc3a28be72ae84077e7863c3375" target='_blank'>
              FAK Inhibition Remodels the Metastatic ECM and Restores CD8⁺ T Cell Trafficking and Immunosurveillance
              </a>
            </td>
          <td>
            Nicole D. Barth, Bo Peng, Michael Papanicolaou, Fatemeh Ahmadi Moughari, Camille L. Duran, Christopher S. McGinnis, John C. Dawson, E. Webb, Morwenna Muir, Fraser Laing, Yookyung Jung, , Ansu Satpathy, M. Egeblad, Syed Haider, R. Natrajan, Maja H. Oktay, D. Entenberg, V. Brunton
          </td>
          <td>2026-01-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I⁻/MHC-II+), we can cure mice with a regimen that includes radiation therapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3⁺ T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4⁺ T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77253e2042c64402b4c27c711448fdd4c49c02c6" target='_blank'>
              Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
              </a>
            </td>
          <td>
            AK Erbe, Arika S. Feils, Anqi Gao, Sabrina N. VandenHeuvel, Simon Boyenga, Alina A. Hampton, M. Heck, Jen Zaborek, Dan Spiegelman, N. Tsarovsky, A. Hoefges, A. Pieper, Peter M. Carlson, Mildred A. Felder, Ravi B Patel, S. Gillies, Alexa R. Heaton, Zachary S. Morris, Huy Q. Dinh, A. Rakhmilevich, Paul M. Sondel
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>54</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8779b2bf6cba17b1530e13526c071bfe44406db3" target='_blank'>
              Regulatory T cells clonally expand and contribute to stromal cell function in fibrotic response to synthetic implants
              </a>
            </td>
          <td>
            Joscelyn C. Mejías, Kavita Krishnan, Anna Ruta, A. S. Ramanujam, Elise F. Gray-Gaillard, Locke Davenport Huyer, David R Maestas, Sushma Nagaraj, Frank Haoning Yu, Alexandra N. Rindone, Peter Abraham, Maria Browne, E. Fertig, Drew M. Pardoll, Jennifer H. Elisseeff
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9bc787e32b19937cc86d82b167fee2834cae712" target='_blank'>
              T CELLS PROMOTE THE GROWTH OF SMALL-CELL LUNG CARCINOMA VIA AN IL-6/CD74 AXIS
              </a>
            </td>
          <td>
            Maya Baron, Zoé Ginestet, Debadrita Bhattacharya, Myung Chang Lee, Alexandros P. Drainas, Clara L. Poupault, Y. Nishiga, Alec E. Dallas, B. Nabet, Julien Sage
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Cancer immunotherapies, from checkpoint blockade to adoptive cell therapies like tumor-infiltrating lymphocytes (TILs), have revolutionized cancer treatment but are limited by variable efficacy and significant toxicities. A central challenge is identifying ideal T-cell populations that effectively eliminate tumors without causing off-target damage, a distinction not captured by existing biomarkers. We show that co-expression patterns of chemokine receptors (CRs) CXCR3, CCR5, and CXCR6 on CD8+ T cells provide a functional “code” defining subsets with divergent roles in on-target immunity versus off-target inflammation. In mouse and human melanoma, a triple-positive (CXCR3+CCR5+CXCR6+) T-cell subset is essential for tumor control, and its genetic signature correlates with positive clinical response, while a distinct CCR5+CXCR6+ subset drives liver immune-related adverse events (IRAEs). Crucially, this CR code reveals that immunotherapy actively reshapes T-cell trafficking patterns, uncovering profound heterogeneity within conventional populations and distinguishing potent anti-tumor progenitors from cells predisposed to exhaustion or off-target migration. This work establishes CR co-expression as a practical tool, providing a surface marker-based strategy to identify and enrich optimized T cells for adoptive therapies, thereby offering a framework to uncouple efficacy from toxicity. One Sentence Summary Co-expression of CCR5, CXCR6, and CXCR3 provides a functional ’code’ that separates T-cell-mediated anti-tumor efficacy from off-target toxicity, enabling the selection of superior cells for safer and more effective cancer immunotherapies. Graphical Abstract Highlights · CXCR6, CXCR3 and CCR5 co-expression signature stratifies patient survival in human melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 are critical effectors with high proliferative, cytotoxic, and activation profile in human and mice melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 drive anti-tumoral responses during checkpoint blockade in both human and mice">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ffb2ffb5ffbc1f04ce6b70ec760612828941d302" target='_blank'>
              A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma
              </a>
            </td>
          <td>
            Rodney Macedo, David W. Harle, Kevin Hoffer-Hawlik, X. Wang, Thomas McMahon-Skates, Alexandra Matschiner, Kirubel Belay, Y. M. Saenger, Benjamin Izar, Elham Azizi, Ran Reshef
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Current therapies for inflammatory bowel disease (IBD) often fail to achieve complete remission and are associated with systemic toxicity owing to their broad immunosuppressive effects. To overcome these limitations, we developed a bioengineered extracellular vesicle (EV) platform that modulates key immune signaling pathways to efficiently restore the T-cell balance in inflamed intestinal tissues. EVs derived from Wharton’s jelly mesenchymal stem cells were engineered to display PD-L1 on their surface and encapsulate miR-27a-3p. Surface PD-L1 engages the PD-1 checkpoint in activated T cells, attenuating T-cell receptor signaling via SHP2-mediated dephosphorylation of ZAP70 and AKT. In parallel, miR-27a-3p suppresses prohibitin 1 (PHB1), a mitochondrial regulator of Th17 cell bioenergetics and inflammatory function, thereby reducing Th17 polarization and increasing the number of FOXP3⁺ regulatory T cells. These dual-targeting EVs preferentially localized to inflamed intestinal tissues via chemokine (CCR2/CXCR4) and PD-1-dependent mechanisms. In humanized mouse models of colitis, these EVs attenuated mucosal inflammation, suppressed effector T-cell responses, and preserved epithelial integrity. In IBD patient-derived colonoid cultures, PD-L1/miR-27a-3p EVs maintained epithelial viability and barrier integrity without inducing cytotoxicity or structural disruption. Transcriptomic and single-cell analyses revealed the downregulation of inflammatory and exhaustion signatures, along with the enrichment of regulatory subsets. Collectively, this study presents a cell-free immunotherapeutic approach that reprograms T cells in inflamed tissues through the PD-1 and mitochondrial signaling pathways while maintaining intestinal epithelial integrity, offering a promising therapeutic strategy for IBD and other T cell-driven inflammatory disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21a759c51278c1cf53050a54d395a9872336d71e" target='_blank'>
              Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease
              </a>
            </td>
          <td>
            Mi-Kyung Oh, Hyun Sung Park, Dong-Hoon Chae, Aaron Yu, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Byeonghwi Lim, Jun-Mo Kim, Jordan Axelrad, Kyung Ku Jang, Jong Pil Im, S. Koh, Byung-Soo Kim, Kyung-Rok Yu
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9d522a0c1e585eda2d8238200dfededee05868fa" target='_blank'>
              Leveraging TNFR2 for antitumour immunity: T reg depletion and myeloid reprogramming versus T cell costimulation
              </a>
            </td>
          <td>
            L. Mårtensson, P. Holmkvist, Kirstie Cleary, Carolin Svensson, M. Semmrich, Niyaz Yoosuf, Alexandra Gabriela Ferreira, M. Kovacek, Mimoza Boden, Therese Blidberg, Osman Dadas, J. Mattsson, David Ermert, Elin Birgersson, Vincentiu Pitic, Martin C Taylor, Mona Yazdani, Ulla-Carin Tornberg, Ingrid Karlsson, Sean H Lim, S. Beers, Mark Cragg, B. Frendéus, I. Teige
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Immune aging is being increasingly recognized as a critical barrier to effective cancer immunotherapy, as the aged tumor microenvironment (TME) drives T cell dysfunction and impairs immune control of cancer1–4. However, the key molecular drivers of this process as well as potential targets to rescue T cell dysfunction in aged tumors remain incompletely understood. Therefore, we performed in vivo single-cell CRISPR screens in CD8⁺ T cells within aged tumors and tumor-draining lymph nodes (tdLNs). We identified Dusp5 and Zfp219 as key regulators of T cell persistence and effector differentiation in aged hosts. Loss of Dusp5, a negative regulator of ERK signaling, increased ERK1/2 phosphorylation and enhanced T cell proliferation in both young and aged tumors. In contrast, loss of Zfp219, a transcriptional repressor, induced epigenetic reprogramming of cytotoxic gene programs, thereby increasing granzyme secretion and enhancing antitumor immunity. Moreover, expression of the human ortholog gene ZNF219 is increased within intratumoral CD8⁺ T cells in older cancer patients. High ZNF219 expression correlates with poorer survival following immune checkpoint blockade (ICB) and reduces persistence of human intratumoral T cells. Notably, Zfp219 ablation synergized with anti-PD-1 blockade in mice to expand effector-like CD8⁺ T cells, leading to significantly enhanced anti-tumor immunity and tumor clearance in aged hosts. Together, these findings highlight Dusp5 and Zfp219 as critical drivers of age-related T cell dysfunction and as potential therapeutic targets to rejuvenate T cell antitumor immunity in older cancer patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/017b5a7413706a4c2c7fbdc538a3a98539127c42" target='_blank'>
              CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer
              </a>
            </td>
          <td>
            Alex C. Y. Chen, Keely Ji, Cansu Yerinde, Nelson H. Knudsen, Kevin Bi, Daniela Martinez, Thomas J Carmona-LaSalle, Kazuhiro Taguchi, Katherine H Xu, Elizabeth M. Seider, Marc A. Schwartz, Maria Zschummel, Linda T. Nieman, Kathleen B. Yates, T. R. Mempel, R. Manguso, N. Hacohen, Debattama R. Sen
          </td>
          <td>2026-01-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>118</td>
        </tr>

        <tr id="Glioblastoma (GBM) remains one of the most lethal brain tumors, characterized by extensive immune evasion and a macrophage-dominated tumor microenvironment (TME). However, the molecular determinants governing tumor-associated macrophage (TAM) states and their immunoregulatory functions remain poorly understood. We integrated bulk- and single-cell transcriptomic datasets (TCGA, CGGA, Ivy GAP, and Brain Immune Atlas) to systematically characterize the expression, prognostic relevance, and immune contexture of the myeloid biomarker membrane-spanning 4-domain A6A, MS4A6A, in GBM. Differential expression, survival, and pathway enrichment analyses were performed. Single-cell mapping and CellChat modeling delineated MS4A6A-associated TAM subpopulations, intercellular communication networks, and ligand–receptor signaling dynamics. Spatial transcriptomic validation and pharmacogenomic modeling were conducted to assess anatomic enrichment and therapeutic vulnerabilities. High MS4A6A expression predicted unfavorable survival and correlated with increased stromal and immune infiltration. Single-cell analyses localized MS4A6A predominantly to TAMs, especially Regulatory- and Ribo-TAM states enriched for antigen presentation, T-cell regulation, and ribosomal biogenesis pathways. CellChat analysis revealed that MS4A6A-high TAMs exhibited markedly enhanced communication with CD4+ T cells and Tregs through upregulated PGE2–PTGER2/PTGER4, PECAM1–CD38, and THBS1–CD36 signaling axes, implicating MS4A6A in prostaglandin-driven immune suppression. Spatial profiling confirmed preferential localization of MS4A6A within perivascular and angiogenic niches. Pharmacogenomic prediction indicated that MS4A6A-high tumors were more sensitive to ERK, mTOR, and CDK4/6 inhibition. MS4A6A defines a macrophage-centered, immunosuppressive ecosystem in GBM, mediated by the activation of the PGE2 signaling axis. These findings position MS4A6A both as a prognostic biomarker and as a potential therapeutic node linking myeloid reprogramming to actionable pathway vulnerabilities in glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2aace77685200c650b039b4e217d58ff78ecf5af" target='_blank'>
              The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis
              </a>
            </td>
          <td>
            Jianan Chen, Qiong Wu, Anders E. Berglund, Robert J. Macaulay, James J. Mulé, Arnold B. Etame
          </td>
          <td>2025-12-20</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Lung adenocarcinoma (LUAD) exhibits substantial heterogeneity in tumor immune microenvironment (TIME) composition, shaping disease progression and therapeutic response. Here, we integrated transcriptomic and clinical data from TCGA‐LUAD to develop a TIME‐associated prognostic model. LASSO Cox regression identified eight key genes—S100P, CPLX2, CD200R1, LINC01857, CLEC7A, CLEC17A, COL6A5, and CX3CR1‐ that yielded a risk score separating patients into two groups with distinct immune states. High‐risk tumors were characterized by diminished CD4+ Th1 and CD8+ T cell infiltration, expansion of M2 macrophages, and cytokine profiles consistent with immune suppression, whereas low‐risk tumors displayed immune‐active features, including elevated IL‐27 signaling. Single‐cell RNA sequencing of a murine LUAD model revealed that early tumors featured a T cell‐enriched microenvironment with elevated IL‐27 signaling, whereas late tumors acquired a macrophage‐driven immunosuppressive landscape. Interstitial macrophages acquired an M2‐like phenotype, upregulated PD‐L1, and suppressed CD4+ and CD8+ T cell activity through the CD86‐CTLA4 and SELPLG‐SELL axes. Functionally, IL‐27 blockade accelerated tumor growth, whereas recombinant IL‐27 restrained tumor progression and enhanced PD‐L1/CTLA‐4 blockade efficacy by augmenting Th1 and cytotoxic T cell responses. These findings define a TME‐based prognostic classifier and position IL‐27 as a stage‐dependent therapeutic target that restores T cell immunity and boosts checkpoint blockade efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2cc2066e706ddd6bc43aa3abe99cd395ec53999b" target='_blank'>
              A tumor Microenvironment‐Derived Prognostic Model Guides IL‐27 as a Therapeutic Strategy to Restore T Cell Immunity in Lung Adenocarcinoma
              </a>
            </td>
          <td>
            Gaopu Xie, Donglin Cai, Gang Zhang, Hongda Zhao, Xu Wang, Li Zhu, Jing Ni, Xia Yi, Jun Liang, Mengmeng Liang
          </td>
          <td>2026-01-01</td>
          <td>Advanced Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of TH1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8+ T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8+ T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f10076dc13711bdee9c69a81615daf0299024df" target='_blank'>
              SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
              </a>
            </td>
          <td>
            Mei Huang, Run Shi, Cong Xu, Yihan Zhang, Xiaoyue Du, S. Wen, Chunbin Wang, F. Jiang, Guoren Zhou, Xin Wang, Bo Shen
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="The role of the tumor immune microenvironment (TIME) in modulating responses to antiestrogen therapy in hormone receptor-positive (HR+) breast cancers remains unclear. We analyzed pre- and on-treatment biopsies from patients with HR+ breast cancer treated with letrozole to induce estrogen deprivation (ED). Stromal tumor-infiltrating lymphocytes, assessed by H&E-staining, and immune-related gene sets, including IFNɣ signaling, measured by RNA sequencing, were increased in ED-resistant tumors. Cyclic immunofluorescence and spatial transcriptomics revealed an abundance of CD8+ T cells and enhanced antigen processing and immune gene signatures in ED-resistant tumors. In this group, the expression of CXCL9, CXCL10, and CXCL11 - chemokine genes involved in CD8+ T cell recruitment - and the CXCR3 receptor were upregulated both before and after letrozole. CXCL11 levels were higher in conditioned media from HR+ breast cancer cells co-cultured with CD8+ T cells. Both recombinant CXCL11 and co-culture with CD8+ T cells promoted MCF7 and T47D cell growth in estrogen-free conditions. Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to co-culture with CD8+ T cells in estrogen-free conditions. These findings suggest that CD8+ T cell-associated CXCL11 in the TIME modulates the response of HR+ breast cancer cells to estrogen suppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/415bbace3afb02abd0c993c7111f884259b3be03" target='_blank'>
              CD8+ T cells in the tumor microenvironment modulate response to endocrine therapy in breast cancer.
              </a>
            </td>
          <td>
            Fabiana Napolitano, Yunguan Wang, D. Sudhan, Paula I. Gonzalez-Ericsson, Luigi Formisano, N. Unni, Shahbano Shakeel, James Z Zhu, Khushi Ahuja, Lei Guo, M. R. Chica-Parrado, Yuki Matsunaga, Pamela Luna, Chang-Ching A Lin, Yasuaki Uemoto, Kyung-min Lee, Hongli Ma, Nathaniel J. Evans, A. Servetto, Saurabh Mendiratta, Spencer Barnes, Roberto Bianco, Yi Fang, Lin Xu, Jeon Lee, Tao Wang, J. Balko, Gordon B. Mills, Marilyne Labrie, A. Hanker, Carlos L. Arteaga
          </td>
          <td>2025-12-09</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>69</td>
        </tr>

        <tr id="Background Myeloid-derived suppressor cells (MDSCs) have a dominating presence in the postoperative period, mediating the suppression of natural killer (NK) cells and promoting cancer metastases after surgery. However, their phenotype and effects on postoperative cellular immunity remain incompletely understood. This study aims to functionally characterize surgery-induced (sx) MDSCs and identify potential therapeutic strategies to mitigate their immunosuppressive effects. Methods We used multicolor flow cytometry to characterize sx-MDSCs from n=55 patients with cancer undergoing surgery at various time points. Furthermore, single-cell RNA sequencing was performed on a cohort of patients. Our functional ex vivo sx-MDSC:NK cell suppression assay was used to investigate the activity of sx-MDSCs and to screen a 147 small molecule library to identify sx-MDSC antagonists. Lastly, we used preclinical murine models of postoperative metastases to evaluate the therapeutic potential of the inhibitors identified. Results Sx-MDSCs significantly expanded after surgery and single-cell RNA sequencing identified signatures resembling immunosuppressive monocytes, including an upregulation of PI3K signaling. These sx-MDSCs also suppressed NK cell activity from patient samples and the small molecule screen identified PI3K-γ inhibitors as potent modulators of sx-MDSC activity. In our murine models, inhibiting PI3K-γ with specific inhibitors reduced postoperative metastases, further corroborating the role of this pathway in sx-MDSC-mediated immune suppression. Conclusions Our findings highlight the critical role of PI3K-γ signaling in postoperative sx-MDSC-mediated immune suppression. Targeting this pathway with PI3K-γ inhibitors represents a promising therapeutic strategy to prevent NK cell suppression and reduce postoperative metastases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb532f80a9f75fcf605458e25b23096cd62d5262" target='_blank'>
              Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            L. Angka, G. Tennakoon, David Cook, Andre B. Martel, M. Market, Christiano Tanese de Souza, Emma Cummins, Ismael Samudio, Natasha Kekre, Michele Ardolino, B. Vanderhyden, M. A. Kennedy, Rebecca C Auer
          </td>
          <td>2026-01-01</td>
          <td>Journal for ImmunoTherapy of Cancer</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4aac0aaca436c5bc7203a87d69b89b490cdfd76a" target='_blank'>
              Mucosal-Associated Invariant T Cells Promote Atherosclerosis Through Monocyte-Driven Inflammation
              </a>
            </td>
          <td>
            Tobias Radecke, Thomas Nipoti, Louise Z. Wang, N. Mouttoulingam, Marc Diedisheim, M. Chajadine, E. Bacquer, Coraline Heron, P. Alayrac, Charles Caër, L. Laurans, Camille Knosp, Pierre Liénart, Kenza Damache, Rida Al-Rifai, Stéphane Camus, Mathilde Lemitre, Marie Piollet, Oliver Soehnlein, Pierre Julia, J. Alsac, S. E. Batti, F. Letourneur, C. Cochain, Alain Tedgui, H. Ait-Oufella, T. Mirault, Z. Mallat, Olivier Lantz, Jean-Sébastien Silvestre, Sophie Lotersztajn, S. Taleb
          </td>
          <td>2026-01-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>94</td>
        </tr>

        <tr id="ABSTRACT Aging is a dominant risk factor for chronic diseases characterized by the functional decline of tissues and organs. During aging, the hematopoietic system declines in regenerative capacity—seemingly attributable to increases in DNA damage, replicative stress, and autophagic flux—resulting in skewing towards a myeloid lineage and away from a lymphoid lineage. Here, we characterized the transcriptomic and cellular landscape of the aged C57Bl/6J mouse hematopoietic system using a combination of bulk RNAseq and single cell RNAseq (scRNAseq). We show that aging leads to global transcriptional alterations in bulk peripheral blood mononuclear cells (PBMCs), lineage marker‐depleted bone marrow cells (Lin‐BM), and in hematopoietic stem and progenitor cells (HSPCs), immunophenotypically lineage marker negative (Lin‐) Sca1+ cKit+ (LSK+). These changes indicate widespread activation of inflammatory processes, namely in PBMCs and Lin‐BM cells. Interestingly, there is also a downregulation of cell cycle genes in HSPCs during aging. ScRNAseq across 39 hematopoietic cell types revealed age‐related skewing in cell composition. Aged PBMCs showed significant decreases in CD4 and CD8 naïve cells concomitant with increases in CD4/8 memory and CD8 exhausted T cell populations. Lin‐BM cells showed significant myeloid skewing in common myeloid progenitor (CMP) cells, as well as in the HSC population. We also identified a unique HSC population marked by increased Vwf, Wwtr1, and Clca3a1 expression that does not exist in young HSCs, thus likely marking true aged HSCs. Collectively, this work should serve as a useful resource for understanding and therapeutically targeting the aged hematopoietic system.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a19cc88f7b5c2f02b7b252356ac23e9d207486aa" target='_blank'>
              A Cellular and Transcriptomic Atlas of the Aged Mouse Hematopoietic System
              </a>
            </td>
          <td>
            Ryan R. White, Kun Xiong, Matthew H. Wakai, Allison Surian, Christina Adler, Nicole Negron, Min Ni, T. Shavlakadze, Yu Bai, David J. Glass
          </td>
          <td>2026-01-28</td>
          <td>Aging Cell</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation are not well defined. This study investigates the role of CD44, a marker of liver tumor-initiating cells (TIC), in age-associated liver pathophysiology. Aged livers showed accumulation of CD44-expressing hepatocytes exhibiting enrichment of immune modulatory genes and activation of the immunosuppressive IL6/JAK/STAT3 pathway. Indeed, in adoptive transfer assays, antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers, indicating an immunosuppressive aged milieu. Concordantly, spatial analyses showed that the proximal neighbourhoods of Cd44-expressing hepatocytes are enriched in T cells exhibiting reduced cytokine and chemokine gene expression. Finally, hepatocyte-specific knock out of Cd44 mitigated the IL6/JAK/STAT3 gene signature in aged livers. Overall, these findings suggest that CD44 expression in aged hepatocytes promotes activation of the immunosuppressive IL6/JAK/STAT3 pathway and this is associated with impaired T cell effector function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b8cfbe41c4f5eea58d4484e39d30b0c559a09da" target='_blank'>
              Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function
              </a>
            </td>
          <td>
            Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A. Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, M. Teneche, Rouven Arnold, Adarsh Rajesh, Jessica Proulx, Shanshan Yin, Aaron P. Havas, Charlene Miciano, Qian Yang, Elizabeth Smoot, S. Mamde, Andrew Davis, Kevin Y. Yip, Allen Wang, Bing Ren, April E. Williams, S. Kaech, Peter D. Adams
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3541227a821e9e9e6e75e4ddf9b12cd905133ab3" target='_blank'>
              A CD40-Targeted IL-21 Fusokine Enables Rapid Generation of Human IL-10⁺Granzyme B⁺ Regulatory B Cells
              </a>
            </td>
          <td>
            A. Pennati, S. Yuan, Rahul Das, Catigan Hedican, Amar Yeware, Jacques Galipeau
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="The remaining unacceptably high mortality of influenza-induced acute respiratory distress syndrome underscores the urgent need to identify key cellular drivers of host responses. Endothelial cells (ECs) are increasingly recognized for their immunomodulatory roles, but whether they function as antigen-presenting cells (APCs) following respiratory viral infection remains unknown. Here, we show that influenza A virus H1N1 restrictively infects pulmonary microvascular ECs (PMVECs) during late-stage acute lung injury, triggering robust MHC class I (MHC-I) upregulation in vitro, in vivo, and in ex vivo human precision-cut lung slices. Infected PMVECs present H1N1 antigens via MHC-I and co-stimulatory CD40 to lung-resident CD8+ T cells, driving their proliferation and effector function (Granzyme B, IFNγ) to promote viral clearance and resolve inflammation. This process is IFNγ-dependent and STAT1-regulated, forming a positive feedback loop that enhances PMVEC antigen presentation and CD8+ T cells activation. By contrast, the emerging H5N1 (A/Texas/37/2024) infect pulmonary ECs earlier and more broadly but elicits weaker pulmonary EC-driven CD8+ T cell responses, potentially contributing to its higher pathogenicity. These findings reveal PMVECs as active APCs in antiviral defense and highlight new avenues for immunotherapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df01e5b451a6c1d5dc9572e59192186af7ff334d" target='_blank'>
              Pulmonary Microvascular Endothelial Antigen Presentation Activates resident CD8+ T Cells to Restrain Influenza Lung Injury
              </a>
            </td>
          <td>
            Lianghui Zhang, Yuanyun Ao, Kamal Bagale, Sophia Hu, Ahmed Mostafa, C. Ye, Kienan Salvadore, Gregory Gibson, Ricardo Pineda, Jiayue Lu, Rachel Covitz, Dejuanna Chan, Ryan A. Langlois, James Zimring, William Duprex, C. S. Croix, John Alcorn, Jalees Rehman, Melanie Koenigshoff, Luis Martinez-Sobrido, Jianhua Xing
          </td>
          <td>2026-01-08</td>
          <td>Research Square</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Background Antiangiogenics promote immune activation by reducing myeloid-derived suppressor cells (MDSCs) and enhancing natural killer (NK) and T cell functions in metastatic RCC patients. However, these effects are transient, leading to compensatory immunosuppression. Platelets (PLT) and their extracellular vesicles (PLT-EVs) modulate immune and angiogenic pathways, suggesting a role in immune reprogramming during therapy. Methods Circulating EVs were longitudinally profiled in metastatic RCC patients (n=8) undergoing Pazopanib therapy. EVs, isolated by differential ultracentrifugation from baseline, 3- and 6-month plasma samples, were characterized by bead-based multiplex assay and nanoparticle tracking analysis. Results were correlated with blood counts, RNA-seq and flow cytometry immune profiles. Results Pazopanib induced temporally structured EV compartment alterations. After three months, EVs were enriched in immune markers (CD8, CD56, CD19, CD1c, HLA-DR), consistent with immune activation, whereas PLT-derived markers (CD41b, CD42a, CD29) were diminished. By six months, PLT-EV markers recovered, with CD62P+ and CD29+ EVs co-expressing immunoregulatory and angiogenic molecules (CD209, CD105). PLT-EV abundance correlated with the expansion of regulatory T cells (Tregs), PD-L1+ monocytes and MDSCs, together with suppression of NK cells. PLT activation and PDGF signaling pathways decreased in PBMC from patients with clinical benefit. Conclusions Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b6ad24127a68aa48867264bc8f9e8e0c3b3b86d" target='_blank'>
              Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC
              </a>
            </td>
          <td>
            Gianpiero Lupoli, Stefano Bergamini, J. Salsetta, A. Mereu, A. Cova, Elisa D’Angelo, Eriomina Shahaj, E. Vergani, Martina Stroscia, Emma Di Carlo, L. Rivoltini, Elena Verzoni, V. Huber
          </td>
          <td>2026-01-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>79</td>
        </tr>

        <tr id="CD19-directed chimeric antigen receptor T (CAR-T) cell therapy is promising for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), yet its long-term efficacy remains limited by CAR-T-cell exhaustion. Given the broad immunomodulatory activities of vitamin D, we investigate whether its active form, 1α,25(OH) 2D 3, enhances CAR-T-cell functionality and improves therapeutic outcomes. We demonstrate that 1α,25(OH) 2D 3 treatment significantly mitigates exhaustion and enhances the antitumor activity of CD19 CAR-T cells derived from both healthy donors and DLBCL patients, which is further validated in xenograft mouse models. Mechanistically, we show that 1α,25(OH) 2D 3 upregulates the expression of the vitamin D receptor (VDR), promoting transcriptional reprogramming associated with memory-like differentiation and downregulation of exhaustion-related genes, thereby reshaping the functional heterogeneity of CAR-T cells under tumor stimulation. Our study highlights 1α,25(OH) 2D 3 supplementation as a safe and accessible approach to mitigate terminal differentiation and exhaustion of CAR-T cells, offering a promising strategy to enhance the clinical efficacy of CAR-T therapy in patients with R/R DLBCL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d57a958be32992e03c454df63622a828b90d5ab" target='_blank'>
              1α,25(OH) 2D 3 prevents CD19 CAR-T cell exhaustion and differentiation via VDR-dependent transcriptional reprogramming.
              </a>
            </td>
          <td>
            Mengke He, Ningzhe Li, Yiwen Cao, Jie Jiang, Fan Zhang, Zeyi Li, Jie Shen, Dehao Zhu, Xiaxin Liu, Qiang Wang, Chenjing Ye, Junmin Li, Zhen Jin, Rufang Xiang
          </td>
          <td>2025-12-01</td>
          <td>Acta biochimica et biophysica Sinica</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f85386d48c7e01ef664edff7d3ed77941ddc14f" target='_blank'>
              Progenitor CD8+ T cells and hyper-Treg crosstalk: a driver of immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma
              </a>
            </td>
          <td>
            Suning Huang, Jingwei Yan, Wenqi Liu, Baijun Li
          </td>
          <td>2026-01-01</td>
          <td>Apoptosis</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) immunotherapy is limited by antigenic heterogeneity and an immunosuppressive microenvironment. This study engineered chimeric antigen receptor macrophages (CAR-Ms) targeting stress-inducible NKG2D ligands (NKG2DLs), broadly overexpressed in HCC, to enhance phagocytic clearance and remodel immunity. NKG2DL expression in HCC and association with survival were analyzed. CAR-Ms were constructed by fusing the NKG2D extracellular domain to FcγRI signaling. In vitro assays assessed phagocytosis, cytokine secretion, signaling, and T cell interactions. Therapeutic efficacy was evaluated in immunocompetent mice bearing subcutaneous, orthotopic, or metastatic HCC models, with or without anti-PD-L1. Tumor progression, immunity, and survival were analyzed via bioluminescence imaging, flow cytometry, histopathology, and serum biochemistry. Statistics analyses were performed using t-tests, ANOVA, and log-rank tests. NKG2DLs were significantly upregulated in human HCC and correlated with poor prognosis. CAR-Ms selectively engulfed NKG2DL⁺ tumor cells, polarized to an M1 phenotype, and activated PI3K-AKT and cGAS-STING pathways, driving phagocytosis and pro-inflammatory cytokines secretion. They enhanced T cell chemokines (Cxcl10, Ccl5) and antigen presentation, boosting T cell recruitment and activation in vitro. In subcutaneous models, CAR-Ms suppressed tumor growth, reprogrammed tumor-associated myeloid cells toward M1, and induced durable immune memory (100% tumor rejection upon rechallenge), with T cell activation. In orthotopic models, CAR-M monotherapy induced complete regression by week 5 and 100% survival, with elevated CD8⁺ T cells and CAR-M specifically homing to liver tumors. CAR-Ms suppressed metastasis in peritoneal/pulmonary models. Combining CAR-Ms with PD-L1 blockade accelerated tumor clearance and survival versus monotherapies, enhancing T cell cytotoxicity. Safety assessments showed no significant organ toxicity based on histopathology and serum biochemistry. NKG2D-directed CAR-Ms eliminate HCC through integrated innate phagocytosis, adaptive immune activation, and myeloid reprogramming, overcoming key therapeutic barriers. Combination with anti-PD-L1 enhances therapeutic efficacy by leveraging innate-adaptive crosstalk, providing a promising approach for HCC immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928340f1c482d3cc3031b9813af988a397a41c2c" target='_blank'>
              Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Zihao Zhao, Wenjing Zheng, Yang He, Han Zhang, Lingling Zhang, Yi Huo, Junwei Jiang, Chen Zhang, Haohan Lyu, Weiwei Qin, Chen Liu, Feng Chang, Lequn Shan, Tao Wang, Wenjie Song
          </td>
          <td>2025-12-13</td>
          <td>Molecular Cancer</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy, with HPV driving approximately 50% of cases and correlating with improved outcomes. In this study, we perform single-cell RNA sequencing on tumor microenvironment (TME) cells from 23 treatment-naive PSCC patients, including 11 cases reported previously, and validate our findings in a larger cohort of 85 patients. Our analysis reveals significant immune cell infiltration in PSCC, with HPV+ tumors exhibiting elevated levels of tumor-infiltrating B cells, plasma cells, tertiary lymphoid structures, and IgA secretion. A subset of malignant epithelial cells in HPV+ PSCC express the polymeric IgA receptor (PIGR), facilitating IgA transcytosis and inducing anti-tumor responses. Functional studies show that PIGR overexpression promotes tumor apoptosis and enhances immune responses, with these effects diminish in IgA-deficient mice. Elevated IgA and PIGR expression correlate with improved survival. These findings provide a single-cell atlas of the PSCC TME, highlighting the B cell–IgA–PIGR axis as a pivotal driver of antitumor immunity and clinical outcomes in HPV+ PSCC. The mechanisms underlying the improved survival in HPV-positive penile squamous cell carcinoma (PSCC) compared to HPV-negative counterparts remain to be explored. Here, single-cell sequencing highlights the role of the B cell-IgA-PIGR axis in enhancing antitumor immunity and improving clinical outcomes in HPV-positive PSCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/410f1998b2c04adc9c0c462f3d613fa02e71a11e" target='_blank'>
              A B cell-IgA-epithelial axis enhances antitumor immunity and improves outcome in HPV-associated penile squamous cell carcinoma
              </a>
            </td>
          <td>
            Tao Tao, Lianbang Zhu, Deyun Shen, Jiayang Zhang, Panrui Zhang, Zhixi Gu, Dan Cao, Jun Xiao, Wen Pan
          </td>
          <td>2025-12-11</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) are key drivers of the immunosuppressive tumor microenvironment (TME), thereby limiting the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear. Methods Both genetic (Akr1b3 knockout) and pharmacologic (epalrestat) approaches were employed to examine the impact of Aldo-keto reductase family 1 member B1 (AKR1B1) inhibition on TAMs and T-cell function in vitro and in vivo. Mechanistic insights were obtained through RNA sequencing, flow cytometry, immunofluorescence staining, and co-culture assays. To assess therapeutic relevance, 4T1 breast cancer and LLC lung carcinoma mouse models were used to evaluate the effects of epalrestat on tumor growth, immune infiltration, and T-cell responses. Clinical relevance was validated in patient cohorts with triple-negative breast cancer (TNBC) and lung adenocarcinoma (LUAD). Results AKR1B1 is highly expressed in TAMs and correlates with CD8+ T-cell dysfunction. Targeting AKR1B1 enhances antitumor immunity by reprogramming TAMs. Mechanistically, AKR1B1 modulates macrophage metabolism via the glutathione/reactive oxygen species axis, suppressing nuclear factor κB activation and downregulating C-C motif chemokine ligand 5 (CCL5) production, thereby inducing CD8+ T-cell dysfunction and establishing an immunosuppressive TME. Inhibition of AKR1B1, either by gene knockout or selective pharmacologic blockade, reprograms TAMs toward an immunostimulatory phenotype, increases CCL5–CCR5 (C-C motif chemokine receptor 5) signaling, restores CD8+T cell effector function, and strengthens antitumor immunity. Clinically, high AKR1B1 expression is associated with poor prognosis and immune suppression in TNBC and LUAD. Notably, targeting AKR1B1 improves responses to ICIs in both breast and lung cancer models. Conclusions AKR1B1 as a critical regulator of TAM-mediated immunosuppression and highlight its therapeutic potential to enhance the efficacy of ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/160f049c2f738290afe33bc6f397a041f83f45c0" target='_blank'>
              Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity
              </a>
            </td>
          <td>
            Yuqing Liu, Chao Zhou, Yabin Tang, Huimin Lei, Ayinazhaer Aihemaiti, Hongyu Liu, Peichen Zou, Jun-ting Xie, Xu Guo, Ruixue Xia, Bao-Hui Han, Hongzhuan Chen, Liang Zhu
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Objectives This study aimed to investigate the role of natural killer (NK) cell and interferon (IFN) signaling in the peripheral circulation of anti-MDA5+ dermatomyositis (DM) patients, particularly in the context of interstitial lung disease (ILD) development. Methods Peripheral blood mononuclear cells (PBMCs) from six newly diagnosed, active anti-MDA5+ DM patients (3 with ILD, 3 without ILD) were analyzed using single-cell RNA sequencing (scRNA-seq), focusing on NK cell features. The correlation between serum cytokine levels and ILD severity assessed by HRCT scores was further analyzed. Flow cytometry in an independent cohort validated NK cell apoptosis, and in vitro experiments evaluated IFN-induced apoptosis in NK-92 cells. Results ScRNA-seq revealed widespread activation of IFN responses in PBMCs from anti-MDA5+ DM-ILD patients, with pronounced upregulation in innate immune cells (e.g., NK cells and monocytes). A reduction in circulating NK cell proportions was observed in ILD patients. Serum levels of cytokines (IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12P70, TNF-α, and IFN-α) positively correlated with the radiologic severity of ILD as quantified by HRCT scores. Flow cytometry confirmed significantly decreased NK cell counts and increased apoptosis in the ILD group. PBMCs from healthy donors exposed to an ILD-like cytokine milieu exhibited upregulated IFN pathway genes (ISG15, MX2, IFIT3), EIF2AK2 (encoding protein kinase R), and apoptosis-related genes (BCL2, BAX2). In vitro, IFN stimulation directly induced apoptosis in NK-92 cells. Conclusion Excessive IFN activation drives NK cell apoptosis in anti-MDA5+ DM-ILD, contributing to NK cell depletion and ILD development. IFN-related biomarkers may serve as valuable indicators for assessing ILD severity in these patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f561d51a5fa1e3b04b78d86a4673eadd69564ec1" target='_blank'>
              Exhaustion of NK cells and interferon activation in anti-MDA5+ dermatomyositis are associated and determine the development of ILD
              </a>
            </td>
          <td>
            Chenyi Shao, Yan Zhen, Nana Xia, Xueliang Zhang, Ninghui Yan, Mengmeng Zhou, Yiyuan Guo, Limin Tan, Qiang Guo
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd5525dc695c7cab7bc678df063ceac946d09faa" target='_blank'>
              Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis
              </a>
            </td>
          <td>
            Cynthia Lebeaupin, Katelyn L. Donahue, S. Lal, Stephen M. Christensen, Shoh Asano, Marc H. Wadsworth, Kathryn Bound, Saurav De, James McMahon, Franklin Schlerman, Chang Wang, Xiao Chen, A. M. Barron, Thomas A. Wynn, Kevin M. Hart, Thomas Fabre
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fda0edb364952e5067fda86230619632242ae72" target='_blank'>
              Cancer-Associated Mesothelial Cells Drive Immune Escape and Therapy Resistance in Ovarian Cancer
              </a>
            </td>
          <td>
            M. Chauvin, Julien Roche-Prellezo, Virginie Lafont, Henri-Alexandre Michaud, Estelle Tromelin, Robin Michel, Clara Freixinos, Marie-Charlotte Meinsohn, Pierre-Emmanuel Colombo, Nathalie Bonnefoy, Laurent Gros, David Pépin
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Background Immunosuppressive breast cancer subtypes driven by regulatory T cells (Tregs) remain under-characterized, limiting precise identification of patients who may benefit from immunomodulatory therapies. Tregs are key mediators of immunosuppression within the tumor microenvironment (TME) and are closely associated with resistance to immune checkpoint inhibitors (ICIs). Therefore, defining and characterizing tumors with predominant Treg-mediated immunosuppression is essential for optimizing the use of Treg-targeted and combination immunotherapies. Methods We applied an unsupervised multi-omics integration approach across four molecular layers — mRNA, miRNA, DNA methylation, and proteomics —to identify immunologically distinct subtypes of breast cancer. Autoencoder-based dimensionality reduction followed by consensus clustering revealed a subgroup characterized by high Treg infiltration and immunosuppressive signaling, referred to as the Treg-enriched subtype. To evaluate therapeutic strategies, we employed a spatial quantitative systems pharmacology (spQSP) model simulating tumor–immune dynamics and tested Treg-targeted and PD-1 blockade therapies both alone and in combination. In vivo efficacy studies were conducted using the EMT6 syngeneic breast tumor model, characterized by an immunosuppressive tumor microenvironment, assessing the antitumor effects of a CCR8-targeted small molecule (IPG7236) as monotherapy or in combination with anti–PD-L1 treatment. Results The C2 cluster exhibited elevated Treg-related signatures and a highly immunosuppressive tumor microenvironment. A similar Treg-enriched cluster was also identified in an independent cohort, supporting the robustness and clinical relevance of this immunosuppressive subtype. In-silico simulations performed under a C2-like, immunosuppressive context predicted that combining Treg-targeted therapy with PD-1 blockade would substantially enhance immune activation and tumor control compared with monotherapy. To experimentally validate these predictions, combination treatment of a CCR8 inhibitor (IPG7236) and anti–PD-L1 antibody demonstrated greater tumor growth inhibition than either monotherapy in the EMT6 model, confirming the predicted therapeutic synergy in Treg-enriched, immune-suppressive tumors. Conclusion This study identifies Treg-enriched and immunosuppressive breast cancer subtype through integrative multi-omics analysis and demonstrates, through both in-silico and in-vivo approaches, the therapeutic potential of combining Treg-targeted and PD-L1 blockade therapies. These findings highlight Treg-mediated immunosuppression as a key determinant of therapeutic responsiveness, providing a biological rationale for patient stratification and guiding the development of personalized combination strategies for clinical translation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e56fa59c2f43f37e3fe48c03bc1996946112404e" target='_blank'>
              Integrative multi-omics stratification and translational evaluation of Treg-targeted combination immunotherapy in breast cancer
              </a>
            </td>
          <td>
            Nari Kim, S. Na, Hyo Jin Lee, Woojin Yi, G. Son, Jin Park, Jisung Jang, Mihyun Kim, Seong-Yun Jeong, Kyung Won Kim
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="The contribution of chemotherapy-induced tissue injury to individual susceptibility to metastasis remains largely unexplored. We report that chemotherapy indirectly prevents colorectal cancer (CRC) liver metastases by inducing a lasting systemic “chemomemory”. Chemotherapy-induced intestinal mucositis alters nutrient availability, promoting the expansion of tryptophan-metabolizing bacteria and production of the microbial metabolite indole-3-propionic acid (IPA). IPA reprograms bone marrow myelopoiesis by redirecting common myeloid progenitor fate toward the macrophage lineage, limiting generation of immunosuppressive Ly6ChighCCR2+ monocytes. This shift enhances CD4+ T cell antitumor function by promoting Th1 differentiation and spatially reorganizing CD8+ and CD4+ T cell interactions within the metastatic microenvironment. In a subset of CRC patients, circulating IPA levels increase after chemotherapy and inversely correlate with monocyte abundance, while high monocyte levels were associated with reduced survival. Our findings reveal that chemotherapy-induced intestinal injury normalizes pathological myelopoiesis through a microbiota-derived metabolite and identify IPA as a potential adjuvant to counteract monocyte-driven immunosuppression and metastasis. The microbiota influences the cytotoxicity of chemotherapy in patients with colorectal cancer but the impact on metastatic relapse is less clear. Here, the authors report that chemotherapy-induced intestinal mucositis induces systemic immune changes via production the microbial metabolite, indole-3-propionic acid (IPA), preventing metastases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/15a21dacb8c45e65545bd42db1f0f3a748edfc8e" target='_blank'>
              Chemotherapy-driven intestinal dysbiosis and indole-3-propionic acid rewire myelopoiesis to promote a metastasis-refractory state
              </a>
            </td>
          <td>
            Ludivine Bersier, L. F. Lorenzo-Martín, Yi-Hsuan Chiang, Stephan Durot, Aleksander Czauderna, T. Yarahmadov, Tania Wyss Lozano, I. Roci, Jaeryung Kim, N. Zamboni, N. Vannini, C. Pot, T. Collet, D. Stroka, J. Bernier-Latmani, Matthias P. Lutolf, Simone Becattini, Thibaud Koessler, Tatiana V. Petrova
          </td>
          <td>2025-12-15</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ce380aea2613d07a2569ea17ef622bcc9b49b6c" target='_blank'>
              Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening
              </a>
            </td>
          <td>
            Ting Pan, Tingting Wang, Jiaqi Wu, Heping Wang, Bo Zeng, Yangyang Li, Ming Yi, Ruirui He, Lingyun Feng, Zhihui Cui, Guoling Huang, Panyin Shu, Yuan Wang, Xi Li, Yanyun Du, Zhen Li, Xue Xiao, Chenhui Wang
          </td>
          <td>2026-01-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/de69e456272d47e1287958aec83b80a0b830f6b6" target='_blank'>
              CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function
              </a>
            </td>
          <td>
            CY Chabu, R. Kazmierczak, M. Hasani, N. Patterson, Q. Wang, L. Canti, M. Tesfay, A. Cios, B. Dhagat, M.Q Pastor, C. De la Nuez, T. Verburg, J. Moyer, K. Gunter, M. Mwanza, O. Moaven, G. Li, P. de Figueiredo, B.M Nagalo
          </td>
          <td>2026-01-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Melanoma remains a major challenge in oncology because of its aggressive behavior and intricate immune interactions. Advances in immunophenotyping and single-cell atlas technologies have revealed heterogeneous regulatory T cell (Treg) subsets, among which peripheral blood CD39+PD-1+ Tregs have emerged as key mediators of systemic immunosuppression. This review summarizes current evidence on their immunoregulatory functions, emphasizing their role in suppressing anti-tumor immunity and contributing to poor clinical outcomes. By integrating immune atlas data with clinical observations, we outline the mechanisms by which this subset shapes both the tumor microenvironment and systemic immune responses. We further discuss their potential as prognostic biomarkers and therapeutic targets to optimize immunotherapy strategies. In addition, we highlight how this subset interacts with other immunosuppressive pathways, reinforcing resistance to immune checkpoint inhibitors. Despite these advances, challenges remain in fully characterizing this population and translating findings into clinical application. This review provides a comprehensive overview of the significance of CD39+PD-1+ Tregs in melanoma immunopathology and highlights future directions to advance precision immunotherapy and improve patient prognosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc33012596eab785fba7e6d8eba704e87044622b" target='_blank'>
              CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers
              </a>
            </td>
          <td>
            Guanlin Qiao, Hongxia He, Xiaobing Wang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8be0d6e509dd7791835e7d4c333379b39ded8d02" target='_blank'>
              Immunotherapy with Pro-regenerative Macrophages from Embryonic Stem Cells Ameliorate Osteoarthritis via TNFAIP3-Mediated Chondroprotection
              </a>
            </td>
          <td>
            Zhumei Zhuang, Zicong Liu, Hang Su, Wei Sun, Qiuwen Zhu, Jingyi Xu, Jinghua Fang, Liying Li, Danni Shen, Xiaohui Zou, Hendrik Marks, Xianzhu Zhang, Hua Liu, H. Ouyang
          </td>
          <td>2025-12-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4eb287f4be34ac61e66b972c8521500710a820fd" target='_blank'>
              Dual inhibition of the nonsense mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and potentiates checkpoint blockade
              </a>
            </td>
          <td>
            Ivan Zadra, Davor Orsolic, Dimitri Kounis, Mario Acera, Guillermo Palou Márquez, Etna Abad, Laura Ortet, Anna Benito, Y. Kharraz, Carlos M. Martínez, Elisabetta Mereu, Fran Supek, Ana Janic
          </td>
          <td>2025-12-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Abstract Mucosal-associated invariant T (MAIT) cells are unique unconventional T cells with diverse roles in immunity, yet how their context informs their function is not well known. This contextual regulation is particularly relevant in cancer, where MAIT cells have an enigmatic role. We performed a systematic review and meta-analysis to identify MAIT cell transcriptomic signatures under different environmental conditions. We identified 4 bulk-RNA-sequencing studies that compared multiple activation stimuli. We found a stimulus-specific transcriptional signature for immune checkpoint genes, that we confirmed in a single-cell RNA-sequencing dataset. We used flow cytometry to examine in vitro human MAIT cells across 4 activation stimuli and confirmed that stimulus drives unique checkpoint signatures upon MAIT activation for Lag3, PD-L1, PD-1, NKG2A, and Tigit. Strikingly, PD-L1 was more highly induced in vitro than PD-1 in MAIT cells up to 72 h. Our data suggest that human MAIT cell regulation is context-dependent. These findings have the potential to critically inform efforts targeting MAIT cells for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ecf762a805ede9d94ba29010a5a748ff3406109" target='_blank'>
              Immune checkpoint expression in mucosal-associated invariant T cells is stimulus-dependent
              </a>
            </td>
          <td>
            C. Clutter, Audrey Re, Kenadee Jacobson, Kendell Clement, Jeffrey Aubé, Ryan M O'Connell, D. Leung
          </td>
          <td>2025-12-06</td>
          <td>Journal of Leukocyte Biology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) of classic Hodgkin Lymphoma (cHL) contribute to the development of immunosuppressive tumor microenvironment (TME) and are associated with worse treatment outcomes. However, detailed features, functions and therapeutic vulnerabilities of cHL TAMs remain largely unknown. To address this, we analyzed cHL diagnostic biopsies by Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) and assessed transcriptional, proteomic and metabolic profiles of in vitro TAM models. We show that Reed–Sternberg (RS) cells induce a disease-specific TAM phenotype, characterized by elevated expression of factors involved in chemotaxis, angiogenesis, extracellular matrix remodeling and tumor immune escape. RS cell-conditioned TAMs expressed TGFβ, CCL17 and tryptophan catabolizing enzymes, IDO1 and IL4I1, promoting regulatory T cell recruitment and activation. In addition, we identified the expression of PIM1/2/3 kinases in cHL TAMs and characterized PIMs as critical hubs orchestrating RS-macrophage interactions. Pharmacological PIM blockade attenuated the RS-induced TAM transcriptional program. In established TAMs, PIM inhibition or PROTAC-mediated degradation decreased the expression of multiple factors associated with pro-tumoral TAM functions, including IL8, MMP9, CHI3L1/2, CD206, CD209, PD-L1, CCL17, TGFβ, IL4I1 and IDO1. PIM blockade attenuated TAM-dependent eosinophil chemoattraction, extracellular matrix remodeling, angiogenesis and regulatory T-cell development. Taken together, our study highlights the role of PIMs in the regulation of pathogenic TAM functions in cHL, further supporting the rationale of PIM targeting in this disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1982195fb047b4fe2306569c314b17e32eb5f1b8" target='_blank'>
              PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma
              </a>
            </td>
          <td>
            Maciej Szydłowski, E. Kurtz, F. Garbicz, Julia Maroszek, Michal Pawlak, Natalia Ochocka, Marcin Tabaka, Monika Prochorec-Sobieszek, A. Szumera-Ciećkiewicz, P. Górniak, O. Szymańska-Giemza, Grzegorz Rymkiewicz, A. Kołkowska-Leśniak, Wojciech Kukwa, E. Paszkiewicz-Kozik, Justyna Totoń-Żurańska, Sylwia Radomska, Z. Pilch, D. Nowis, Jakub Gołąb, M. Kurlapski, J. Zaucha, Alicja Braczko, Marcin Kaszkowiak, Paweł Wołkow, K. Wiktorska, J. Brognard, Sabina Lichołai, E. Lech-Maranda, P. Juszczyński
          </td>
          <td>2025-12-26</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Bispecific T cell engagers (TCEs) often exhibit limited efficacy in solid tumors, in part due to immunosuppressive cues in the tumor microenvironment and low expression of targetable tumor antigens. Therapeutic strategies to improve TCE target sensitivity and enhance T cell effector functions therefore have significant translational potential. Here, we engineered TCEs that induce T cell activation in vitro against the low-abundance target antigens, TRP2/Kb and DLL3. Despite in vitro activity in these models, TCE monotherapy showed limited control of tumor growth in immunocompetent mice. Leveraging this in vivo model of TCE treatment failure, we discovered that co-treatment with TCE and a CD25-biased Interleukin-2 (IL2) rescues anti-tumor activity. Further, multimodal single-cell transcriptomic and immune repertoire analyses revealed that TCE-IL2 combination therapy controlled tumors by recruiting and activating new CD8+ T cells into the tumor microenvironment. These findings demonstrate that TCE-mediated anti-tumor responses function through a CD8+ T cell clonal replacement mechanism that can be augmented by cytokine therapy. One Sentence Summary Combining TCE therapy with IL-2 enhances TCE efficacy in aggressive small-cell lung cancer and melanoma models with low target antigen density through T cell clonal replacement and CD8+ effector T cell differentiation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b88f987398014e44f618252c969f839bb8ea3a65" target='_blank'>
              Bispecific T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells
              </a>
            </td>
          <td>
            Matthias Obenaus, Clara L. Poupault, Chris McGinnis, Céline Prange, Hua Jiang, Leon L. Su, Xiaojing Chen, Zhuang Miao, Joseph J. Muldoon, Winnie Yao, Deepa Waghray, Qinli Sun, Justin Eyquem, Rogelio A. Hernandez-Lopez, Ansu Satpathy, Julien Sage, K. C. Garcia, Christopher Garcia
          </td>
          <td>2025-12-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="The gut microbiota plays an essential role in mucosal immunity, with secretory immunoglobulin A (IgA) acting as a key effector in neutralizing pathogens and maintaining host-microbiota homeostasis. IgA production occurs via T cell-dependent (TD) and -independent pathways, with T follicular helper (Tfh) cells driving high-affinity, antigen-specific IgA responses. However, the specific microbial taxa and metabolites that regulate Tfh-mediated IgA responses under steady-state conditions remain poorly understood. This study investigated how gut microbiota-derived signals shape Tfh responses and IgA production, with implications for enhancing mucosal vaccine efficacy. We demonstrate that Peyer’s patches (PP)-derived Tfh cells exhibit superior IgA-inducing capacity compared to splenic Tfh cells. RNA sequencing revealed distinct transcriptional profiles in PP-Tfh cells, including upregulation of the genes associated with Tfh differentiation and activation (Bcl6, Cd40lg, Maf), T-B cell interactions (Il21, Sh2d1a, Fyn), and migration (Ccr6, Cxcr5). Functionally, PP-Tfh cells formed larger T-B cell contact areas and induced significantly higher IgA secretion in co-culture than their splenic counterparts. Microbiota depletion experiments revealed that eliminating neomycin-depleted bacteria reduced fecal IgA levels and diminished PP-Tfh cell frequencies. Fecal microbiota transplantation from neomycin-treated mice restored both IgA production and Tfh responses in germ-free (GF) mice. Bioinformatic analysis (PICRUSt2 and LEfSe) identified butyrate-producing Lachnospiraceae and Ruminococcaceae as key drivers of the Tfh-IgA axis. Butyrate supplementation enhanced Tfh differentiation and IgA⁺ germinal center B cell development in vitro and increased fecal IgA levels in vivo. Mechanistically, butyrate promoted IgA production via GPR43 signaling, as its effect was lost in co-cultures with Gpr43⁻/⁻ Tfh cells. Moreover, treatment with tributyrin, a butyrate prodrug, enhanced vaccine-induced IgA and protected mice against Salmonella Typhimurium infection, reducing bacterial burden and tissue damage. These findings define a functional microbiota-Tfh-IgA axis sustained by neomycin-depleted, butyrate-producing bacteria. Our study underscores the crucial role of the gut microbiota, particularly neomycin-depleted butyrate producing taxa, in regulating PP-Tfh cell function and IgA production. Butyrate emerges as a metabolite linking microbial metabolism to Tfh differentiation and IgA class switching. Together, these findings establish a microbiota-metabolite-Tfh cell axis essential for mucosal immune homeostasis and suggest novel strategies for enhancing vaccine efficacy and protection against enteric infections. 65SkT5T5U4s1JHPzYWZphR Video Abstract Video Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/258f08bfcfc4875278debbc54438c4cb8dd78ba9" target='_blank'>
              Commensal microbe-derived butyrate enhances T follicular helper cell function to boost mucosal vaccine efficacy
              </a>
            </td>
          <td>
            Haeun Ko, Chan Johng Kim, Seungyeon Choi, Jaegyun Noh, Seung Won Kim, Juhun Lee, Seohyun Byun, Haena Lee, J. Park, H. Park, Amit Sharma, Minhyuk Park, Junghwan Park, Choong-Gu Lee, Kwang Hyun Cha, Sin-Hyeog Im
          </td>
          <td>2026-01-21</td>
          <td>Microbiome</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="ABSTRACT Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8+ T cells and CD16A+ NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A+ NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b68faec76c8019914aaaeb0bb112e3f2ed84b4a" target='_blank'>
              NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells
              </a>
            </td>
          <td>
            L. Heger, Tomasz Kaszubowski, L. Amon, C. H. Lehmann, Susanne Wingert, J. Medina-Echeverz, Joachim Koch, Holger Hackstein, A. Purbojo, Arndt Hartmann, Christoph Alexiou, R. Cesnjevar, J. Pahl, Diana Dudziak
          </td>
          <td>2026-01-18</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. Despite advances in surgery and chemotherapy, outcomes remain poor in metastatic cases, with five-year survival rates below 30%. This stagnation highlights the urgent need for novel therapeutic strategies. Growing evidence indicates that the tumor immune microenvironment (TIME) plays a central role in OS progression, metastasis, and resistance to treatment. Immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), dominate the TIME, while cytotoxic T cells often exhibit exhaustion. Stromal barriers, hypoxia, and metabolic constraints further impair immune activity. Recent single-cell and spatial transcriptomic studies reveal that immune and stromal architectures strongly correlate with prognosis and therapeutic response. These features contribute to the limited efficacy of current immunotherapies, including immune checkpoint inhibitors (ICIs) and CAR-T cells. In this review, we summarize the cellular, molecular, and spatial components of the OS TIME, critically evaluate current immunotherapeutic strategies, and highlight emerging translational approaches aimed at overcoming immune resistance and improving clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f2b045dec1043e90d16aee9ed935ba08b0a4239" target='_blank'>
              Targeting the osteosarcoma immune microenvironment for improved immunotherapy and translational applications
              </a>
            </td>
          <td>
            Jinlin Cai, Shijie Qiu, Biao Sun, Jianbin Ge, Zhe Yu, Chao Wang
          </td>
          <td>2025-12-21</td>
          <td>Discover Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The CD40 pathway has become one of the most promising immunologic axes in oncology. As a central intermediary between innate and adaptive immunity, CD40 activation engages dendritic cells (DCs), amplifies antigen presentation, and stimulates potent cytotoxic T‐cell (CTL) activity. Therapeutic CD40 agonists have been studied in a broad range of cancers over the past decade to reconfigure the tumor's immune microenvironment (TIME) and overcome immune refractoriness to standard immunotherapies. Clinical development has been most significant in pancreatic cancer, an exemplar cold tumor resistant to immune checkpoint blockade. Here, CD40 agonists have demonstrated efficacy to repolarize immune‐desert phenotypes to a more inflamed and treatable phenotype, particularly in combination with chemotherapy or programmed cell death protein 1 (PD‐1) inhibitors. Clinical evidence has also been gained in melanoma and non‐small cell lung cancer, where CD40‐targeted strategies are examined in combination with current checkpoint inhibitors to accelerate T‐cell priming. In hematologic malignancies and B‐cell lymphomas, in particular, CD40 agonists exploit the natural activity of the B‐cell activating receptor, providing a strong biological rationale for their clinical efficacy. Exploratory studies have gone on to extend into bladder, prostate, mesothelioma, and head and neck cancers, demonstrating the broad translational relevance of this pathway. Hopes fostered by preliminary signs of activity remain to be qualified in light of the difficulties. Systemic immune activation‐associated toxicities, such as cytokine release syndrome, have justified cautious dosing schedules and exploration of local routes of drug administration. Additionally, heterogeneity between tumors in response underscores an urgent need for predictive biomarkers to enable the selection of patients and to tailor optimal clinical effects. In the future, drug development will be reliant on prudent combinations and novel delivery methods. Conjugation to vaccines, bispecific antibodies, radiotherapy, and oncolytic viruses is an attractive route to achieve their fullest immunostimulatory capabilities. Through a flexible approach to reeducate the immune microenvironment within tumors, CD40 agonist therapy can extend the use of immunotherapy to traditionally immune‐refractory malignancies. This review intends to present a cross‐cancer approach to CD40 agonist therapy, compiling existing clinical evidence while highlighting common issues and prospects for harnessing this pathway across various tumor settings.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be05bece04ba4f9ae6c853fd6509daabc054db80" target='_blank'>
              Cross‐Cancer Perspectives on CD40 Agonist Therapy: Modulating the Tumor Immune Microenvironment
              </a>
            </td>
          <td>
            Xudong Hua, Junyan Hua, Yanzhong Wang
          </td>
          <td>2026-01-01</td>
          <td>Journal of Biochemical and Molecular Toxicology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c872e20ed96ce9671cd91e8697d416593c662410" target='_blank'>
              Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis
              </a>
            </td>
          <td>
            Barathan Muttiah, A. Wahab
          </td>
          <td>2025-12-24</td>
          <td>Clinical Rheumatology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="CD8⁺ T lymphocytes are pivotal effectors of adaptive immunity, executing cytotoxic mechanisms essential for pathogen clearance, tumor surveillance and tissue protection. Their activity is shaped by antigenic stimulation, cytokine networks and the metabolic and structural architecture of the tissue microenvironment. Physical exercise has emerged as a potent, non-pharmacological modulator of CD8⁺ T cell biology, capable of influencing recruitment, activation, differentiation and functional persistence. Acute exercise mobilizes effector and memory subsets, enhances trafficking to peripheral tissues and transiently alters activation thresholds, while sustained training remodels subset composition, preserves mitochondrial competence and attenuates immunosenescence. These adaptations are orchestrated through integrated neuroendocrine, vascular and metabolic pathways that recalibrate chemokine gradients, nutrient availability and energetic support. However, the magnitude and direction of these effects are highly context-dependent, varying with host physiology, disease state and microenvironmental constraints. This Review integrates mechanistic and translational evidence across physiological and pathological settings—including cancer, infectious, neurological and metabolic diseases—to clarify when and how exercise can be leveraged to reinforce cytotoxic immunity. We highlight key methodological and biological challenges, and propose biomarker-guided, microenvironment-informed and adaptively titrated exercise interventions as a framework for advancing exercise from an adjunctive measure to a modulatory, precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/697b8e18eede93afa0da0c621d293296cae7424c" target='_blank'>
              Modulating CD8⁺ T cell immunity through exercise: mechanistic insights and implications for precision immunotherapy
              </a>
            </td>
          <td>
            Xinyuan Zhao, Xu Chen, Pei Lin, Yunfan Lin, Weiyao Feng, Meiyan Zou, Nina Li, Li Cui
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01d5126518bd32b0020b208551073217d7b6d6e1" target='_blank'>
              Selective infection and loss of PRDM1+ LN Tfh cells in uncontrolled HIV infection precludes formation of Tfh reservoirs under ART
              </a>
            </td>
          <td>
            V. Wu, J. Nordin, M. Pampena, Suzanna Rachimi, William L. Burgess, Michael Clark, Jake A. Robinson, P. D. R. Estrada, M. Schleimann, Fernanda Torres-Ruiz, Mauricio González-Navarro, Gonzalo Salgado, Y. Luna-Villalobos, Gustavo Reyes-Teran, Katharine J. Bar, Jacob D. Estes, O. Søgaard, Neil Romberg, S. Ávila-Ríos, Michael R. Betts
          </td>
          <td>2025-12-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47a86c6d791fa4b2001ba0e3619947d81149d6fc" target='_blank'>
              Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
              </a>
            </td>
          <td>
            Francesco Maura, Ciara L. Freeman, K. Maclachlan, Marta Larrayoz Ilundain, B. Ziccheddu, Erin W. Meermeier, Juan-Jose Garcés, Michael A Durante, Holly Lee, Ross S. Firestone, M. Menges, Kayla Reid, B. Diamond, M. Papadimitriou, A. Silva, P. Sudalagunta, Noémie Leblay, S. Ahn, Ethan Fuller, Edward Briercheck, Meaghen E. Sharik, Megan T. Du, Phaedra Agius, Doris K. Hansen, Xiaofei Song, Xiaohong Zhao, M. Meads, Jamie K. Teer, T. Jelínek, P. Hagner, Rachid C. Baz, Melissa Alsina, A. Ramasubramanian, Eric L. Smith, S. Giralt, S. Mailankody, Leif Bergsagel, Paola Neri, M. Chesi, Jose-Al Martinez-Climent, Frederick L Locke, N. Bahlis, O. Landgren, Issam S. Hamadeh, S. Usmani, K. Shain
          </td>
          <td>2025-12-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="The cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) pathway acts as a pivotal innate immune sensor that detects cytosolic DNA and links genomic instability to antitumor immune activation. Therapeutic activation of this pathway has garnered substantial interest as a strategy to enhance cancer immunotherapy by promoting dendritic cell maturation, augmenting antigen presentation, and facilitating cytotoxic lymphocyte infiltration. However, the functional outcomes of cGAS–STING signaling are highly context dependent and influenced by both cell type and tumor microenvironmental (TME) conditions. Recent advances in single-cell and spatial transcriptomic profiling have revealed profound heterogeneity in cGAS–STING activation across distinct cellular and regional compartments within tumors. Acute and spatially restricted activation of the pathway can elicit potent antitumor immune responses, whereas chronic or dysregulated signaling may promote immune tolerance and tumor progression. Moreover, metabolic stress, epigenetic silencing, and microenvironmental immunosuppressive factors such as TGF-β and IL-10 can further modulate STING activity, leading to resistance to immunotherapy. Current translational efforts focus on next-generation STING agonists, nanoparticle-based delivery systems, and rational combination strategies with immune checkpoint blockade and metabolic modulators to overcome tumor-intrinsic resistance and minimize systemic toxicity. Understanding the cell-type-specific and spatial dynamics of cGAS–STING signaling is crucial for the rational design of precision immunotherapies. Future research should emphasize context-dependent modulation of STING activity to maximize therapeutic benefit while limiting adverse effects. Integrating multi-omics technologies and spatially guided drug delivery may ultimately enable personalized modulation of the cGAS–STING axis, transforming it into a clinically effective and safe strategy for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7109afa0c002a7c13c763c36487000288fa7135" target='_blank'>
              Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Lusheng Wang, Sudi Zhu, Zhixian Ding, Jie Hong, Lijie Zheng, Jiting Sun, Yu Tang, Xiaohui Chen, Xiang Yong, Mengxue Hu, Zhimin Jiang, Yan Liu, Dan Wang, Heng Tang
          </td>
          <td>2026-01-07</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy is one of the cornerstones of cancer treatment regimens, but the overall response rates remain low because of suppressive immune cells, such as myeloid-derived suppressor cells (MDSC). Therefore, it is unmet need to target MDSC to achieve better outcomes of ICB therapy. Inositol-requiring enzyme 1α (IRE1α) is identified as a key regulator for the generation of MDSC. Here, we evaluated the potential of KIRA6, an inhibitor for IREα kinase activity and RNase activity, to abrogate MDSC-mediated immune suppression. KIRA6 significantly suppressed 4T1 tumor growth, decreased MDSC population and enhanced T cell infiltration. Two dosages of KIRA6 treatment directly inhibited extramedullary myelopoiesis and MDSC generation in vivo. KIRA6 abrogated the induction of MDSC from bone marrow cells and abolished the immunosuppressive capability of MDSC in vitro. Meanwhile, KIRA6 not only attenuated G-CSF production from tumor cells thereby blocking the induction of MDSC, but also caused apoptosis of tumor cells. Moreover, KIRA6 treatment diminished MDSC generation, restored T cell proportion in both local and systemic immune landscapes and eventually overcame resistance to anti-PD-1 therapy. Our work establishes the evidence for KIRA6 as an impressive agent for abrogating MDSC-mediated immune suppression, killing tumor, and overcoming ICB resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5734c0f30eda05dc79c00e03122bb8b481259562" target='_blank'>
              KIRA6 restrains the generation of myeloid-derived suppressor cells and overcomes resistance to anti-PD-1 therapy
              </a>
            </td>
          <td>
            Chun Chen, Jing Chen, Xiaowen Lin, Jiali Hu, Yuncong Zhang, Dingjie Liu, Xumei Ouyang, Jing Li, Wenting Li, Shiying Xie, Ya Meng, Meixiao Zhan, Yongjun Peng, Hong-Wei Sun
          </td>
          <td>2025-12-27</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Silicosis is a progressive lung fibrosis lacking effective treatment. Mesenchymal stem cells (MSCs) show antifibrotic potential, but their survival is impaired by the early inflammatory microenvironment. The therapeutic value of repeated MSC administration remains unclear. A murine silicosis model was analyzed by single-cell RNA sequencing, bronchoalveolar lavage fluid (BALF) cytokine assays, and human Bone Marrow-Derived Mesenchymal Stem Cells (hBMSCs) transcriptomics after BALF exposure. Mice received either single or repeated intratracheal hBMSCs doses. Cell retention, lung function, imaging, histology, and fibrosis markers were assessed. The role of ZC3H4 in macrophage activation was examined by in vivo expression profiling, in vitro knockdown, and functional assays. Early silica exposure triggered strong M1 inflammation, high BALF cytokines, and hBMSCs senescence signatures. Repeated hBMSCs dosing improved cell persistence, reduced fibrosis on imaging and histology, enhanced lung function, and decreased collagen deposition compared with a single dose. Mechanistically, MSC therapy suppressed macrophage ZC3H4 expression, while ZC3H4 knockdown reduced macrophage activation and fibroblast migration. Repeated hBMSCs administration enhances therapeutic efficacy in silicosis by improving cell persistence and attenuating fibrosis, partly through ZC3H4-mediated regulation of macrophages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ac0b00294ed8c4f98e0c63883faa1d16f5193df" target='_blank'>
              Enhanced therapeutic efficacy of repeated bone marrow–derived MSC administration in a murine model of pulmonary fibrosis
              </a>
            </td>
          <td>
            Zihan Zhou, Jiawei Ding, Shuhua Han, Yuanfang Duan, Jie Chao, Jie Huang
          </td>
          <td>2025-12-23</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Glucocorticoids (GCs) regulate diverse physiological processes, comprising metabolism, immune responses, stress adaptation, and inflammation. Synthetic GCs are widely used for their powerful anti‐inflammatory and immunosuppressive effects, in the treatment of autoimmune diseases, allergies, and inflammation. Here, we investigated the role of the glucocorticoid receptor (GR) in B cell development and survival using both B cell‐specific GR‐deficient mice and continuous in vivo GR agonist treatments. Deletion of the GR in B cells altered splenic B cell subpopulations, increasing follicular and CD21lo B cells and leading to the accumulation of IgM−/IgD− B cells. In vivo treatment with GR agonists, such as Dexamethasone (Dex) and Prednisolone (Pred), selectively depleted IgDhi follicular while enriching IgMhi marginal zone B cells. IgMhi B cells, which were more resistant to GC‐induced cell death, showed an increased expression of IL‐10 and genes involved in survival, suggesting a potential regulatory function. In vitro, B cell activation via CpG or lipopolysaccharide (LPS) altered IgM/IgD expression and B cell sensitivity to GR agonists, thereby leading to improved B cell survival and increased plasma cell differentiation. Together, these findings suggest that IgD downregulation and IgM upregulation are critical for B cell survival under GC exposure and that GR agonists promote the enrichment of IgMhi cells resistant to apoptosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b855ec64e7900b8bc1fa27d67a4d06a01447dadf" target='_blank'>
              IgD‐Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid‐Induced Cell Death
              </a>
            </td>
          <td>
            Kais Almohammad, Marc Young, S. Vettorazzi, Franziska Greulich, Mahmoud Alkhatib, J. Tuckermann, H. Jumaa, Corinna S. Setz
          </td>
          <td>2026-01-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9c592da5f3c0f4f7f748992e9cf8d10cdb0615b" target='_blank'>
              An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapy
              </a>
            </td>
          <td>
            Xiang Li, Jing Hu, Tian Zhang, Hongceng Li, Tao Wang, Yuxin Liu, Lan Zhang, Yonglong Wei, Shi Wei, Panpan Zhang
          </td>
          <td>2025-12-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Mesenchymal stem cells (MSCs) are recognized for their capacity to modulate immune responses, including those directed against tumors. In this study, we investigated the temporal effects of MSCs administration on anti-tumor immunity in a murine 4T1 breast cancer model. BALB/c mice were intraperitoneally injected with MSCs either 24 h (MSC1d) or 14 days (MSC14d) after orthotopic implantation of 4T1 mammary carcinoma cells. Early MSC administration (MSC1d) exhibited changes in immune cell phenotypes consistent with enhanced antitumor potential, including increased activity of natural killer (NK) cells, dendritic cells (DCs), macrophages, and T lymphocytes. These immunological changes correlated with reduced tumor growth and prolonged survival. Mice in the MSC1d group exhibited elevated serum levels of pro-inflammatory and anti-tumor cytokines (TNF-α, IFN-γ, IL-6, and IL-17), alongside decreased concentrations of immunosuppressive cytokines (TGF-β and IL-10). Tumor tissue analysis revealed increased infiltration of NK cells expressing markers associated with antitumor activity (IFN-γ-producing CD178⁺), CD80⁺/CD86⁺/I-A⁺ TNF-α-producing DCs, Th1-type CD4⁺ T cells, and Granzyme B-expressing CD8⁺ cytotoxic T lymphocytes (CTLs). Additionally, spleens of MSC1d-treated mice displayed significantly elevated populations of CD11c⁺ DCs, TNF-α/IFN-γ-secreting NK cells, CD4⁺ Th1 and Th17 cells, and CD8⁺ CTLs expressing markers associated with cytotoxic function (TNF-α, IFN-γ, and IL-17). Conversely, late MSCs administration (MSC14d) was associated with immunosuppression. Tumors from MSC14d-treated mice showed a decreased presence of IFN-γ⁺ and IL-17⁺ NK1.1⁺ cells, F4/80⁺ macrophages, IL-12⁺ DCs, and cytotoxic T cells. Spleens from these mice revealed a significant expansion of regulatory T cell (Treg)-like populations, including CD25⁻, FoxP3⁻, CD25⁺FoxP3⁻ cells, and TGF-β/IL-10-producing CD3⁺ and CD4⁺ T cells. Furthermore, serum levels of immunosuppressive mediators TGF-β and vascular endothelial growth factor (VEGF) were significantly elevated in the MSC14d group. Collectively, these findings demonstrate that the immunomodulatory effects of MSCs on breast cancer are highly dependent on the timing of their administration. Mesenchymal stem cells delivered during early tumor development enhance phenotypes consistent with antitumor potential and suppress tumor progression, whereas administration during later stages promotes immune evasion and tumor growth.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c808072251961d94efaa18f265914925e1e7ece9" target='_blank'>
              Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model
              </a>
            </td>
          <td>
            Dragana Papic, Dragica Pavlovic, Danijela Nićiforović, V. Jurišić, V. Volarevic
          </td>
          <td>2026-01-01</td>
          <td>Cell Transplantation</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Secreted phosphoprotein 1 (SPP1+) macrophages are a recurrent and functionally critical immune cell subset across multiple cancer types. They drive adverse clinical outcomes by promoting immunosuppression, tumor invasion, metastasis, and therapy resistance. Given their prevalence and pivotal role, SPP1+ macrophages have become a major focus in cancer immunology and a promising target for therapeutic development. SPP1+ macrophages have been identified in a wide range of human malignancies through single-cell RNA sequencing and spatial transcriptomics studies. Their differentiation and maintenance are strongly influenced by reciprocal cellular interactions and hypoxic conditions within the tumor microenvironment (TME). Within the tumor microenvironment (TME), SPP1+ macrophages promote tumor progression by interacting with cancer-associated fibroblasts (CAFs) and helping to form a physical barrier that restricts immune cell infiltration into the tumor core. Specifically, they impair the recruitment of CD8+ T cells and promote T cell exhaustion (TEX). In this review, we focus on recent advances in understanding the differentiation of SPP1 macrophages in hypoxic tumor microenvironment and the role of SPP1+ macrophages in immunosuppression and their therapeutic implications in cancer. Targeting this subset of macrophages has emerged as a highly promising therapeutic strategy, with several approaches demonstrating encouraging results in preclinical models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7c7489149a391c5b3e442dad42f10334718f488" target='_blank'>
              SPP1+ macrophages in tumor immunosuppression: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Juanjuan Wang, Ya Wang, Yuqing Liu, Rongcun Yang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Immunology</td>
          <td>1</td>
          <td>6</td>
        </tr>

        <tr id="Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic programmed cell death protein 1 (PD-1) antibodies nivolumab and pembrolizumab significantly improved the survival of patients with melanoma with distant metastasis, prognosis remains poor. PD-1 is not only expressed by αβ T cells but also by γδ T cells, making this numerically minor population of unconventional T cells, whose role in melanoma is still elusive, a target of ICB. Methods Here, we present a detailed γδ T-cell profiling study in late-stage melanoma at single-cell level using mass and polychromatic flow cytometry, T-cell receptor repertoire analyses and immunohistochemistry. Results Our analyses link high frequencies of peripheral Vδ1 T cells before the start of anti-PD-1 therapy to a significantly reduced overall survival. In these patients, the Vδ1 compartment is dominated by a late-differentiated senescent-like phenotype that is presumably unresponsive to therapy. This phenotype is less prevalent at the tumor site and analysis of RNA sequencing data revealed that the abundance of Vδ1 T cells within the tumor was positively associated with survival. Conclusions Our study suggests that Vδ1 T cells are associated with clinical outcomes, with a responsive subset expanding under ICB in patients where such a response remains possible. The observed clinical effects may be supported by the infiltration of these cells into the tumor, where they contribute to cancer immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad77c14a3cfc3aa02688cb2c4360370f794926a0" target='_blank'>
              Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma
              </a>
            </td>
          <td>
            Nicola Herold, Jonas Bochem, Johanna Leyens, Svenja Wingerter, Stephan Forchhammer, Janine Spreuer, M. Deseke, Can Yurttas, Paola Nocerino, Rita Antunes Dos Reis, T. Amaral, N. Wagner, K. Thiel, Daniel Soffel, Kristin Bieber, P. Terheyden, D. Wesch, H. Oberg, Susanne Sebens, Manfred Claassen, Alfred Königsrainer, Claus Garbe, Graham Pawelec, F. Meier, Markus W. Löffler, B. Weide, I. Prinz, S. Ravens, Shahram Kordasti, T. Eigentler, K. Wistuba-Hamprecht
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>61</td>
        </tr>

        <tr id="Immunotherapy has transformed cancer treatments, but the majority of cancer patients would inevitably develop resistance to immunotherapy. Th17 cells play complex but crucial roles in anti-cancer immune response, although their therapeutic potential remains underutilized. Segmented filamentous bacteria (SFB) function as prototypical commensal bacteria that can induce intestinal Th17 cells and impact host immune response. In this study, we investigated how SFB antigen-mediated immune responses modify the tumor microenvironment and enhance anti-tumor efficacy through a coordinated gut–lung immunological axis. We engineered B16F1 melanoma cells to express either the SFB3340 epitope (B16-3340, an I-Ab-restricted epitope derived from SFBNYU_003340 and recognized by 7B8 TCR) or a control vector (B16-MEM) to evaluate SFB antigen effects on tumor immunogenicity. We found that expression of the SFB epitope in cancer cells decreased the number of lung tumor nodules, and SFB colonization further reduced tumor growth in a lung metastasis model. In addition, Th1, Th17, and CD8+ Tc1 cells were all increased in the lungs of the B16-3340 tumor-bearing mice compared with B16-MEM control tumor-bearing mice without triggering a compensatory expansion of immunosuppressive Tregs. Interestingly, SFB triggers systemic metabolic changes and an increase metabolites from aromatic amino acid degradation pathways, providing biochemical evidence for a functional gut–lung conduit, which integrates innate microbial detection with adaptive tumor-specific immunity. Our research provides evidence to further investigate and develop novel cancer immunotherapies that utilize microbial antigens and microbiome modifications to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5429a38be4e5ce2d81f913e703a35d6e85fa2f2" target='_blank'>
              Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity
              </a>
            </td>
          <td>
            Jessica Tzu-Chieh Lee, Soo Ngoi, Brian Deng, Megan Hill, Kai He, Yi Yang, Bei Liu
          </td>
          <td>2025-12-24</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="During the progression of acute myeloid leukemia (AML), extramedullary hematopoiesis (EMH) compensates for impaired bone marrow hematopoiesis. However, the specific cellular dynamics of EMH and its influence on AML progression remain poorly understood. In this study, we identified a substantial expansion of the CD81+ erythroblast subpopulation (CD81+ Erys) in the spleens of AML mice, which promoted AML cell proliferation and reduced survival. Mechanistically, CD81+ Erys secrete elevated levels of macrophage migration-inhibitory factor (MIF), which interacted with the CD74 receptor on AML cells, activating the mTORC1 signaling pathway and upregulating Egln3. Consequently, AML cells cocultured with CD81+ Erys exhibited reprogrammed phospholipid metabolism, characterized by an increased phospholipid-to-lysophospholipid ratio. Modulating this metabolic shift, either by supplementing exogenous lysophospholipids or depleting Egln3 in AML cells, restored the phospholipid balance and mitigated the protumorigenic effects induced by CD81+ Erys. Overall, our findings elucidate the molecular crosstalk between erythroblasts and AML cells, extend our insights into the mechanisms driving AML progression, and suggest potential therapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ddcd58c64a7ed082f251f1c3eec4cbc61b660c5d" target='_blank'>
              Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism
              </a>
            </td>
          <td>
            Yue Li, Jiaxuan Cao, Jingyuan Tong, Peixia Tang, Haoran Chen, Guohuan Sun, Zining Yang, Xiaoru Zhang, Fang Dong, Shangda Yang, Jie Gao, Xiangnan Zhao, Jinfa Ma, Ding Wang, Lei Zhang, Lin Wang, Tao Cheng, Hui Cheng, Lihong Shi
          </td>
          <td>2025-12-15</td>
          <td>The Journal of Clinical Investigation</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed50cf99fb67ea8136c8c566f1253db09fe9441" target='_blank'>
              Modeling anti-tumor immune responses using patient-derived melanoma organoids
              </a>
            </td>
          <td>
            Kamila Kaminska, B. Phung, Jacob Karlström, M. Lauss, K. Harbst, Teresa Svensson, Kristian Pietras, Kari Nielsen, Ana Carneiro, Henrik Ekedahl, K. Isaksson, G. Jönsson
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="In preclinical models, optimum tumor control by radiation therapy incorporates CD8 T cell control of residual cancer cells. Tumor control by these CD8 T cells is negatively regulated by myeloid and T regulatory cell expansions in the tumor following radiation treatment. We demonstrate using ex vivo 3D tumor models and novel in vivo cell tracking models that radiation results in upregulation of the costimulatory molecules CD80 and CD86 on tumor macrophages and on monocytes that enter the tumor following radiation. This regulation of CD80 is not dependent on adjuvant signaling via MyD88 or STING in the myeloid cells. While we would anticipate that CD80 and CD86 would have a positive impact on anti-tumor immunity, we demonstrate that blockade of CD80 and CD86 signaling limits CD4 infiltrates in tumors and prevents the Treg expansion caused by radiation treatment. Importantly, this treatment results in improved tumor control following radiation therapy. These data link the inflammatory activation of myeloid cells in irradiated tumors to the Treg expansion following radiation and ensuing suppression of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b1ce60db011c72d77a0495e2fb83689f7db3d3d" target='_blank'>
              Radiation therapy causes a STING and MyD88-independent upregulation of CD80 and CD86 in macrophages and monocytes that limits tumor control
              </a>
            </td>
          <td>
            Aanchal Preet Kaur, J. Baird, Alejandro F. Alice, Gwen F. Kramer, David J. Friedman, Eva Moran, M. Crittenden, Michael J. Gough
          </td>
          <td>2025-12-19</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Background Acute myeloid leukemia (AML) is characterized by a complex interplay between genomic alterations, aberrant hematopoiesis, and immune evasion. The aryl hydrocarbon receptor (AHR) pathway is a critical player in this phenomenon determining the fate of stem cell differentiation as well as dictating immune cell development and function. Despite this critical connection, little is known about how AHR regulates the immune microenvironment in AML. Methods We performed a retrospective study examining the pre-treatment effect of immune cell numbers (T and NK cells) in the bone marrow and their impact on overall survival in AML patients undergoing 7+3 induction chemotherapy. Utilizing flow cytometry and both bulk and single-cell RNA sequencing of AML patient samples, we characterized the immune signature of blast cells and the influence of AHR on the immune microenvironment. Lastly, we performed functional studies to determine impact of pharmacological and genomic AHR inhibition on NK cell function. Results Higher bone marrow NK cell percentage in ND-AML correlated with poorer OS and expression of HLA-E on leukemic blasts. AHR upregulation was associated with HLA-E expression on blasts and an innate immune resistant signature defined by upregulation of key cytokine pathways, interferon gamma (IFN-g) pathway, and MHC class I/II as well as impaired NK cell profiles. High AHR expression in AML was associated with monocytic maturation and discrepant MHC class I/II profiles. Pre-treatment of blasts with an AHR inhibitor (AHRi) prior to NK cell killing assay downregulated key checkpoint molecules, including HLA-E, and key IFN-g signaling transcription factors (STAT1, IRF1) and led to enhanced NK cell killing among multiple FAB subsets in AML. Conclusion The data support targeting the AHR pathway as a dual tumor intrinsic and immune targeting therapeutic strategy for AML, particularly in combination with NK cellular therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7893eab44f440eeeac15c67dc9e41e9217e3fc7f" target='_blank'>
              The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor
              </a>
            </td>
          <td>
            Jennifer N Saultz, D. Bottomly, Faith Burns, K. Byrd, Yoko Kosaka, Bernhard Alber, Daniel J Chandra, Stephen Kurtz, Guang Fan, A. Kaempf, Nicola Long, Marta Sanchez-Martin, Lei Wang, Karen McGovern, D. S. Kaufman, Shannon K. McWeeney, B. Druker, Jeffrey W. Tyner, Evan F. Lind
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>128</td>
        </tr>

        <tr id="Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are crucial mediators of tumor-induced immunosuppression, while their heterogeneity and spatial dynamics across malignancies remain poorly understood. By integrating single-cell RNA sequencing data from 576 samples across 19 cancer types and spatial transcriptomics data from three distinct malignancies, we identified a PMN-MDSC population. This cell population demonstrated characteristic upregulation of immunosuppressive genes and was associated with poor prognosis across multiple cancer cohorts. Notably, TREM1 was highly expressed in PMN-MDSCs and may mediate immunosuppressive processes. Multiplex immunofluorescence demonstrated that TREM1+ PMN-MDSCs exhibited significantly higher distribution in tumor regions compared to non-tumor tissues. Spatial transcriptomics analysis revealed their co-localization with fibroblasts and exhausted T cells. Moreover, CellChat analysis showed that TREM1+ PMN-MDSCs remodeled the tumor microenvironment through interactions with diverse cellular components. Collectively, our study revealed the conserved immunosuppressive features and spatial interaction networks of TREM1+ PMN-MDSCs from a pan-cancer perspective, highlighting TREM1 as a pivotal therapeutic target to disrupt PMN-MDSC-mediated tumor immune evasion. A pan-cancer analysis reveals TREM1+ PMN-MDSCs as key mediators of immunosuppression by remodeling the tumor microenvironment, highlighting TREM1 as a therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d5174fd91c2ae4f071c06cfa6c978a0e63d85760" target='_blank'>
              Pan-cancer analysis reveals TREM1+ PMN-MDSCs as critical regulators of immune suppression and tumor microenvironment remodeling
              </a>
            </td>
          <td>
            Yangjie Cai, Shanhang Li, Hening Li, Zhuan Zou, Xinda Zheng, Haijun Tang, Mingxiu Yang, Pintian Wang, Weizhen Wu, Hongcai Teng, Kai Luo, Xinyu Huang, Wenyu Feng, Shijie Liao, Juliang He, Yun Liu
          </td>
          <td>2025-12-18</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Sepsis remains a Major global health burden, accounting for an estimated 11 million deaths annually, and is characterized by a profoundly dysregulated host immune response to infection. Despite its significant morbidity and mortality, the immunopathogenesis of sepsis—particularly within underrepresented populations—remains inadequately understood. Here we report distinct immunological signatures associated with clinical outcomes among Vietnamese septic patients. To our knowledge, this represents the first comprehensive investigation of both cellular and cytokine immune parameters in the sepsis population. Our findings demonstrate that survivors of sepsis exhibited a higher proportion of circulating B cells, whereas non-survivors showed increased activation of T and natural killer (NK) cells, marked by elevated expression of activation molecules such as CD69 and GITR. There was a notable reduction in B cell numbers, and further phenotypic analysis revealed signs of B cell exhaustion, indicated by increased CD21low expression, as well as depletion of both memory and naïve B cell subsets. Collectively, these results establish compromised humoral immunity in septic patients. T cells in septic patients displayed a skewing toward effector memory phenotypes, and NK cells demonstrated impaired cytotoxic potential, as evidenced by decreased expression of key the key activating receptors including NKG2D and DNAM-1. Concurrent cytokine profiling revealed significantly elevated concentrations of both pro- and anti-inflammatory mediators in septic patients. A significantly diminished percentage of CD8+CD45RA+CD197⁻ T cells, alongside markedly elevated interleukin-6 (IL-6) levels, was observed in non-survivors, strongly supporting their role as key prognostic biomarkers for predicting sepsis-related mortality. Interestingly, tumor necrosis factor-alpha (TNF-α) levels did not significantly differ between those who survived and those who did not, a result that diverges from some prior reports and highlights the possibility of population-specific immunological nuances.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d9ba93ec66c35e90540391732ef84f8ac8a5d76" target='_blank'>
              Molecular analysis of immune cell subsets and cytokine profiles in septic Vietnamese patients
              </a>
            </td>
          <td>
            Chien Dinh Huynh, Phuong Minh Nguyen, Trung Dinh Ngo, Hung Xuan Nguyen, Tu Dac Nguyen, Hien Thi Mai, Huyen Thi Le, Duy Hoang, Linh Khac Le, Quan Khoi Nguyen, Hoang Viet Nguyen, Keith W. Kelley
          </td>
          <td>2025-12-05</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Although significant progress has been made in immune-targeted therapy for multiple myeloma (MM), it remains highly recurrent and incurable. Consequently, there is still an urgent need to develop more effective strategies against the recurrent and refractory tumor subsets. LILRB4, which is expressed on MM and Myeloid-Derived Suppressor Cells (MDSC) and plays an important role in promoting tumor progression and regulating the immuno-suppressive microenvironment. Therefore, it is an attractive target for MM treatment. We developed a bispecific natural killer cell engager (BiKE), LILRB4/CD16A, to mediate NK cell-mediated lysis of MM cells. BiKE combined with CD16A strongly activated NK cells derived from human peripheral blood, and at the same time, BiKE bridged tumor cells to NK cells and promoted NK cytotoxicity, showing significant antitumor activity against LILRB4-high MM cells. NK cell cytotoxicity was further enhanced by the combined stimulation of innate immunity using cGAS-STING signaling agonists. In xenograft MM tumor models in immunodeficient mice, NK cells derived from human peripheral blood and expanded in vitro were combined with BiKE and cGAS-STING signaling agonists, demonstrating effective anti-tumor activity and inhibition of MM cell proliferation. Collectively, the combination of cGAS-STING agonists and LILRB4-targeting NK cell engagers offers a promising approach for treating relapsed/refractory MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ca8c9caa017ad4c2d23fdf37525626e42f6b4d1b" target='_blank'>
              The combination of LILRB4-targeting NK cell engagers and cGAS–STING agonists enhances the anti–multiple myeloma immune activity of NK cells
              </a>
            </td>
          <td>
            Meng Li, Yuwei Zhao, Lizhou Zhao, Xue Chen, Jianxun Kang, Aiping Tong, Chen Yang, Ping Wang, Minjun Yang, Kejiang Wang, Jialiang Gao, Ying Li, Xuemei Fu
          </td>
          <td>2025-12-19</td>
          <td>PLOS One</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Vaccination is the preferred strategy for preventing infections such as influenza in elderly individuals; however, its efficacy is often suboptimal due in part to age-related declines in immune function. In this study, we discovered that the infusion of mesenchymal stromal cells (MSCs) restored defects in the splenic stromal cell network and lymphocyte architecture in aged mice while also increasing specific antibody levels following vaccine immunization. This significantly protected aging mice from influenza infection. Mechanistically, the delivered MSCs localized in the splenic marginal zones, where they positioned themselves near marginal reticular cells (MRCs) and stimulated MRC proliferation, partially through the action of vascular endothelial growth factor A (VEGFA). This MSC‒MRC interaction orchestrated the reconstruction of the stromal network, thereby restoring lymphocyte homeostasis and germinal center reactions. Importantly, the MSC-mediated enhancement of the vaccine response was further validated in aged cynomolgus monkeys. Collectively, our findings provide new insights into the application of MSCs in addressing age-related immune decline and highlight splenic MRCs as critical therapeutic targets.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a624280664a2bdb72020df258084df4d8fd37533" target='_blank'>
              Mesenchymal stromal cells counteract with age-related immune decline and enhance vaccine efficacy by modulating endogenous splenic marginal reticular cells in elderly models
              </a>
            </td>
          <td>
            Jialing Liu, Zhishan Li, Qiong Ke, Qiuli Liu, Yueming Sun, Rong Yan, Huolin Ye, Yuxi Zhang, Jie Ren, Hong Chen, Gang Li, Tao Wang, Xubo Li, Yuzhe Wang, Yuan Qiu, Xiaoran Zhang, Zhenxiao Yao, Rui Fang, Jianqi Feng, Lili Chen, Weiqiang Li, Xiaoyong Chen, Andy Peng Xiang
          </td>
          <td>2026-01-09</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3b3b7c8b4c7d00c21b220678d75895ad9433bf9" target='_blank'>
              BATF3 controls the homeostatic maintenance and function of innate-like γδ T cells
              </a>
            </td>
          <td>
            P. Papotto, Elena Hernández-García, Ángela Zarco-Cuadrillero, Ana Redondo-Urzainqui, JE. Parkinson, R. Pinheiro, Andrew S. MacDonald, D. Sancho, B. Silva‐Santos, J. Allen, A. Hayday, S. Iborra, Miguel Muñoz-Ruiz
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="Infection-associated thymic atrophy is common and results in T-cell imbalance and immune dysfunction. Severe dengue, caused by infection with the dengue virus (DV), is associated with perturbation of T cell functions. However, it is unclear whether perturbation of T cell functions is linked to changes in thymic function during dengue infection. Herein, we employed a dengue virus serotype 2 (DV-2)-infected mouse model and Neonatal Thymic Organ Culture (NTOC) to study the impact of DV-2 infection on thymic function. Further, the contribution of infiltrating immune cells, especially myeloid cells, and reactive oxygen species (ROS) in the thymus on DV-2-induced thymic atrophy was studied by depleting Gr-1 + myeloid cells and quenching ROS in mice. We have demonstrated that DV-2 infection caused a massive thymic atrophy, dominated by a loss of CD4+ CD8+ double-positive (DP) thymocytes, reduction in naïve T cells in blood and spleen, a significant increase in the infiltration of myeloid cells, and a reactive oxygen species (ROS) burst in the thymus. Using Neonatal Thymic Organ Culture (NTOC), we confirmed that DV-2 infection alone cannot induce thymic atrophy. Further, we documented that depletion of Gr-1 + myeloid cells, or quenching of ROS using N-acetylcysteine (NAC) during DV-2 infection, partially protected thymic architecture. This protection of thymus function is also reflected in the thymic interstitial fluid proteome profile, where myeloid cells depletion or NAC treatment in DV-2-infected mice confirmed the reversal of protein expression associated with oxidative stress and neutrophil degranulation pathways within the thymus. Further, managing oxidative stress also influenced cytokine production by T cells in the spleen of infected mice. Thus, our study confirms that thymic atrophy does not depend on viremia level but on the interaction between immune cells and the virus, highlighting the contribution of infiltrating myeloid cells and, thus, ROS in DV-2-associated thymic atrophy. Dengue virus serotypes 2 & 3 (DV-2, DV-3) infection, but not serotype 1 (DV-1), leads to thymic atrophy in an experimental mouse model. Thymic atrophy depends not on the viremia level but on the specific host-virus interaction. Myeloid cells abundance and ROS level affect thymic output in severe dengue. The thymic interstitial fluid (TIF) protein profile reflects the atrophied. and non-involuted thymus status. Myeloid cells depletion or ROS quenching reverses the thymic atrophy-associated proteins in the TIF. ROS inhibition modulates the cytokine expression profile of T cells in the splenocytes of DV-2-infected mice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8942ce52edd462ca76dfcec73d01cf4c11f1f50e" target='_blank'>
              Depletion of myeloid cells in AG129 mice reduces the infection-mediated oxidative stress and restrains dengue virus-induced thymic atrophy
              </a>
            </td>
          <td>
            B. Kusuma, Surender Rawat, Oindrila Saha, Sakshi Nimesh, Srikanth Sadhu, Amit Awasthi, T. K. Maiti, Arup Banerjee
          </td>
          <td>2025-12-06</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9487b7d55d4857b031bd0974fcc9aeac38c92126" target='_blank'>
              Neonatal liver niches program T cell tolerance
              </a>
            </td>
          <td>
            Eva-Lena Stange, T. Nguyen, Dustyn Mendoza, Aiara Lobo Gomes, Marlene Sophia Kohlhepp, Jonas Pes, Shahed Al Bounny, Julian Brueck, Yunus Cetiner, Urs Moerbe, Milas Ugur, Cristina Kalbermatter, Jarrett Lopez-Scarim, Aline Dupont, Susan A. V. Jennings, Julia Heckmann, A. Silva-Sánchez, Solveig Runge, C. Kuppe, Oliver Pabst, Thomas Clavel, Dorothee Viemann, S. Rosshart, V. Cerovic, S. C. Ganal-Vonarburg, Adrien Guillot, E. Billerbeck, Mathias W. Hornef, N. Torow
          </td>
          <td>2026-01-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Extracellular vesicles (EVs) are central mediators of intercellular communication in both healthy and malignant states. In normal B lymphocyte (cell) biology, EVs derived from B cells, mast cells, T cells, and mesenchymal stromal cells regulate maturation, antigen presentation, and activation. B cell-derived EVs can either suppress excessive activation to maintain immune homeostasis or amplify responses during an active immune response. Modulation of these responses often occurs via phosphoinositide 3-kinase signaling pathways in recipient cells. In B cell malignancies, such as leukemias, lymphomas, and multiple myeloma, EVs play pivotal roles in disease progression and therapy resistance. Tumor- and stromal-derived EVs can transfer pro-survival proteins, regulatory RNAs, and drug-resistance factors to directly promote tumor progression. In addition, EVs can shape the tumor microenvironment to indirectly promote tumor progression through macrophage polarization, stromal cell reprogramming, and suppression of anti-tumor immunity. Conversely, under certain conditions, B cell EVs can enhance immune surveillance by stimulating T cells and presenting antigen, highlighting their dual potential in cancer biology. Clinically, B cell-derived EVs represent promising liquid biopsy biomarkers: increases in EV abundance, expression of surface antigens, altered protein cargo, and distinct RNA signatures have been associated with disease stage, treatment response, and patient outcomes. Despite this potential, variability in EV isolation and analysis methods remains a barrier to clinical translation. Moving forward, identifying robust biomarker signatures across platforms and clarifying mechanisms of cargo selection and EV uptake will be critical for advancing diagnostic and therapeutic applications. Overall, B cell-derived EVs act as contextual regulators of immune function and malignancy, positioning them as both modulators of disease progression and promising clinical tools.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62930a7e9c707674957a1f9402a815a0e545b47b" target='_blank'>
              Extracellular vesicles in malignant and normal B lymphocyte growth and development
              </a>
            </td>
          <td>
            Kaitlyn E. Mayne, Rashid Jafardoust, Hong-Dien Phan, S. L. Christian
          </td>
          <td>2025-12-10</td>
          <td>Extracellular Vesicles and Circulating Nucleic Acids</td>
          <td>1</td>
          <td>19</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dc6a28b4224c2b2503480a6b2e0edc6bbd8d9c3" target='_blank'>
              Innate antiviral readiness drives the expansion of protective T stem cell memory against influenza
              </a>
            </td>
          <td>
            Ivan Tomic, David J Ahern, J. Tomalka, Alba Escalera, T. Aydillo, Matthew D. Pauly, Nadine G Rouphael, S. Lakdawala, Naseem Sadek, E. Clutterbuck, Nisha Singh, P. Aley, H. Robinson, S. Marinou, Stephanie Hao, Matthew Fish, Helder Nakaya, Claudia Monaco, Adolfo García-Sastre, Andrew J Pollard, Adriana Tomic
          </td>
          <td>2025-12-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Although most immunotherapy research focuses on T cells, increasing evidence highlights the significant role of tumor-infiltrating B lymphocytes (TIL-Bs) in cancer therapy. CSDE1 has been implicated in various cancers and immune responses. This study investigates the role of CSDE1 in lung cancer progression and its impact on the tumor immune microenvironment. We found that CSDE1 promotes lung cancer progression in vivo but not in vitro. Using the tumor-bearing mice model with Csde1 knockout, we demonstrated that Csde1 deletion significantly inhibited tumor growth. Single-cell RNA sequencing revealed that Csde1 knockout reshaped the tumor immune microenvironment, particularly by significantly increasing TIL-B levels, a finding confirmed by flow cytometry and immunofluorescence. Moreover, Csde1 knockout enhanced B-cell-mediated humoral immunity. Notably, depleting B cells in Csde1 knockout mice reversed the inhibitory effect of Csde1 deletion on tumor progression, underscoring the critical role of B cells in this process. These findings suggest that CSDE1 facilitates tumor progression by modulating TIL-Bs and the broader immune microenvironment. This study provides a new potential target and valuable insights into tumor immunotherapy, emphasizing the importance of B cells in cancer treatment strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c42094f34aada269cfe9f93f39068d0d4f8803c9" target='_blank'>
              CSDE1 depletion inhibits tumor progression through enhancing B-cell infiltration in NSCLC
              </a>
            </td>
          <td>
            Wanting Li, Shijian Xiang, Ke Liu, Yang Wang, Qiuqi Li, Qianying Ouyang, Yan Zhan, Bing Yu, Hui Chen, Bingchen Ge, Jiajia Cui, J. Yin, Aoxiang Guo
          </td>
          <td>2025-12-06</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/df66cae290474308d3bd343d797357a5e58b1777" target='_blank'>
              Embryonic lympho-epithelial cell interactions play an essential role in the establishment of adult T cell tolerance
              </a>
            </td>
          <td>
            G. Nogueira, A. Chervova, F. Soares-da-Silva, A. Sergé, M. Irla, Cabe C. Moraes, A. Gaudin, P. Ferreirinha, A. Bandeira, N. L. Alves, P. Pereira, A. Cumano
          </td>
          <td>2026-01-19</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Background The spatial organization of intratumoral microbiota and its metabolic impact on immunotherapy response in colorectal cancer (CRC) is unclear, limiting targeted interventions. Methods We integrated single-cell RNA-seq, spatial transcriptomics, and microbial multi-omics from a discovery cohort of 23 treatment-naïve CRC patients. Findings were validated in an independent validation cohort from The Cancer Genome Atlas (TCGA-CRC, n = 159). Results Spatial depletion of Streptococcus and Acetivibrio in tumor niches disrupts butyrate-histone deacetylase (HDAC) signaling, leading to programmed cell death 1 (PDCD1) hyperacetylation and CD8+ T-cell exhaustion. The Colorectal Cancer Microbiome Score (CMS) may serve as a predictive biomarker for immunotherapy response and HDAC inhibitor-based combination therapy. We developed the CMS, a spatial biomarker that stratifies patients by microbial-metabolic dysfunction, predicting immunotherapy resistance (e.g., higher tumor immune dysfunction and exclusion (TIDE) scores; p < 0.01) and guiding combinatorial HDAC inhibition for CMS-defined subgroups. In silico fecal microbiota transplantation (FMT) validated CMS as an actionable target for microbiota modulation. Butyrate supplementation in vitro restored HDAC activity and reduced PD-1 expression on CD8+ T cells, validating the proposed mechanism. Conclusion Our study unveils a spatially defined, microbiome-driven metabolic niche that epigenetically programs CD8+ T-cell exhaustion via the butyrate-HDAC axis, revealing a targetable mechanism to overcome immunotherapy resistance in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05e76f003e01e2ed69ff57c86f85148cdc3bca8a" target='_blank'>
              Spatial microbiome-metabolic crosstalk drives CD8+ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer
              </a>
            </td>
          <td>
            Xiaoyang Chen, Yinxu Zhang, Guangyu Zhang, Dai Wang, Linhua Dou, Yuxi Wang, Zining Huang, Xiaomei Liu
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Microbiology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Dysfunctional microglia contribute to the pathology of numerous neurological diseases. Depletion of harmful microglia and repopulation with healthy progenitors represents a new therapeutic option for neurodegenerative diseases with an urgent need for effective treatments. However, repopulation with patient-derived progenitors could result in similar dysfunction over time. We therefore propose obtaining microglia-like cells (MLCs) derived from healthy donors for allogeneic transplantation. We hypothesize that the immunosuppressive phenotype of MLCs, combined with the brain´s high immune tolerance, would enable effective engraftment. Additionally, the allogeneic origin of MLCs may increase immune tolerance, with additional therapeutic outcomes, particularly in multiple sclerosis (MS). MLCs were generated from MHC-mismatched mouse strains in vitro and exposed to IL-10/IL-4/TGF-β or LPS/IFN-γ to induce specific immunophenotypes. Phagocytosis and T cell proliferation assays assessed MLC responses to pathogenic insults that could arise in autoimmune contexts. Microglial depletion was achieved using Cx3cr1CreER/−R26DTA/− mice or PLX3397 treatment. A protocol administering MLCs directly into the brain via the intracisterna magna was optimized to facilitate repopulation of the microglial niche. Repopulation with MHC-mismatched IL-10/IL-4/TGF-β-polarized MLCs was tested in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, with immune profiling of cellular populations conducted using flow cytometry. BALB/c- and C3H-derived MLCs developed more pronounced anti-inflammatory profiles than did C57BL/6 MLCs, and promoted tolerogenic phenotypes when encountering MHC-mismatched C57BL/6 T cells. In vivo experiments demonstrated a partial repopulation of an emptied microglia-niche by pre-differentiated MLCs administered intracisternally (i.c) into the CNS. The adoptive transfer of MHC-mismatched MLCs led to enhanced immune tolerance mechanisms and the amelioration of disease progression in the EAE mouse model. Our findings support the therapeutic potential of anti-inflammatory MHC-mismatched MLCs in promoting immune tolerance within autoimmune neuropathologies. Specifically, disease progression was attenuated and tolerogenic mechanisms were activated in the MS mouse model. While a polarization protocol towards an anti-inflammatory phenotype confers MLCs with beneficial features in a pro-inflammatory disease context, the MHC-mismatch interaction within the host´s CNS promotes additional tolerogenic processes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7a7c159393bd71a2aabacfa48a7c4768becbc016" target='_blank'>
              Allogeneic MHC-mismatched microglia-like cell replacement as a therapeutic approach for multiple sclerosis
              </a>
            </td>
          <td>
            Irene Benito-Cuesta, Jin-Hong Min, Yuxi Guo, G. Virgilio, Valerie Suerth, Stefan Bencina, Paula Trigo-Alonso, Keying Zhu, Shin-Yu Kung, Majid Pahlevan Kakhki, Heela Sarlus, Robert Harris
          </td>
          <td>2026-01-08</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c884624194df8c0680f4019f2ac1093daf979a9b" target='_blank'>
              Macrophage immunosenescence prolongs intraocular inflammation in aged mice via impaired induction of regulatory T cells
              </a>
            </td>
          <td>
            Taku Yamamoto, Keitaro Hase, Joseph B. Lin, Shinobu Yamaguchi, Norihiko Misawa, Jiayi Li, Kenta Kato, Ryo Terao, Brian S. Sohn, Daniel Du, Mitsukuni Yoshida, Charles W Pfeifer, Tae Jun Lee, Jason J. Colasanti, A. Santeford, James T. Walsh, R. Apte
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/265e958113f433b5dea05d742ab1ff7740228ea8" target='_blank'>
              BET bromodomain inhibition potentiates antitumor activity of tumor-associated macrophages and enhances anti-CD47 immunotherapy in triple-negative breast cancer
              </a>
            </td>
          <td>
            Fuxing Mei, Delin Li, Nannan Zhu, Tao Zhu, Han Xie, Yue Liu, Lei Chen, Xiao Zhang, Wei Ji
          </td>
          <td>2026-01-01</td>
          <td>Apoptosis</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Autoimmune regulator (Aire) orchestrates the presentation of self-antigens to developing thymocytes, playing a key role in central tolerance. However, it remains unclear how Aire deficiency influences immune cell development and function. Recent studies show that Aire-expressing thymic epithelial cells produce type I and III interferons, but how impaired IFN signalling from Aire deficiency contributes to immune dysregulation remains unclear. Single-cell RNA sequencing was used to profile immune cells from Aire-deficient and wild-type mice across thymus, bone marrow, and lymph nodes. In the thymus, thymocytes at late maturation stages, non-conventional T cells, myeloid cells, immature Ccl21+ mTECs and cTECs had reduced expression of type I interferon-stimulated genes in the absence of Aire. In contrast, interferon-stimulated gene expression in bone marrow immune cells appeared independent of Aire. These findings support a role for Aire in thymic interferon production and highlight type I IFNs’ influence on transcriptomes of developing immune cells. Single cell RNA sequencing reveals reduced expression of type I interferon-stimulated genes in late stage thymocytes and thymic epithelial cells when Aire is deficient, suggesting a role for Aire in thymic interferon production.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f56bfeb46496a9aad0771517571da08f962e5b04" target='_blank'>
              Aire-dependent interferon signalling shapes thymocyte maturation and central tolerance in mice
              </a>
            </td>
          <td>
            Adrianna Jebrzycka, L. Breivik, David Dolan, Yael Goldfarb, Jakub Abramson, Anette S. B. Wolff, Eystein S Husebye, Anagha Joshi, B. Oftedal
          </td>
          <td>2025-12-09</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Despite the promise of immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC), mediators of response are poorly understood. To address this, here we analyzed oropharyngeal HNSCCs treated with neoadjuvant durvalumab (anti-PDL1) alone or in combination with tremelimumab (anti-CTLA4) from the CIAO clinical trial (NCT03144778). We found that only the total abundance of intratumoral bacteria predicted ICB response, which was validated in multiple independent cohorts. High intratumoral bacteria abundance was associated with an immunosuppressive tumor microenvironment, characterized by an accumulation of neutrophils coupled with depletion of T cells and other adaptive immune cells. Experimental elevation or reduction in intratumoral bacteria abundance in orthotopic models of HNSCC in female mice recapitulated immunological associations observed in participant tumors. Increasing intratumoral bacteria abundance was sufficient to induce resistance to anti-PDL1 ICB, irrespective of bacterial species tested. Together, these findings demonstrate that high intratumoral bacteria abundance is a key suppressor of antitumor immunity and promotes immunotherapy resistance. McGrail and colleagues report that high intratumoral bacteria abundance is associated with an immunosuppressive microenvironment and resistance to immune checkpoint blockade in head and neck squamous cell carcinoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ff6bc6b862a40ed54d2a498d13ad74d8fec00fa9" target='_blank'>
              Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma
              </a>
            </td>
          <td>
            Natalie L. Silver, Jin Dai, Travis D. Kerr, Jessica Altemus, Rekha Garg, Hannah Simmons, Tyler J. Alban, Laura Noȅl-Romas, Vladimir Makarov, David J. H. Shih, Shweth V. Kumar, Akeem Santos, Rehan Akbani, Adam Burgener, Mohammed Dwidar, Neil D. Gross, Andrew G Sikora, Elias J Sayour, Apollo R Stacy, Christian Jobin, Timothy A. Chan, R. Ferrarotto, Daniel J. McGrail
          </td>
          <td>2026-01-01</td>
          <td>Nature Cancer</td>
          <td>3</td>
          <td>75</td>
        </tr>

        <tr id="During neuroinflammation, CD11c+CD11b+ myeloid cells accumulate at the cribriform plate, a key cerebrospinal fluid (CSF) and antigen outflow site in mice. At this site, podoplanin (PDPN)-expressing cells, including lymphatic vessels and meningeal layers, expand to create a distinct drainage microenvironment. In this study we sought to characterize myeloid cells which populate this region using a mouse model of neuroinflammation, experimental autoimmune encephalomyelitis (EAE). Utilizing a combination of immunohistochemistry, flow cytometry, and scRNAseq, we report that macrophages and dendritic cells (DCs) from this region display unique expressional signatures related to tolerance, cell death, and reduced inflammatory profile. Together this data supports that myeloid retention at the cribriform plate and olfactory bulb meninges promotes a local immunosuppressive environment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e549a88421337952511a13714c86e5c4e653df94" target='_blank'>
              Cribriform Plate Microenvironment Assembles a Suppressive Myeloid Network during EAE-induced Neuroinflammation
              </a>
            </td>
          <td>
            C. Laaker, Martin Hsu, Andy Madrid, Jenna M Port, Sophia M. Vrba, Melinda Herbath, Cameron M Baenen, Mohan Kumar, Thanthrige Thiunuwan Priyathilaka, Matyas Sandor, Z. Fabry
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f495b98f4c0f97cebf2e9a7ca186d0b80891a93" target='_blank'>
              CD160+ intraepithelial lymphocytes and CCRL2+ macrophages drive differential repair in cardiac and liver injuries
              </a>
            </td>
          <td>
            Kang Sun, Jia-xin Dong, Xin-tao Mao, Wen-ping Li, Yu Wang, Xiao-Mei Teng, Dan-Dan Liu, Bing Yang, Jiang-yan Zhong, Zhenya Shen, Yi-Yuan Li, Jin Jin
          </td>
          <td>2025-12-24</td>
          <td>Cellular & Molecular Immunology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and involving both innate and adaptive immunity. Dendritic cells (DCs) play a crucial role in linking innate and adaptive immune responses, and therefore they deeply participate in the initiation and development of SLE. Deleted in breast cancer‐1 (DBC1) is a negative regulator of deacetylase SIRT1 (the mammalian homolog of silent information regulator 1) and involves in tissue inflammation. Roles of DBC1 in immune cells remain largely unknown, especially in DCs. We here identified that DBC1 is upregulated in activated DCs, and DBC1 deficiency weakened DC maturation while promoting B7‐H1 expression. DC conditional knockout of DBC1 ameliorated murine lupus pathology by decreasing autoantibodies, complement C3, plasma cells, and follicular T helper (Tfh) cells, whereas promoting regulatory T‐cell development. We further demonstrated that Dbc1−/− DC lowered proinflammatory cytokine secretion such as IL‐4, IL‐6, and IL‐12, and reduced signal transducer and activator of transcription 5 (STAT5) signal. With STAT5 overexpression, the protective effect by Dbc1−/− DC was abolished in the lupus model. Therefore, targeting the DBC1‐STAT5 axis in DCs diversifies the therapeutic strategies for SLE.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d1facac1c1eb12f3330a72458012f015712e82b1" target='_blank'>
              Regulation and Mechanism of Deleted in Breast Cancer‐1 on Dendritic Cell Function in Systemic Lupus Erythematosus
              </a>
            </td>
          <td>
            Z X Xiao, Rongzhen Liang, Yan Liu, Changyuan Huang, Qiannan Fang, Xiaojiang Hu, Julie Wang, Nancy Olsen, Dehua Wu, S. Zheng
          </td>
          <td>2026-01-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Although chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable therapeutic effects in treating hematologic cancers, its effectiveness in solid tumors remains significantly restricted. the primary reason is the immunosuppression mediated by the tumor microenvironment (TME), which leads to rapid exhaustion of infiltrating CAR-T cells. To enhance CAR-T cell efficacy against solid tumors, we pursued improvements in two aspects. First, we constructed fibroblast activation protein (FAP)-directed CAR-T cells to enhance their anti-CAF capability within the TME, thereby alleviating the immunosuppressive barrier. Second, we utilized IL-15, an efficient activator of CAR-T cells that inhibits activation-induced cell death, restores effector functions, and increases the proportion of the T stem cell memory (TSCM) subpopulation. In this study, we report the generation of FAP/IL-15 CAR-T cells, which target FAP and autonomously synthesize and secrete IL-15. Our data demonstrate that treatment with FAP/IL-15 CAR-T cells exhibited stronger activation characteristics in a FAP antigen-dependent manner, selectively targeting CAFs within the solid TME. Moreover, endogenous IL-15 secretion enabled CAR-T cells to adopt a TSCM-like phenotype with enhanced memory characteristics, thus improving cell survival, proliferation, activation, and therapeutic efficacy against solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00800864326cc50fb8931bc76773d901179d7f53" target='_blank'>
              A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a TSCM subset in the TME
              </a>
            </td>
          <td>
            Yanyang Pang, Leiyuan Chen, Qinghui Sun, Na He, Zhiheng Lai, Xi Wang, Zhihao Xie, Wenli Yang, Wu Wang
          </td>
          <td>2025-12-27</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Bacillus Calmette-Guérin (BCG) remains the standard treatment for non-muscle invasive bladder cancer (NMIBC), yet approximately 30% of patients fail to respond. To enhance therapeutic efficacy, we developed rBCG-LTAK63, a recombinant BCG strain, as a novel immunotherapeutic candidate. In vitro, rBCG outperformed BCG in MB49 cell/splenocyte co-cultures by enhancing T cell activation and improving spheroid growth control. In vivo, rBCG demonstrated superior antitumor efficacy, significantly reducing the growth of subcutaneously implanted MB49 tumor cells. Immune profiling revealed that rBCG uniquely promoted systemic activation of both CD4⁺ and CD8⁺ T cells, alongside stronger activation of NK and dendritic cells in the spleen. Within the tumor microenvironment, rBCG increased immune cell infiltration, enhanced activation of CD8⁺ T cells and dendritic cells, and decreased the frequency of regulatory T cells, fostering a less immunosuppressive environment. Unlike parental BCG, rBCG-LTAK63 sustained a potent immunostimulatory profile, marked by robust activation of dendritic cells and effector T cells. Similar results were also observed in the orthotopic model, suggesting a translational potential of rBCG-LTAK63. Collectively, our findings demonstrate that rBCG outperforms conventional BCG and represents a promising strategy for improving NMIBC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e4e9e8703be24629b575d1f1ca3d777b67f2abfa" target='_blank'>
              rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model
              </a>
            </td>
          <td>
            Matheus Ferreira de Almeida, Bruna Gennari Rosa, Daniela Delechiave, Lucas Francisco Annequin, Lázaro M Marques-Neto, M. Trentini, Johanna Christine van Vliet, Isabelle Carolina Cotrim Gozzi, Ana Carolina de Oliveira Carvalho, Dunia Rodriguez, L. R. Pereira, G. Gaboardi, Luís Carlos de Souza Ferreira, Luciana Cezar de Cerqueira Leite, Ana Carolina Ramos Moreno
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Immune dysregulation is a hallmark of human immunodeficiency virus (HIV) infection, characterized by persistent immune activation and systemic inflammation that drive T cell exhaustion and senescence, contributing to disease progression and non-AIDS comorbidities, most notably tuberculosis (TB). With rising HIV prevalence, the incidence of HIV-TB co-infection continues to rise, highlighting the need to understand their immunopathological interplay. This narrative review aims to examine the association between immune dysregulation in HIV-TB co-infection, with a focus on cytokine profiles and immunological biomarkers. Relevant literature was retrieved from multiple databases, with evidence demonstrating differential expression of cytokines—IL-17A, IFN-γ, TNF, IL-10, IL-6, IL-4, and IL-2—and T cell activation markers, such as CD38 and HLA-DR on CD4+ T cells in latent and active TB among HIV-infected individuals. These immune mediators are consistently co-expressed at higher levels in active TB compared to latent TB, suggesting heightened immune activation of both innate and adaptive immune responses in HIV-TB co-infection. However, these findings are largely based on observational data, and the precise mechanism by which cytokine and T cell biomarker dysregulation contributes to HIV-TB pathogenesis remains incompletely understood, underscoring the need for larger, mechanistic studies to address these gaps in the pathogenic pathway.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f8710218f39c3691e0e971a9da488e3a8f2ec29a" target='_blank'>
              Immune Dysregulation in HIV-TB Co-Infection: Role of Cytokines and T Cell Biomarkers—A Narrative Review
              </a>
            </td>
          <td>
            C. Gunawan, Anton Sumarpo, A. Indrati
          </td>
          <td>2026-01-01</td>
          <td>Pathogens</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to chimeric antigen receptor (CAR)-T cell therapy. Insufficient T cell infiltration, a highly immunosuppressive microenvironment, and antigen loss pose major challenges for CAR-T cell therapy. Methods We investigated therapeutic synergies of synthetic 5′-triphosphate RNA (3p-RNA), an agonist of the cytoplasmic double-stranded RNA sensor Retinoic Acid Inducible Gene I (RIG-I), and CAR-T cell therapy using syngeneic and human xenograft PDAC models. Tumor growth, chemokine secretion, immune-cell composition, CAR-T persistence, and endogenous T cell responses were assessed by flow cytometry, multiplex cytokine arrays, Enzyme-linked Immunospot (ELISpot), and vaccination-challenge. Results 3p-RNA provoked rapid type I interferon accompanied with chemokine ligand CCL5 and CXCL9/10/11 secretion, creating chemokine gradients that recruited chemokine receptor CCR5+/CXCR3+ CAR-T cells into tumors. RIG-I activation enhanced CAR-T cell proliferation, activity, and CAR-T persistence. Combination therapy eradicated established tumors in 60%–70% of mice, whereas either monotherapy was largely ineffective. Cured animals rejected CAR antigen-negative tumor cell rechallenge, demonstrating antigen-spreading and endogenous T cell responses. Conclusions Intratumoral RIG-I priming reprograms the PDAC microenvironment, transforming a non-responsive cancer into a CAR-T-permissive one, supporting durable, poly-antigenic immunity. These findings position 3p-RNA as a rapid, clinically tractable co-therapy to extend CAR-T efficacy to solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0740cdf905664a78725635003b567ad13fe803cb" target='_blank'>
              RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma
              </a>
            </td>
          <td>
            Anne Marie Senz, B. Cadilha, Julia Teppert, Simone Formisano, Charlotte Marx, T. Lorenzini, D. F. Boehmer, Christine Hoerth, Simon Delahais, S. Endres, P. Duewell, M. Schnurr, S. Kobold, Lars M Koenig
          </td>
          <td>2026-01-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Cancer cells employ diverse strategies to evade immune surveillance and resist therapy, including immune exclusion—a phenomenon where cytotoxic T cells fail to infiltrate the tumor microenvironment (TME), severely limiting immune checkpoint inhibitor (ICI) efficacy. Emerging evidence suggests that platelets, traditionally known for their role in hemostasis, may act as key players within the TME. This review introduces a novel perspective on tumor-infiltrating platelets (TIPs) as potential orchestrators of immune exclusion, linking them to the six Delphi-defined criteria, which were established through international cancer experts based on modified consensus Delphi process: lack of chemotactic factors, immunosuppressive cytokines, specific cancer-associated fibroblast (CAF) subtypes, mechanical barriers, disordered vasculature, and increased T-cell apoptosis. We further explore TIP-mediated contributions to related features, such as epithelial-mesenchymal transition (EMT), M2 macrophage polarization, and CXCL12 signaling, which exacerbate exclusion and promote metastasis. Through integration of mechanistic studies and pan-cancer TCGA analyses, we reveal that TIPs exhibit significant, yet heterogeneous, correlations with immune exclusion features across diverse solid tumors. By elucidating these mechanisms, this review underscores the potential role of TIPs as promising therapeutic targets to dismantle immune barriers, enhance ICI responses, and curb metastasis, advocating for platelet-targeted combinations in future immunotherapy trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9c997ce4b80550d0a9dd461920b0a62532e9689" target='_blank'>
              Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy
              </a>
            </td>
          <td>
            Atefeh Nasir Kansestani, M. Zare, Jun Zhang
          </td>
          <td>2026-01-29</td>
          <td>Cellular Oncology (Dordrecht, Netherlands)</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Triple-negative breast cancer (TNBC) is a highly invasive and refractory subtype of breast cancer. Despite the promise of immune checkpoint blockade (ICB) therapy, response rates remain limited. The immune resistance driven by the tumor microenvironment has not yet been understood entirely, which hinders the personalized precision treatment of TNBC. We integrated single-cell RNA data from 12 cohorts with TNBC and performed a multi-omics analysis combining spatial transcriptomics (ST), bulk RNA sequencing, and multiplex immunofluorescence (mIF) staining to identify immune-resistant subpopulations. Cell-to-cell communication was explored based on NicheNet and CellChat, and the function of CAF was verified by gene knockdown and overexpression in human mammary fibroblasts, followed by co-culture experiments with TNBC cell lines. ST and mIF data were used to analyze and verify cellular co-localization, while deconvolution was used to examine the relationship between two-cell characteristics and immunotherapy or antibody–drug conjugates (ADC) agent benefit. We identified CA9+cancer-associated fibroblasts (CA9+CAF) as a key subset enriched in non-responders to ICB that promotes immune resistance by establishing a hypoxic and immunosuppressive microenvironment via abnormal angiogenesis and glycolysis. ST and mIF analyses revealed a strong co-localization and interaction between CA9+CAF and SPP1+tumor-associated macrophages (SPP1+TAM), forming a stroma-myeloid axis that promotes immune escape through VEGFA/NRP2 axis in co-localization core region compared to the boundary. In vitro experiments demonstrated that the over-expression of CA9 in fibroblasts enhanced the proliferation, invasion, and migration of TNBC cells, while CA9 knockdown inhibited the tumorigenic effects. The high CA9+CAF/SPP1+TAM profile indicated a poor prognosis, reduced effector T cell infiltration, and attenuated response to immunotherapy, may benefit from TROP2, MUC1, and NECTIN4-based ADC agents. The result was validated in TNBC samples treated with neoadjuvant immunotherapy from our center. This study unveils the critical immunosuppressive axis orchestrated by CA9+CAF and SPP1+TAM in TNBC, offering novel insights into the stromal regulatory mechanisms driving immune resistance. The cell-to-cell interaction signature holds promise as predictor of immunotherapy response and potential therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9990df240d9cf9afd4d976bdcb6753a231a07876" target='_blank'>
              CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer
              </a>
            </td>
          <td>
            Qin Ma, Jing Wang, Qian Jiang
          </td>
          <td>2026-01-09</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>1</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a13c6180d1c62c5b4b9f5ea6f97cc1e7fee85670" target='_blank'>
              Antigen presentation requirements for effective cDC1-based cancer immunotherapy
              </a>
            </td>
          <td>
            Josué E. Pineda, Tomoyuki Minowa, Li Shen, Yifan Zhou, Allison M. Dyevoich, B. Patel, Sarah M. Schneider, Sunita Keshari, Akata Saha, Morgan N. Riba, Jing Wang, S. Watowich, Matthew M. Gubin
          </td>
          <td>2026-01-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Tolerogenic dendritic cells (tolDC) are currently in clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The methods for producing therapeutic tolDC vary widely, with little being known about the commonalities and differences of distinct cell products in terms of their regulatory actions on CD4+ T cells. We compared human monocyte-derived tolDC generated with vitamin D3 alone or in combination with dexamethasone. We found marked differences in the surface expression of HLA-DR and immune regulatory molecules, but also found commonalities, e.g. a strongly reduced capacity to produce interleukin-12 and a concomitant decreased ability to induce interferon-γ secretion by allogeneic CD4+ T cells. To gain a deeper understanding of how these tolDC types exert their regulatory effects, we co-cultured them with CD4+ T cells from rheumatoid arthritis patients or healthy controls and analysed the gene expression profile and function of the responding T cells. We found that tolDC generated with vitamin D3 alone, but not in combination with dexamethasone, induced potent cytotoxic activity in the responding CD4+ T cells as demonstrated by an enhanced cytotoxic gene signature, increased levels of intracellular granzyme B, and superior cytotoxic activity towards myeloid and B cells. These data identify cytotoxicity as an atypical CD4+ T helper cell effector function induced by some but not all tolDC types, with implications for their individual clinical applications.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e6376b65c8f61913f7a1c8c2873d5f5d98c5c617" target='_blank'>
              Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells
              </a>
            </td>
          <td>
            Gabrielle Barran, N. Naamane, Abdul Mannan Baru, Amy E Anderson, Jane Falconer, C. Hilkens
          </td>
          <td>2025-12-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="Mesenchymal stem/stromal cells (MSCs) exhibit broad differentiation capability and strong immunoregulatory potential mediated through intercellular communication and the release of diverse paracrine mediators. They represent a promising but still investigational therapeutic approach for managing complications associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). This review provides an updated synthesis of MSC biology, their bidirectional interaction with immune cells, and their functional contribution to the hematopoietic niche. It also evaluates current clinical evidence regarding the therapeutic roles of MSCs and MSC-derived extracellular vesicles (EVs) in acute and chronic graft-versus-host disease (aGVHD/cGVHD), as well as in poor graft function. Mechanistic insights encompass macrophage polarization toward an anti-inflammatory phenotype, inhibition of dendritic cell maturation, enhancement of regulatory T-cell expansion, and modulation of cytokine signaling pathways. Within the bone marrow milieu, MSCs contribute to stromal restoration and angiogenic repair. Recent phase II/III trials in steroid-refractory (SR)-aGVHD have demonstrated overall response rates ranging from 48 to 71%. Efficacy appears particularly enhanced in pediatric patients and with early MSC administration. Across studies, MSC therapy shows a favorable safety profile; however, heterogeneity in response and inconsistent survival outcomes remain notable limitations. For poor graft function, limited prospective studies indicate hematopoietic recovery following third-party MSC infusions, and combination approaches such as co-administration with thrombopoietin receptor agonists are under investigation. MSC-derived EVs emulate many immunomodulatory effects of their parental cells with a potentially safer profile, though clinical validation remains in its infancy. MSC-oriented interventions hold substantial biological and therapeutic promise, offering a favorable safety margin; however, clinical translation is hindered by product variability, suboptimal engraftment and persistence, and inconsistent efficacy across studies. Future directions should emphasize standardized manufacturing and potency assays, biomarker-driven patient and timing selection, optimized conditioning and dosing strategies, and the systematic appraisal of EV-based or genetically modified MSC products through controlled trials.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/73302ce93894dc67dc4c78b9abd8a8e4bdc0a83f" target='_blank'>
              Mesenchymal Stem/Stromal Cells: A Review for Its Use After Allogeneic Hematopoietic Stem Cell Transplantation
              </a>
            </td>
          <td>
            A. Durdu, U. Hatipoglu, Hakan Eminoglu, Turgay Ulaş, M. S. Dal, F. Altuntaş
          </td>
          <td>2026-01-01</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are key drivers of immunosuppressive inflammation in the breast cancer microenvironment, promoting tumor progression and resistance to immune checkpoint blockade. Our previous work identified extracellular IFI16/IFI202 as tumor-derived damage-associated molecular patterns which activate pro-inflammatory signaling in TAMs via Toll-like receptor 2, thereby facilitating immune evasion. In this study, we investigated the therapeutic potential of a monoclonal antibody (mAb) targeting extracellular IFI202 to suppress tumor-promoting inflammation and to restore antitumor immunity. We developed a mAb against IFI202 and evaluated its functions in bone marrow-derived macrophages (BMDMs) using ELISA and western blotting. In vivo efficacy was assessed in the mouse mammary tumor virus-polyoma virus middle T-antigen breast cancer model by treating with IFI202 mAb, or anti–programmed death-1 (PD-1) antibody, as monotherapies or in combination. Tumor volume, metastasis, cytokine levels, and immune cell infiltration were analyzed. Statistical significance was assessed using Mann–Whitney U test or ANOVA, with P < 0.05 considered significant. Conditioned medium obtained from 4T1 breast cancer cells pre-incubated with IFI202 mAb suppressed secretion of IL-6 and TNF-α, and inhibited activation of ERK and NF-κB in BMDMs. Intraperitoneal injection of IFI202 mAb in mouse mammary tumor virus-polyoma middle T-antigen mice significantly reduced tumor growth and lung metastasis. In addition, IL-1β expression, CD8+ T cell infiltration, and levels of granzyme B and interferon-γ, were enhanced in the tumors of IFI202 mAb-treated mice, indicating that IFI202 mAb restored cytotoxic function of CD8+ T-cells. Combination of IFI202 mAb with PD-1 mAb significantly improved antitumor efficacy compared to monotherapy. Neutralization of extracellular IFI202 suppresses TAM-mediated inflammation and supports a tumor microenvironment favorable for T-cell–mediated immunity. In combination with anti–PD-1 therapy, IFI202 mAb further enhances antitumor responses, suggesting a promising and tumor-selective strategy that may help overcome resistance to immune checkpoint blockade in breast cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc369356ec770be8eb843d59aff9a9f3d18ca8d9" target='_blank'>
              IFI16/IFI202 blockade suppresses tumor growth through CD8+ T-cell–mediated immunity
              </a>
            </td>
          <td>
            G. Lim, Na-Lee Ka, Seung-Su Kim, Mi-Ock Lee
          </td>
          <td>2026-01-03</td>
          <td>Breast Cancer Research : BCR</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized tumour therapy by relieving immunosuppression and restoring effector T cell cytotoxicity. However, its clinical utility is constrained by low response rates and acquired resistance. Tumour‐associated neutrophils (TANs), key players in tumour immunoregulation, have emerged as critical mediators of ICB responsiveness and resistance, highlighting the therapeutic potential of combining TAN‐targeted strategies with immune checkpoint inhibitors (ICIs). This review systematically synthesizes current knowledge of neutrophils in ICB resistance from several dimensions: (1) clinical indicators of neutrophils, such as the neutrophil‐to‐lymphocyte ratio (NLR) and tissue TANs abundance, as predictors of ICI response and patients prognosis; (2) multifaceted TAN‐involved resistance mechanisms, including direct T cell inhibition, antigen presentation impairment, function modulation of other immune cells, promotion of tumour angiogenesis, and elevation of tumour mutation burden (TMB); (3) combination therapeutic strategies targeting TAN generation/ exhaustion, recruitment, phenotypic polarization, activation, proangiogenic functions, and neutrophil extracellular traps (NETs), along with progress in related clinical trials. Combinatorial approaches integrating TAN‐targeted therapies with ICIs hold substantial promise for overcoming resistance by reshaping the immune microenvironment. Elucidating neutrophil‐mediated resistance mechanisms and optimizing combination strategies will pave the way for precision tumour immunotherapy. Key points TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI resistance. Numerous clinical trials are evaluating combination therapies targeting neutrophils to enhance immunotherapy efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb8c196a123899665e6475d21ebf9639c6d4e4b" target='_blank'>
              Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance
              </a>
            </td>
          <td>
            Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren
          </td>
          <td>2026-01-01</td>
          <td>Clinical and Translational Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Most colorectal cancers are resistant to immune checkpoint inhibitors due to an immunosuppressive tumor microenvironment. LINC00673, previously classified as a long non-coding RNA, has been implicated in tumor progression, but its role in antitumor immunity remains poorly understood. We used single-cell RNA sequencing, flow cytometry, and functional assays in Linc00673 knockout and wild-type mouse models treated with programmed death 1 (PD-1) blockade to dissect changes in immune landscape and tumor cell behavior. Linc00673 deletion enhanced the efficacy of PD-1 therapy, reducing tumor burden and prolonging survival. KO tumors showed increased infiltration of cytotoxic CD8⁺ T cells, reduced exhaustion, and improved antigen presentation. The tumor microenvironment shifted toward a pro-inflammatory state, with elevated dendritic cell function, reduced immunosuppressive macrophages, and improved T cell–tumor interactions. Linc00673 also promoted tumor cell migration and immune evasion independently of immune cells, suggesting dual tumor-intrinsic and -extrinsic roles. LINC00673 suppresses antitumor immunity and promotes tumor aggressiveness. Its deletion synergizes with PD-1 blockade, revealing a promising therapeutic target to overcome immune resistance in colorectal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb9ef0a9a3f2685b8b34be389ae9c671f82a1666" target='_blank'>
              Single-cell RNA sequencing unveils enhanced antitumor immunity in colorectal cancer with PD-1 blockade and LINC00673 deletion
              </a>
            </td>
          <td>
            Yifei Zhu, Yanxi Yao, Yaxian Wang, Zhibing Qiu, Dingpei Zhou, Huixia Huang, Keji Chen, Qingyang Sun, Jiayu Chen, Yuxue Li, Jianqiang Tang, Dawei Li, Ping Wei
          </td>
          <td>2026-01-03</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf87d56103e47056c8390c382a196ac0a7304b81" target='_blank'>
              Rasal1 impairment unleashes anticancer immunity - a focus on T cells
              </a>
            </td>
          <td>
            Mark E. Issa, Alejandro Schcolnik-Cabrera
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/58ad21f0ac78d5c82537932a36fb92c178b210c8" target='_blank'>
              Microenvironment-specific modulation of macrophage function and tumour progression by ADAMTS1 through Syndecan-4 shedding
              </a>
            </td>
          <td>
            Silvia Redondo-García, R. Caracuel-Peramos, F. J. Rodríguez-Baena, Salvador Muñoz-Mira, Ana García-Muñoz, R. López-Domínguez, María del Carmen Plaza-Calonge, Belén López-Millán, P. Carmona-Sáez, J. C. Rodríguez-Manzaneque
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Immune dysregulation by aberrant chemokine production underlies many diseases. Targeting chemokine receptors with small molecule inverse agonists, antagonists, or neutralizing antibodies has proven challenging due to non-specific effects and receptor upregulation. Locked dimers of chemokines, generated via cysteine substitutions to produce constitutively homodimeric molecules, offer a promising alternative for receptor-specific inhibition. This study evaluates the in vivo safety and dosing of an engineered CCL20 locked dimer (CCL20LD), which selectively binds CCR6 without inducing chemotaxis. The antagonist-like properties of CCL20LD make it a potential therapeutic for CCL20-CCR6 driven diseases. Daily 14-day subcutaneous administration of CCL20LD at doses previously shown to be therapeutically effective in preclinical models of psoriasis or psoriatic arthritis did not result in weight loss or immune suppression. CCL20LD administration had little to no effects on the complete blood count with differential, comprehensive metabolic panel, urinalysis, organ weights, or bone marrow progenitors. At single cell resolution, doses near 7.5mg/kg/day modestly disrupted T cell dependent B cell activation. While splenomegaly due to extramedullary hematopoiesis was observed at the highest tested dose, serum cytokine levels were largely unchanged. Combined, these findings indicate that selective targeting of CCR6 with an engineered CCL20 dimer is broadly safe in vivo, exhibiting a wide therapeutic window with minimal adverse or immunomodulatory effects.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/220a4f0e75021e255061aed1908741e2decb7407" target='_blank'>
              Biosafety assessment of engineered CCL20 locked dimers in vivo
              </a>
            </td>
          <td>
            Donovan Drouillard, Maria Poimenidou, Marissa Davies, Donna McAllister, William R Clarke, Samuel T Hwang, Francis C. Peterson, Brian F Volkman, Michael B Dwinell
          </td>
          <td>2025-12-19</td>
          <td>Cell Biology and Toxicology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a445e1ca795ad9ffc13ccb78dc0d267f18bdd859" target='_blank'>
              Monocyte reprogramming by nociceptors impedes T cell-mediated tumor immunity
              </a>
            </td>
          <td>
            P. Hanč, Adrian Blair, Harold R. Neely, Changwei Peng, I. Mazo, Matthias Mack, Ulrich H. von Andrian
          </td>
          <td>2026-01-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Head and neck squamous cell carcinoma (HNSCC) remains a prevalent epithelial malignancy. Immune-checkpoint inhibitors have reshaped first-line therapy for recurrent/metastatic disease; yet durable benefit is confined to a subset, reflecting myeloid-centric mechanisms—SPP1+ TAM barriers, cDC1/IL-12 insufficiency, and CXCL8–CXCR1/2–driven neutrophil trafficking—distinct from, and complementary to, classical lymphoid exhaustion. In this review we summarize advances from single-cell RNA and ATAC profiling and spatial transcriptomics that resolve macrophage, dendritic-cell and neutrophil programs, and appraise translational opportunities spanning myeloid reprogramming, innate–adaptive combinations and spatial biomarkers. We also discuss enduring challenges—including HPV-status heterogeneity, limited assay standardization and a scarcity of predictive metrics—that temper implementation. By integrating myeloid-informed readouts (e.g., SPP1–TAM burden, cDC1 competency, serum IL-8) with PD-1–based regimens, EGFR-directed antibodies and myeloid checkpoints (CD47–SIRPα, PI3Kγ, CXCR1/2), emerging strategies aim to restore antigen presentation, improve lymphocyte trafficking and remodel tumor–stroma interfaces. Our synthesis provides an appraisal of the evolving landscape of myeloid-informed precision immuno-oncology in HNSCC and outlines pragmatic standards and avenues for clinical translation. We hope these insights will assist researchers and clinicians as they endeavor to implement more effective, individualized regimens.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1e1e89f3eb622744a2cb356a1f52faae72322d69" target='_blank'>
              Myeloid-driven immunosuppression in head and neck cancer: single-cell ATAC/RNA and spatial transcriptomic perspectives
              </a>
            </td>
          <td>
            Rui Luo, Jianzheng Yang, Zimeng Cao, Bing Li
          </td>
          <td>2025-12-18</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/91f5289f8825f96f9b5ed71bde8ad5e7096c4e75" target='_blank'>
              Metabolic Reprogramming of Human Macrophages Drives the Formation of Hybrid M1/M2 Pro-Regenerative Extracellular Vesicles
              </a>
            </td>
          <td>
            C. Gorgun, P. Klavina, C. S. Martins, Cloé Payet, Brenton L. Cavanagh, M. Pultar, M. Hackl, Annie M. Curtis, D. Hoey
          </td>
          <td>2026-01-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Cellular senescence is a heterogeneous phenotype characterized primarily in mesenchymal cells, but the extent to which immune cells differ in their senescence phenotype, or "senotype", is unclear. Here, we applied single-cell approaches alongside both global and cell-specific genetic senolytic mouse models to evaluate the senotype of immune cells in the bone marrow of aging mice. We found that myeloid-lineage cells exhibited the highest expression of p16 and senescence-associated secretory phenotype markers among all immune cell types. In contrast to clearance of p16+ senescent mesenchymal cells, targeted clearance of p16+ myeloid cells in aged mice only had minor effects on age-related bone loss in male mice, with no effects in females. In more detailed analyses, p16+ myeloid cells were only acutely cleared, being repopulated back to basal levels within a short time period. This led to a lack of long-lasting reduction in senescent cell burden, unlike when targeting bone mesenchymal cells. In vitro, myeloid-lineage cells differed markedly from mesenchymal cells in the development of a senescent phenotype. Collectively, our findings indicate that aged bone marrow myeloid cells do not achieve the fully developed senescent phenotype originally described in mesenchymal cells, justifying further characterization of senotypes of immune cells across tissues.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b2537eef02c1e8d746fcb5406a98e0af5e48fdb" target='_blank'>
              Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes.
              </a>
            </td>
          <td>
            Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, J. Farr, David G Monroe, Sundeep Khosla
          </td>
          <td>2026-01-27</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="Non-tuberculous mycobacteria (NTM) infections are difficult to cure completely with current treatments, and no specific drugs are available. However, recent reports have indicated that immune checkpoint inhibitors may effectively treat pulmonary NTM infections. In this study, we investigated the expression of immune checkpoint molecules in macrophages, the host cells of NTM, and assessed their impact on the microenvironment of infected lesions. Bulk-RNA sequencing and western blot analyses revealed that macrophages infected with Mycobacterium avium, an NTM species, exhibited a pro-inflammatory phenotype and increased PD-L1 expression. Additionally, immunostaining of an NTM-infected mouse model and human tissues showed that increased PD-L1 expression in macrophages was associated with decreased T cell infiltration and increased T cell exhaustion (upregulated PD-1 expression) within infected lesions. These findings suggest that NTM infections evade cellular immunity by enhancing PD-L1 expression in macrophages. Therefore, PD-L1 inhibition may be a promising therapeutic strategy against NTM infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ac4e6d1c3dbb18bdbd00c3822726e374ee76d3e" target='_blank'>
              Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape
              </a>
            </td>
          <td>
            H. Yano, Yukio Fujiwara, R. Mito, C. Pan, Katsuhiko Ono, K. Imamura, T. Niidome, Tomohiro Sawa, Masahiro Yamamoto, T. Sakagami, Yoshihiro Komohara
          </td>
          <td>2026-01-09</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d9d9e99d312aee7d3e8959371325610d5ce9af0" target='_blank'>
              MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapy
              </a>
            </td>
          <td>
            Ziwen Zhu, Noah C. Kanis, Anthony E. George, Michael Albdewi, Yingxiang Li, Anzar A. Mujeeb, Brandon L. McClellan, Gurveer Singh, Jialin Liu, W. Al-Holou, J. Heth, Joshua D. Welch, Justin D. Lathia, Pedro Lowenstein, Richard Bucala, Maria G. Castro
          </td>
          <td>2026-01-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) are best known for their outstanding ability to rapidly produce large amounts of type I interferons (IFN‐I), which are key antiviral mediators. However, after their initial IFN‐I burst, the pDC lineage undergoes a number of adaptations that converge on the attenuation of pDC‐derived interferons, ensuring their production remains short‐lived regardless of whether the pathogen is cleared or persists. The convergence of multiple host adaptations that result in reduced pDC numbers and/or function after infection highlights the double‐edged sword nature of pDCs: while they can be beneficial for antiviral defense, they can also drive tissue pathology. In this review, we summarize selected pDC‐lineage adaptations that arise after their initial IFN‐I peak following a viral infection, including compromised pDC development from bone marrow progenitors, fate plasticity that enables pDC conversion into conventional dendritic cells type 2 (cDC2)–like cells, and loss of the pDCs' hallmark capacity to produce IFN‐I. We also provide an overview of the underlying molecular mechanisms contributing to the aforementioned adaptations, discuss potential evolutionary advantages, and highlight future avenues to dissect the fundamental biology of pDC reprogramming with the ultimate goal of leveraging these insights to therapeutically target pDCs in infections and beyond.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cb1bc29ce0ad99c199dec49375e6c4567352274b" target='_blank'>
              Plasmacytoid Dendritic Cell Lineage Adaptations During a Viral Infection
              </a>
            </td>
          <td>
            Carolina Chiale, S. Dallari, Elina I. Zúñiga
          </td>
          <td>2025-12-12</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db7963f819719f5d174aa6e308c691c9523b680d" target='_blank'>
              Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)
              </a>
            </td>
          <td>
            T. Kan, Y. Barsheshet, Tharwat Haj Khalil, B. Brant, T. Voloshin, K. Ben-Meir, Simona Zisman Rosen, M. Giladi, U. Weinberg, Y. Palti
          </td>
          <td>2025-12-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and a dismal prognosis. While immunotherapy has shown promise in treating some solid tumors, the treatment of GBM has been mostly unsuccessful because of a lack of targetable tumor antigens and high tumor heterogeneity. Here, we report RCAN1-4 as a novel tumor antigen derived from alternative splicing induced by the transcription factor C/EBPβ. Both C/EBPβ and RCAN1-4 are highly expressed in GBM and glioma stem cells as mesenchymal subtype hallmarks. We report an immunogenic HLA-A24-specific splicing junction epitope within exon 4 and exon 5 that is unique to RCAN1-4. This epitope was validated for its ability to stimulate T cell responses in HLA-A24+ donors and GBM patients, leading us to identify RCAN1-4-reactive T cell receptors (TCRs) for the construction of TCR-engineered T cells (TCR-T cells). Functional studies of TCR-Ts demonstrated the in vitro and in vivo killing of RCAN1-4pos GBM tumor cells, highlighting its potential as an immunotherapeutic target in mesenchymal GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9431f57db16fa14c7bf510b22de1e580e92e77" target='_blank'>
              C/EBPβ-induced alternative splicing of RCAN1 generates a potent TCR-T target in mesenchymal glioblastoma
              </a>
            </td>
          <td>
            Zujian Xiong, Qinglin Kong, Bhuvi Chagantipati, Amelia L Stepniak, Ambika P Jaswal, Chaim T Sneiderman, Yuanyuan Han, Sydney A Jackson, Rebecca A Raphael, Wei Zhang, Muzi Li, Yapeng Chao, Bin Qin, Zeynep Dulkadir, Lance Schwegman, Yihao Zhang, Chloe R Kuminkoski, Megan A Mahlke, Poulomi Nath, Baoli Hu, Pascal O. Zinn, M. Mantica, S. Agnihotri, Yael Nechemia-Arbely, Ian F. Pollack, L.H. Rigatti, Thomas G. Forsthuber, Xuejun Li, Itay Raphael, G. Kohanbash
          </td>
          <td>2025-12-23</td>
          <td>Cellular and Molecular Immunology</td>
          <td>1</td>
          <td>18</td>
        </tr>

        <tr id="Terminally exhausted CD8+ T cells (Ttex) are emerging as clinically relevant immune subsets across solid tumors, marked by sustained inhibitory receptor expression, loss of TCF1, and limited proliferative capacity. Once considered functionally inert, Ttex are now recognized for their residual cytotoxic potential and strong associations with tumor immunogenicity, including microsatellite instability (MSI), high tumor mutational burden (TMB), and neoantigen load. Importantly, the prognostic significance of Ttex is highly tumor-context-dependent, shaped by stromal architecture, mutational burden, and progenitor Tpex availability. This review examines the biology, spatial localization, and prognostic value of Ttex, highlighting the Ttex/CD8+ ratio as a promising biomarker in cancers such as colorectal, lung, and esophageal carcinoma. We summarize recent advances in multiplex imaging, digital pathology, and AI-driven quantification that support the clinical integration of Ttex assessment. In addition, we discuss emerging therapeutic strategies targeting Ttex through immune checkpoint combinations, thymocyte selection-associated high mobility group box protein (TOX) and circRNA-mediated reprogramming, and exhaustion-resistant T cell engineering. Finally, we outline translational priorities including assay harmonization, functional validation, and longitudinal profiling to advance Ttex-based precision oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/af1a0b32b60b15c52819ffc31235e60745d2593b" target='_blank'>
              Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology
              </a>
            </td>
          <td>
            Xuejun Guo, Shuhan Ma, Jingwen Wang, Yilin Fu, Wenxue Ma
          </td>
          <td>2026-01-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition resulting from dysregulation of the intestinal immune system. CD4+FoxP3+ regulatory T cells (Tregs) play a crucial role in regulating this immune response. The heat shock response (HSR) regulates the inflammatory cascade, preventing misfolding of proteins and regulating immune responses. We have previously shown that Heat Shock Factor 1 (HSF1), the master regulator of the HSR, regulates Tregs in inflammation. Based on this finding, we hypothesized that targeting HSF1 with celastrol, a pentacyclic triterpenoid that activates HSF1, would activate Treg cells and ameliorate intestinal inflammation. To test this, we investigated the impact of celastrol on Tregs both in vitro and in vivo, evaluating its efficacy in HSF1fl/fl-CD4cre mice, and in two murine models of IBD: the adoptive transfer colitis, and TNFΔARE+/− ileitis. Our results demonstrate that celastrol activates HSF1 in Tregs, enhances Treg suppressive function, increases Treg populations in vivo, and ameliorates intestinal inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/204e8c3bffdaa0f6e62b6113f69d15672aaebfe4" target='_blank'>
              Celastrol Activates HSF1 to Enhance Regulatory T Cells Function and Ameliorate Intestinal Inflammation
              </a>
            </td>
          <td>
            Kibrom M. Alula, Colm B. Collins, Tom T. Nguyen, C. M. Aherne, Paul Jedlicka, E. D. de Zoeten
          </td>
          <td>2025-12-31</td>
          <td>Biomolecules</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Abstract Bone metastases represent a common and devastating complication of breast cancer; however, the immune determinants of skeletal colonization, particularly the role of adaptive lymphocyte subsets, have only recently been elucidated. In this study, we identified a nonclassical regulatory role of CD19+ B cells in the modulation of bone remodeling and breast cancer metastatic progression. Using murine models of metastatic 4T1 and nonmetastatic 67NR mammary tumors, we show that 67NR-bearing mice exhibit increased trabecular bone mass, associated with osteoprotegerin (OPG) secretion by CD19+IgD+IgM+CD138− B cells. Functional assays demonstrated that 67NR-primed B cells suppressed bone resorption in vitro and counteracted 4T1-specific T cell–mediated osteolytic activity in vivo. Adoptive transfer of 67NR-primed CD19+ B cells into 4T1-bearing immunocompetent or immunodeficient hosts preserved bone architecture, reduced RANKL production, inhibited metastases, and limited tumor growth. These effects are T cell–independent at the effector phase but require T cell-licensing for the acquisition of the OPG-producing phenotype. Silencing OPG abrogated this protective function. Mechanistically, B cells must be transferred during the early stages of tumor progression to retain their therapeutic potential. Molecular analyses supported the enrichment of RANKL+CD4+ T cells in tumors and lymph nodes, whereas OPG+ B cells were restricted to tumors. Transcriptomic data from The Cancer Genome Atlas further support the prognostic relevance of these immune phenotypes. In a retrospective human cohort, high RANKL+ lymphocyte infiltration in primary tumors correlated with bone metastases, whereas OPG+ infiltration predominated in bone metastasis–free cases. These findings uncover a B cell–driven axis that restrains osteolysis and tumor progression. Significance: This study identifies opposing RANKL+ T cell and OPG-producing B cell immune phenotypes that shape bone metastasis risk in breast cancer. By revealing how these adaptive lymphocyte subsets influence osteolysis and skeletal colonization, our findings define prognostic immune signatures with potential utility for early risk stratification and clinical decision-making.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35cd146bea92a7259d752847ade47a20756d5b7a" target='_blank'>
              OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer
              </a>
            </td>
          <td>
            Ana Carolina Monteiro, Diego D Garcia, A. P. A. Fontão, Bárbara Du Rocher, Maria E Globa Masset, Isabella N Alves, Lucas Gonçalves Carvalho, C. Andrade, Gabriel Fidalgo, M. V. Colaço, L. Nogueira, Maria de Fatima Dias Gaui, Adriana Bonomo
          </td>
          <td>2025-12-09</td>
          <td>Cancer Research Communications</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Introduction Sepsis leads to expansion of myeloid-derived suppressor cells (MDSC) and their subtypes. These normally transitory MDSCs suppress T cell activation and alter T cell cytokine production while simultaneously promulgating systemic low-grade inflammation. Immune metabolism can shape cell responses, regulate immune suppression, and enhance effector activity. Although MDSC metabolism has been extensively studied in cancer, the metabolic phenotype of this heterogeneous population in sepsis remains unclear. Our goal was to assess metabolic flux in blood MDSCs during and after sepsis and to stratify these patients’ clinical features and outcome with differences in metabolic flux that may guide treatment decisions. Methods Peripheral blood mononuclear cells (PBMC) from healthy subjects and sepsis patients at 4 days, 2-3 weeks, and 6 months underwent CD66b+ or CD3+ enrichment, followed by assessment of metabolic flux, flow cytometry, mRNA sequencing, and chromatin accessibility. Results Mitochondrial basal oxygen consumption rates (OCR) and maximal oxygen consumption rates (SRC, spare respiratory capacity) were decreased in MDSC from septic patients at 4 days after infection and persisted for up to 6 months after sepsis onset. Sepsis was not associated with differences in glycolysis. In contrast, oxidative metabolism in CD3+ T cells was similar between sepsis patients and healthy subjects. Reduced MDSC oxidative metabolism was linked to adverse clinical outcomes. The decline in oxygen consumption from MDSCs in septic patients was also associated with significant reductions in MDSC mitochondrial content. Transcriptomic analysis of CD66b+ cells isolated from PBMC of healthy participants and patients with sepsis at 4 days, 2-3 weeks, and 6 months revealed 19 differentially expressed genes and three long non-coding RNAs as potentially responsible for this decline in mitochondrial mass. Specifically, NR4A3, NR4A2, and TAMLIN/NR4A1 expression, all critical for mitochondrial biogenesis, were persistently decreased with reduced chromatin accessibility indicative of gene silencing. Discussion After sepsis, blood CD66b+ cells present with reduced mitochondrial mass and oxidative metabolism that continue at least 6 months after sepsis. These changes in mitochondrial function result from a reduced content of these organelles. We have also identified gene silencing, reduced gene expression of key transcription factors that regulate mitochondrial biogenesis, as well as increased long non-coding RNA as potential drivers of this unique metabolic phenotype. These results highlight the potential benefit of targeting metabolism in sepsis to promote immune homeostasis and recovery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48dac9de2c81b45da57ef12b64fdabc04b31fc63" target='_blank'>
              Prolonged Loss of Oxidative Phosphorylation and Mitochondrial Mass Characterize CD66b+ Leukocytes from Patients with Sepsis
              </a>
            </td>
          <td>
            Christine Rodhouse, Evan L. Barrios, Leilani Zeumer-Spataro, Leandro Balzano-Nogueira, Ruoxuan Wu, Xuanxuan Yu, Guimei Tian, Jason O. Brant, Marie-Pierre L. Gauthier, Jing Chen, Miguel Hernández-Ríos, Valerie E. Polcz, Whitman Wiggins, Angel M. Charles, M. Dirain, Ricardo F. Ungaro, J. Rincon, Tyler J. Loftus, Feifei Xiao, Guoshuai Cai, L. Moldawer, Robert Maile, Michael P. Kladde, Philip A. Efron, Clayton E. Mathews
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="In the ovarian cancer microenvironment, the polarization of tumor-associated macrophages (TAMs) is closely associated with immunosuppressive phenotypes. Although elevated levels of circulating interleukin-7 (IL-7) have been linked to a poor prognosis, the regulatory mechanisms underlying this association remain incompletely understood. This study demonstrated that increased IL7R expression in ovarian cancer is correlated with the polarization of CD206+ macrophages, the remodeling of the immunosuppressive microenvironment, and unfavorable patient prognosis. By employing 3D bioprinted co-culture systems and mouse models, we showed that the knockdown or knockout of IL7R inhibits tumor progression and intraperitoneal dissemination. Mechanistically, IL7R signaling promotes the polarization of macrophages toward an immunosuppressive phenotype through the NF-κB/CXCL1 axis. This is supported by the upregulated expression of Arg1 and IL-10, as well as the downregulated expression of pro-inflammatory markers. These polarized macrophages further enhance tumor cell proliferation and invasion, thereby forming a tumor-immune feedback loop. In conclusion, this study clarifies how IL7R signaling mediates crosstalk between ovarian cancer cells and macrophages to maintain the homeostasis of the immunosuppressive tumor microenvironment (TME).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7116126aaada33b14ed91a0ba7aab0478ac13e27" target='_blank'>
              IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancer
              </a>
            </td>
          <td>
            Yeqing Zheng, Cheng Qian, Shuyi Zhang, Meichen Wen, Xun Xu, Xuan Zhou, Y. Wan, Lin Zhang, Wenjun Cheng
          </td>
          <td>2025-12-08</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) have redefined the therapeutic paradigm of non-small cell lung cancer (NSCLC), offering durable remission in select patients by reactivating anti-tumor T cell responses. Yet, this clinical triumph is tempered by the reality that most patients experience either primary resistance or relapse due to acquired resistance, underscoring an urgent need for mechanistically grounded solutions. Resistance arises through a complex interplay of tumor-intrinsic mechanisms, including defects in antigen presentation, interferon signaling disruption, and oncogenic pathway activation (EGFR, KRAS, MET), and tumor-extrinsic factors such as immunosuppressive cell populations, inhibitory cytokines, and metabolic rewiring of the tumor microenvironment (TME). This review provides a comprehensive synthesis of emerging pharmacological strategies aimed at reversing ICI resistance in NSCLC. Promising avenues include dual or multi-checkpoint inhibition (targeting LAG-3, TIGIT, TIM-3), integration of epigenetic reprogrammers to resensitize immune-silent tumors, and metabolic interventions that normalize the TME. Additionally, combination regimens with oncogene-directed therapies, engineered cytokine analogs, neoantigen-based vaccines, and adoptive T cell therapies are reshaping the frontier of immunoresistant NSCLC management. We also highlight pivotal clinical trials—both completed and ongoing that illuminate translational breakthroughs and therapeutic pitfalls. Looking ahead, the field must grapple with key challenges: the refinement of predictive biomarkers, stratification of patients through genomic, immunologic, and microbiome-based profiling, and the management of toxicity in complex combination protocols. Ultimately, a shift toward highly personalized, biomarker-guided therapeutic strategies holds the greatest promise for overcoming resistance and extending the reach of immunotherapy in NSCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a4fa2fc3480e331167df24fb59d6d5857202d4b" target='_blank'>
              Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer
              </a>
            </td>
          <td>
            Yuyu Xu, Huiling Shen, Dong Shang, Cailin Zhu
          </td>
          <td>2026-01-08</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Intracellular pathogens must evade cytotoxic immunity to establish persistent infection. Although immune escape is typically viewed through a biochemical lens, the ability of certain pathogens to alter the mechanical properties of infected cells suggests that biophysical mechanisms may also contribute to the process. Here, we show that a subset of CD4+ T cells infected with the human immunodeficiency virus (HIV) resist elimination through a soft phenotype that inhibits killing by mechanosensitive cytotoxic T lymphocytes (CTLs). This phenotype arises from the combined effects of the HIV virulence factor Nef, which remodels the actin cytoskeleton, and intrinsic heterogeneity in the basal cytoskeletal properties of infected T cells. Pharmacological or genetic perturbations that reverse Nef signaling to the cytoskeleton or that stiffen the filamentous-actin cortex sensitize infected cells to CTL-mediated lysis. Taken together, these findings define a novel, biophysical paradigm of immune evasion with implications for HIV cure strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1a4f51743a919ef271e4cd1d83a51db2f6165482" target='_blank'>
              HIV Nef amplifies mechanical heterogeneity to promote immune evasion
              </a>
            </td>
          <td>
            Louise Leyre, Farah Mustapha, Alberto Herrera, Esther Lee, Emily Huntsman, P. Zumbo, J. Weiler, Parul Sinha, Ethan Naing, Connor Smith, Colin C. Kovacs, Micheal Galiano, Nada Wahman, D. Betel, Kiera L. Clayton, Morgan Huse, R. B. Jones
          </td>
          <td>2025-12-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor survival. The immunosuppressive tumor microenvironment (TME) drives resistance to therapy, including immunotherapy. This may be, in part, mediated by the formation of neutrophil extracellular traps (NETs), formed when neutrophils release their intracellular contents. NETs are elevated in PDAC and are associated with nearly every stage of tumor progression. We investigated the influence of NETs on the PDAC TME and immunotherapy response. An orthotopic PDAC model was utilized in C57BJ6 or PAD4-/- mice receiving one of the following: control, DNase, anti-PD-1 therapy, or DNase and anti-PD-1. NET markers, fibrosis, and the TME immune profile were evaluated. Human PDAC patients were also evaluated for levels of NETs and tumor-infiltrating T cells. Circulating NET markers correlated with intra-tumoral CD8+ cells in PDAC patients. Patients with high NET levels also experienced more post-operative complications. NET inhibition in mice reduced tumor growth and enhanced survival. Decreased expression of collagen and matrix metalloproteinase (MMP) genes, as well as reduced intra-tumoral collagen deposition were found in NET deficient mice. Additionally, an increase in TCF1+PD-1+CD44+CD8+ progenitor T cells, a subpopulation of T cells responsive to immunotherapy, were identified. These changes resulted in further tumor burden reduction and prolonged survival when anti-PD-1 therapy was given in conjunction with NET inhibition. NETs influence extracellular matrix remodeling and the T cell response to PDAC, allowing for a significant response to anti-PD-1 therapy. These findings support the combination therapy of immunotherapy and NET inhibition in patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c46e4293b48b999ce9a40d9b92499a2b9823b8d" target='_blank'>
              Neutrophil extracellular trap inhibition revitalizes PDAC immunotherapy responsiveness via reduced fibrosis and TCF1+CD8+ progenitor T-cell expansion
              </a>
            </td>
          <td>
            Britney Niemann, Abby D Ivey, Quinn Hopen, Duaa Dakhlallah, Kathleen Brundage, Nicole E Mihalik, Timothy D Eubank, Brian A. Boone
          </td>
          <td>2025-12-01</td>
          <td>OncoImmunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Interleukin-2 (IL2) has potent anticancer properties but its clinical use is limited by severe dose-dependent side effects, notably capillary leak syndrome (CLS) - a life-threatening condition marked by vascular barrier disruption and multi-organ dysfunction. Despite extensive efforts to engineer IL2 variants with improved pharmacokinetics or reduced toxicity, none of the 45 IL2-based agents currently under investigation across 139 trials have secured regulatory acceptance for cancer or autoimmune applications, largely due to unresolved safety concerns and limited efficacy, suggesting an incomplete understanding of IL2-induced CLS pathogenesis. Here, we describe the development of an immune-competent in vitro model of IL2-induced CLS comprising human primary endothelial cells co-cultured with donor-derived peripheral blood mononuclear cells (PBMCs) that recapitulates IL2 dose-dependent endothelial barrier loss. We demonstrate that neither IL2 alone nor cytokines released from IL2-stimulated PBMCs are sufficient to impair barrier integrity and show that direct cell-cell proximity is required for barrier loss and endothelial activation. Proteomic profiling identified key IL2-induced inflammatory, adhesion, and matrix remodeling pathways and pharmacological inhibition of selected targets mitigated IL2-mediated vascular dysfunction. This platform recapitulates key hallmarks of IL2-induced CLS, provides a mechanistically relevant, human-specific tool to study CLS pathogenesis and supports the development of safer IL2-based therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7242c15b7c8257703280c378aa7cb6c4b182baf0" target='_blank'>
              An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights and evaluation of mitigation strategies
              </a>
            </td>
          <td>
            Tamara Zimmermann, Edith Philipp, Sabine Marget-Muller, Gabrielle Leclercq-Cohen, S. Golling, Juliane Siebourg-Polster, A. Augustin, Remi Villenave
          </td>
          <td>2025-12-06</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="The pathogenesis of rheumatoid arthritis (RA) involves an aberrant number and/or activation of dendritic cells (DCs) within the synovial microenvironment. Targeting synovial DCs represents an attractive approach for the treatment of RA. Spleen tyrosine kinase (SYK), a pivotal molecule in immune cell receptor signaling pathways, is known to play a critical role in RA progression. However, the impact of SYK on DC biology under RA-specific pathological conditions remains incompletely understood. In this study, we employed a spontaneous RA mouse model carrying a gain-of-function SYK variant (SYKS544Y) to investigate the effects of SYK activation on DCs. Our findings demonstrate that SYK activation promotes the expansion of the DCs population (CD11C+MHCII+), particularly the CD11C+MHCII+CD11B+CD8a− subtype, in blood, spleen, and ankle. Furthermore, SYK activation enhances DC maturation and endocytosis by upregulating CD40 and CD86. Additionally, bone-marrow-derived DCs from SYKS544Y mice exhibit increased T-cell proliferative activity. Collectively, these results suggest that gain-of-function SYK may contribute to RA pathogenesis by promoting DC expansion and maturation, thereby modulating immune responses in the synovial environment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/90d45bd28b2a8c3fdbadb028c0f87f36c8d6fc15" target='_blank'>
              SYK Activation Enhances Dendritic Cell Functions in Spontaneous Rheumatoid Arthritis
              </a>
            </td>
          <td>
            Zhiyang Zeng, Xiya Cao, Haozhe Guo, Yuxuan Lai, Weihua Yang, Youyuan He, Jialiang Sun, Zhenliang Sun, Dali Li, Yamin Tan
          </td>
          <td>2025-12-30</td>
          <td>Inflammation</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7eec5092ca04ca50d54f7a273e3e46cdc98efcc8" target='_blank'>
              Aging increases ovarian cancer growth, metastasis, and immunosuppression that can be alleviated by inhibiting hedgehog signaling
              </a>
            </td>
          <td>
            Asha Kumari, M. H. Elbahoty, Resha Rajkarnikar, Khushi Sureja, M. Monavarian, L. Quintero, K.C. Fuh, Daniel J. Tyrrell, L. Shevde, Camilla Margoli, Karthikeyan Mythreye
          </td>
          <td>2025-12-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="The induction of immune responses in tissues and mucosa has emerged as one of the most promising strategies for the development of more effective vaccines and immunotherapies. In this context, CD8+ resident memory T cells (CD8+ TRM) have arisen as key players in local immune surveillance, acting persistently within non-lymphoid tissues. These cells represent a new and promising frontier in local immune responses and as potential clinical tools. CD8+ TRM are being extensively investigated as therapeutic targets against viral infections and cancer, although their clinical applications have yet to be fully established. Understanding the molecular signals that regulate their generation, differentiation, maintenance, and activation is crucial for the precise targeting of their immune functions. This review explores the main mechanisms involved in the formation and maintenance of CD8+ TRM, from the strength of MHC: TCR interactions to the coordinated role of cytokines, chemokines, and transcription factors in tissue retention and the expression of markers such as CD69, CD103, and CD49a. By integrating this knowledge, we discuss strategies to manipulate these pathways with the goal of developing more effective vaccines and personalized therapies based on resident memory T cells. We also examine how these molecular signals and pathways, either independently or in combination, can be explored both in the fight against viral infections and cancer, and in identifying CD8+ TRM predictive biomarkers for response to anticancer immunotherapies across various tumor types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7a54040a23911cb44878186479043eac242cce4" target='_blank'>
              Keeping it local: how CD8 TRMs regulate viral and cancer immunity
              </a>
            </td>
          <td>
            Luiz Rodrigues Junior, Cristina Bonorino, Alisson F. Haubert, Marvin Paulo Lins, Gabriel Pozo Pereira, Pedro R. Torres Romao, Barry T. Rouse
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Purpose Conventional type 1 dendritic cells (cDC1s) mastermind anti-cancer immunity and play a pivotal role in determining the efficacy of cancer immunotherapies. In this study, we sought to decipher the dynamic changes in the tumor immune landscape during intrahepatic cholangiocarcinoma (iCCA) development and harness the therapeutic potential of targeting cDC1s for cancer therapy. Methods We constructed spontaneous murine iCCAs via hydrodynamic tail vein injection (HDTVi) of plasmids encoding AKT/YAP. To characterize tumor-infiltrating immune cell populations throughout iCCA carcinogenesis and progression, we performed time-of-flight mass cytometry (CyTOF). To expand and activate cDC1s, we combined Flt3L with poly I:C (FL-pIC) therapy and assessed its therapeutic efficacy in both AKT/YAP-induced iCCAs and a subcutaneous tumor injection model. Flow cytometric analyses were used to evaluate intra-tumoral infiltration levels of cDCs and CD8+ T cells. Results CyTOF analysis revealed the progressive formation of an immunosuppressive tumor microenvironment as iCCA advances. Crucially, infiltration of cDC1s dramatically decreases in advanced iCCAs compared to early-stage tumors. Combined FL-pIC therapy preferentially expanded CD103+ cDC1s, powerfully inhibiting tumorigenesis in AKT/YAP-driven murine iCCAs and sensitizing these tumors to anti-PD-1 therapy. Moreover, FL-pIC therapy markedly suppressed the growth of established mIC-23 subcutaneous tumors. Conclusions Our findings demonstrate that recruiting and activating intra-tumoral cDC1s is feasible and essential for driving anti-tumor CD8+ T cell immune responses and enhancing anti-PD-1 therapeutic effectiveness in iCCA.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0302218b55971d224461dce8f8bbf85290ab2de1" target='_blank'>
              Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinoma
              </a>
            </td>
          <td>
            Dong-ni Pei, Yang Song, Yingxia Zhou, Bo Shu, Shao-wei Huang, Fa-zhao Li, Wei-dong Dai, Bao-Ye Sun
          </td>
          <td>2025-12-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Colorectal cancer (CRC) exhibits a striking dichotomy in response to immune checkpoint inhibitors (ICIs), with durable benefit largely restricted to dMMR/MSI-H disease while most pMMR/MSS tumors remain refractory. Central to this resistance is an immunosuppressive myeloid ecosystem—dominated by SPP1high tumor-associated macrophages, neutrophils/PMN-MDSCs, and LAMP3+ mregDCs—that enforces chemokine-driven exclusion, attenuates antigen presentation, and sustains metabolite-mediated T-cell suppression. Despite advances in checkpoint blockade and biomarker stratification, these microenvironmental circuits constitute a major therapeutic hurdle. Moreover, single-cell and spatial proteomic platforms (e.g., CITE-seq, CODEX, imaging mass cytometry) now resolve the composition and topology of suppressive neighborhoods and highlight their utility for patient stratification and pharmacodynamic monitoring. This mini review summarizes cellular and spatial mechanisms by which myeloid states drive ICI non-response in CRC, emphasizing stromal TGF-β–coupled SPP1+ TAM programs, granulocytic chemokine axes (CXCL1/2–CXCR2; IL-8–CXCR1/2), and mregDC-mediated co-inhibition. We outline current and emerging myeloid-reprogramming strategies—including PI3Kγ and CSF1–CSF1R targeting, TREM2 antagonism, COX-2–PGE2 blockade, and adenosine-axis inhibition—and their integration with PD-(L)1 therapy, alongside single-cell/spatial endpoints to quantify on-treatment remodeling. The purpose of this mini-review is to provide a mechanistic and technology-informed framework to reference rational trial design and clinical translation for overcoming checkpoint resistance in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9edfc8b67748eb23273fb2effc39b0c690cbbf02" target='_blank'>
              Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches
              </a>
            </td>
          <td>
            Yu Dai, Xinyu Luo, Li Zhang, Jin Yan
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that strongly suppress immunity and expand during tumor progression. Various antitumor chemotherapy agents can induce MDSC accumulation, reducing treatment effectiveness. We investigated the impact of the CHOP regimen and its components (cyclophosphamide (CTX), doxorubicin, vincristine, and prednisolone) on the dynamics of MDSC accumulation and the associated changes in immune cell profiles in the peripheral blood and spleen of healthy and lymphosarcoma RLS40-bearing CBA mice. CHOP induced significant thymic atrophy and splenomegaly, T-cell depletion, and robust accumulation of MDSCs, primarily polymorphonuclear MDSCs. Kinetic analysis in healthy mice revealed splenic MDSC expansion and T-cell depletion peaked 10-day post-CHOP, driven mainly by CTX; whereas doxorubicin, vincristine, and prednisolone exerted minimal immunological effects. To mitigate CTX-induced MDSCs, glycyrrhizic acid (GLZ), a natural triterpenoid with known immunomodulatory properties, and febroxolone methyl (FM), its novel cyano enone derivative, were administered to CTX-treated mice. GLZ significantly attenuated splenic MDSC accumulation, partially restored T-cell function, and improved immune organ morphology. Conversely, FM exacerbated immunosuppression by expanding MDSCs, enhancing their function by upregulation of Nos1 and Ido1 in vivo, and promoting the generation of highly immunosuppressive bone marrow-derived MDSCs in vitro. Thus, our results highlight CTX’s central role in CHOP-induced MDSC expansion. The structure-dependent duality of triterpenoids, countering (GLZ) or promoting (FM) MDSC expansion, offers therapeutic potential for pathologies ranging from chemotherapy-induced side effects to autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7552027a881146da8a9871bda6ded9bf7a0d48b5" target='_blank'>
              Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids
              </a>
            </td>
          <td>
            M. Awad, A. Sen’kova, A. Markov, O. Salomatina, M. Zenkova, O. Markov
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Regulatory B cells (Bregs) are integral to the tumor microenvironment (TME) and influence immune responses through the secretion of immunosuppressive cytokines such as IL-10, IL-35, and TGF-β. This review highlights recent findings on the phenotype and mechanisms of Bregs, emphasizing their dual role in regulating immune responses within the TME. Importantly, we further explored the latest advances in Breg regulatory mechanisms from the novel perspectives of epigenetics and metabolic remodeling, including the effects of DNA methylation, histone acetylation, glycolysis, and oxidative phosphorylation on Bregs. We also investigate the therapeutic targeting of Bregs, with a focus on STAT3 inhibitors such as lipoxin A4, cucurbitacins, and resveratrol, which show promising potential in mitigating the suppressive function of Bregs. Furthermore, this review provides a detailed analysis of the impact of Bregs on tumorigenesis and metastasis, emphasizing the importance of inhibiting specific immune pathways to prevent tumor escape. Finally, this review offers a prospective outlook on immunotherapy strategies based on Bregs, foreseeing a more nuanced understanding of their TME function and the evolution of targeted treatments with enhanced therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/89845b10942cf1fb9d00d8bf5893d8221d0e0a22" target='_blank'>
              Regulatory B Cells in Tumor Microenvironment
              </a>
            </td>
          <td>
            Zhuoyan Cai, Lin Xie
          </td>
          <td>2026-01-01</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/954805b24a989a5a800c8a228d8a6b54b8ed322d" target='_blank'>
              Cooperative Interaction Between IL-4 Signaling and FLT3 in Multipotent Progenitors Restore Lymphopoiesis in Inflammation and Aging
              </a>
            </td>
          <td>
            Jingfei Yao, Yuting Wang, Yi Zhang
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Introduction We have recently shown that the DNA hypomethylating agent decitabine (DAC) rescues lung allografts from acute rejection. This involves a mechanism that is dependent on host CD4+ FoxP3+ T cells for maximal benefit. DAC treatment also reduces host T-cell IFN-γ production. We therefore hypothesized that DAC may also reduce host macrophage activation. Our objective was to determine if an effect on macrophages contributes to the beneficial effects of DAC in transplantation. Methods In murine orthotopic lung transplant, hosts were treated on post-op day 3-8 with Clodronate (n = 5), DAC (n = 9), or DMSO (n = 11). Results Partial macrophage depletion (clodronate) improves allograft gross and histologic integrity. DAC-mediated allograft rescue was associated with reduced host macrophage recruitment into allograft airways, reduced activation of recruited macrophages, and regeneration of donor resident alveolar macrophages. Discussion These findings suggest that infiltrating host macrophages promote allograft rejection. They also suggest that donor alveolar health is indicative and/or promoting of allograft tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1c63160c7629dcafa8b9f8bf95ff593b261fc72b" target='_blank'>
              The role of macrophages in the mitigation by decitabine of acute allograft rejection
              </a>
            </td>
          <td>
            W. Daccarett-Bojanini, Manuel Sollmann, Kristine Yarnoff, Nicola M. Heller, J. Dodd-o
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Transplantation</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Dendritic cells (DCs) are crucial in regulating immune responses, making them a compelling target for immunotherapy. While DC vaccines have demonstrated safety and feasibility, their limited clinical efficacy underscores the need for strategies to enhance DC functionality. Emerging evidence highlights the regulatory roles of sialoglycans in DC biology, yet the structure-function relationships of other glycans remain poorly understood. To aid the understanding of DC glycobiology, we recently developed and validated a human model system based on genetically glycoengineered MUTZ-3-derived DCs and showed that ST6GAL1-mediated α2,6-sialylation specifically modulates CD4+ T cell activation. In this study, we knocked-out (KO) mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1) to investigate how the shift from complex to oligomannose N-glycans affects DC biology and function. MGAT1 KO completely abolished the synthesis of complex and hybrid N-glycans. Differentiation of MGAT1 KO MUTZ-3 cells into immature DCs (iDCs) induced upregulation of DC markers including CD1a, CD80, CD86, CCR6, and CD209, comparable to the upregulation observed in WT iDCs. Interestingly, MGAT1 KO iDCs displayed an enhanced immunostimulatory profile, marked by increased surface densities of CD40, HLA-ABC, and HLA-DR, in combination with elevated mRNA levels of NFKB1 and IFNB1. Consistent with this profile, MGAT1 KO iDCs highly enhanced the activation and proliferation of allogeneic human CD8+ T cells in vitro, resulting in significantly higher levels of secreted proinflammatory cytokines compared to WT iDCs. This enhanced CD8+ T cell activation persisted under PD-L1 blockade, underscoring the robustness of the MGAT1 KO–driven effect. Significantly elevated NFKB1 levels in the MGAT1 KO iDCs suggest enhanced NF-κB activity driving HLA and costimulatory molecule upregulation and robust CD8+ T cell activation. We further demonstrate that MGAT1 KO promotes accelerated DC differentiation, yielding DCs that after three days of differentiation acquire the capacity to activate T cells. Building on previous research into sialic acids in DC biology, our findings reveal a regulatory role for complex and hybrid N-glycans and specifically demonstrate how sialic acids on N-glycans influence distinct functional outcomes in T cell activation. Our findings support cell-based glycoengineering as an effective strategy to improve DC-based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c295253393fc514495236e9da28c6d51c5c72e86" target='_blank'>
              MGAT1 knockout in human dendritic cells enhance CD8+ T cell activation
              </a>
            </td>
          <td>
            Anne Louise Blomberg, Betina L. Henriksen, Weihua Tian, Kerstin Skovgaard, S. L. Skovbakke, Steffen Goletz
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Rheumatoid arthritis (RA) represents a major global public health challenge, with approximately 1% of the world's population suffering from this disease. In the absence of a cure, patients require ongoing and very often lifelong treatment. While environmental, genetic, and epigenetic factors have all been linked to the development of RA, a key, universally accepted initiating factor in disease development is the loss of immunological tolerance to self‐antigens. Currently, most treatment approaches utilise agents that suppress the immune system or inflammatory response. However, there is no currently available treatment to re‐establish self‐tolerance, the key driving factor in the initiation of the disease. In this review, we will explore how peripheral tolerance mechanisms fail in RA, leading to disease initiation and progression. We will explore how dendritic cells (DCs), a central and nonredundant cell type in maintaining immune tolerance, contribute to RA and discuss molecular strategies to switch these immunogenic and self‐reactive cells to tolerogenic cells. Finally, in addition to understanding the fundamental mechanisms of how peripheral tolerance mechanisms are lost, it is also important to know where this dysregulation occurs. Therefore, in this review, we will also discuss emerging research on sites of disease initiation in the context of tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42e0c982411e47309fe287def4e254144769c5b8" target='_blank'>
              Restoring Immunological Tolerance via Dendritic Cells in Rheumatoid Arthritis
              </a>
            </td>
          <td>
            H. Costello, Andrea Woodcock, Mary Canavan
          </td>
          <td>2026-01-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="The regulation of T cell exhaustion within the tumor microenvironment plays a pivotal role in shaping the immune response to cancer and determining the efficacy of immunotherapy. However, the molecular factors governing this process in colon cancer remain poorly understood. This study investigates the expression characteristics and functional significance of the transmembrane protein CD82 in the colon cancer immune microenvironment, with emphasis on its regulatory role in CD8+ T cell exhaustion and clinical outcomes. Publicly available transcriptomic datasets were integrated with multiplex immunohistochemistry on colon cancer tissue microarrays to characterize the cell–type–specific distribution of CD82 and its associations with key markers of T cell dysfunction. CD82 expression was markedly increased in tumor-infiltrating immune and epithelial cells compared with normal tissues, particularly within exhausted CD8+ T cells. Elevated CD82 levels showed strong positive correlations with canonical exhaustion markers such as programmed cell death protein 1 and T cell immunoglobulin and mucin domain-containing protein 3. Multiplex immunohistochemical analysis further revealed that enrichment of CD82-positive epithelial regions and expansion of the CD82+TIM-3+PD-1+CD8+ T cell subset were associated with poor prognosis and were confirmed by multivariate Cox regression as independent risk factors for unfavorable survival. In patients who failed to achieve a complete pathological response following immunotherapy, exhausted CD8+ T cells exhibited significantly higher CD82 expression. Single-cell regulatory network analysis identified BATF and BHLHE40 as potential transcriptional regulators of CD82. Collectively, these findings demonstrate that CD82 promotes CD8+ T cell exhaustion, contributing to tumor progression and immunotherapy resistance in colon cancer. This study provides novel insight into the molecular mechanisms underlying immune dysfunction and offers a potential therapeutic target for reversing immunosuppression and improving immunotherapy efficacy in colon malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/254f481971ba1782bc6c638ef396c6a18b14c937" target='_blank'>
              CD82-associated exhausted CD8+ T cells define prognosis and immunotherapy resistance in colon cancer
              </a>
            </td>
          <td>
            Jingfeng Zhang, Hengwei Cui, Shaoxian Wu, Hongwei Shi, Haitao Wang, Jingting Jiang
          </td>
          <td>2026-01-13</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to its late-stage diagnosis and the establishment of an immunosuppressive tumor microenvironment (TME). Natural killer (NK) cells, key effectors of innate immunity, exhibit impaired cytotoxicity within this hostile niche. The dysfunction arises from multiple mechanisms, including suppression by immunosuppressive cytokines (TGF-β, MUC16), shedding of activating ligands (MICA/B, B7-H6, CD155), overexpression of inhibitory immune checkpoints (PD-1, TIGIT), and metabolic reprogramming shaped by glucose and lipid competition. Recent advances in NK cell–based immunotherapies—such as cytokine modulation, adoptive NK transfer, and checkpoint blockade—have demonstrated potential to reverse NK exhaustion and enhance antitumor efficacy. In this review, we systematically dissect the molecular and cellular pathways underlying NK cell suppression in ovarian cancer and evaluate emerging strategies to reinvigorate NK-mediated immunosurveillance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c24208516b5c52a573a3fe8e8a63ee815d757d8" target='_blank'>
              Natural killer cell exhaustion in ovarian cancer: from molecular suppression to therapeutic revival
              </a>
            </td>
          <td>
            Jun Ning, Lan Yao
          </td>
          <td>2026-01-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="This research elucidates a novel strategy wherein CD8⁺ T cells overcome tumor immune evasion by initiating ferroptosis and establishing a self-sustaining positive feedback loop. Unlike traditional cytolytic pathways employed by CD8⁺ T cells (e.g., Fas-L/Fas and perforin/ granzyme mechanisms), the interferon-gamma (IFN- γ)-facilitated ferroptosis pathway unveils a distinct immunoregulatory role. Ferroptosis is an iron-dependent, non-apoptotic form of cell death driven by excessive lipid peroxidation, loss of mitochondrial membrane integrity, and eventual plasma membrane disruption. Crucially, beyond direct tumor cell killing, the process leads to emission of damage-associated molecular patterns (DAMPs), which potently stimulate dendritic cell maturation and enhance antigen-specific T cell responses. This establishes a cyclic “immune activation--ferroptosis- -immune reactivation” cascade, effectively alleviating immunosuppression within the tumor microenvironment (TME). Our comprehensive analysis demonstrates that CD8⁺ T cell-secreted IFN-γ downregulates SLC7A11, limiting cystine uptake and impairing glutathione (GSH) biosynthesis, thereby inactivating GPX4. Concurrently, IFN-γ upregulates ACSL4, promoting esterification of polyunsaturated fatty acids (PUFAs) into phospholipids and increasing susceptibility to lipid peroxidation. Together, these synergistic changes induce robust ferroptosis. This mechanism offers a transformative therapeutic perspective for tackling resistance to immune checkpoint inhibitors, with considerable theoretical and clinical implications for next-generation cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc592830024c2ef74ca04dbb64f75f144610d41c" target='_blank'>
              CD8⁺ T Cell-Induced Ferr optosis via a Positive Feedback Mechanism to Overcome Immune Resistance
              </a>
            </td>
          <td>
            Jiaqi Mou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background: Lung metastasis is a leading cause of breast cancer (BC)-related mortality, driven by the immunosuppressive traits of the metastatic tumor microenvironment. However, the mechanisms underlying cell–cell crosstalk in shaping immune evasion within the metastatic niche remain poorly defined. Neutrophil extracellular traps (NETs) and their associated proteins, such as cathelicidin, have emerged as key mediators of metastatic regulation in cancer. Here, we aimed to decipher the interaction between a neutrophil subset characterized by high expression of lymphocyte antigen 6 complex locus g (Ly6ghigh) and cluster of differentiation 8-positive T lymphocytes (CD8+ T cells), mediated via cathelicidin embedded in NETs, as well as their synergistic mechanism and cooperative role in promoting lung metastasis of BC. Methods: We characterized neutrophil heterogeneity and functional dynamics by performing single-cell RNA sequencing and flow cytometry on lung tissues derived from murine models of BC lung metastasis. We utilized cathelicidin-related antimicrobial peptide (Cramp) knockout mice to dissect the role of cathelicidin in NETs. The spatial colocalization of apoptotic CD8+ T cells and NETs was analyzed using multiplex immunofluorescence, and the molecular interactions were probed by protein binding assays. Results: Neutrophils in the lung metastatic niche were classified into 2 subsets based on the Ly6g expression: Ly6ghigh and Ly6glow neutrophils. Ly6glow neutrophils, which were recruited in the macrometastatic stage, exhibited myeloid-derived suppressor cell-like characteristics. Notably, Ly6ghigh neutrophils induced CD8+ T cell apoptosis through NET formation, with apoptotic CD8+ T cells spatially clustered within NET-rich areas. Mechanistically, NET-derived cathelicidin (Cramp in mice) directly bound to mitochondrial adenine nucleotide translocator 1 (Ant1) in CD8+ T cells, triggering conformational changes and complex formation with voltage-dependent anion channel 1 (Vdac1). These events resulted in the opening of the mitochondrial permeability transition pore and loss of mitochondrial membrane potential. Conclusions: Our study demonstrates that Ly6ghigh neutrophils play a critical role in immunosuppression and immune evasion through NET-induced apoptosis of CD8+ T cells. These findings underscore the importance of NETs and cathelicidin in BC lung metastasis, suggesting their potential as therapeutic targets in restoring antitumor immunity and in preventing metastatic progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9ef68cd25c376c469635ba05f3d36dd4afd991fe" target='_blank'>
              The Ly6ghigh Neutrophil Subset Dictates Breast Cancer Lung Metastasis via CD8+ T Cell Death
              </a>
            </td>
          <td>
            Rui Wang, Xiaoqi Liu, Yixuan Hou, Shanchun Chen, Yongcan Liu, Zexiu Lu, Chao Chang, Die Meng, Jing Chen, Xiaojiang Cui, Zhengrong Shi, Xueying Wan, Man-ru Liu
          </td>
          <td>2025-12-15</td>
          <td>Cancer Communications</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Inflammation plays a pivotal role in every stage of cancer development, from tumor initiation to progression, largely by influencing the balance between immune surveillance and immune evasion. At the heart of this inflammatory signaling is the transcription factor Nuclear Factor κB (NFκB), widely recognized as a key orchestrator of immune responses in malignancies. Within the framework of cancer immunoediting, comprising the three key phases Elimination, Equilibrium, and Escape, NFκB emerges as a double-edged sword. While it can enhance the activity and infiltration of effector immune cells that promote tumor destruction, it can also reprogram these cells into immunosuppressive subsets, thereby facilitating tumor immune evasion and growth. This dual functionality makes NFκB both a promising and challenging target in cancer immunotherapy. Despite its significance, comprehensive insights into NFκB’s roles across the immunoediting continuum remain limited. This review aims to bridge that gap by systematically exploring the multifaceted contributions of NFκB in modulating tumor-immune interactions, from immune-mediated tumor surveillance to immune escape, highlighting its potential and complexity as a therapeutic target. Plain Language Summary Inflammation has a key role in cancer’s development and spread. It influences whether the immune system can fight cancer or if the cancer escapes detection. NFkB, a protein that regulates the immune system, plays an important role in this process. Within the framework of cancer immunoediting, involving three important phases: Elimination, Equilibrium, and Escape, NFkB emerges as a double-edged sword. It can assist the immune system fight cancer, but it can also suppress immune cell function, allowing cancer to spread. NFkB is a complex target for cancer treatment due to its potential for both beneficial and detrimental effects. This review examines how NFkB influences the immune system's interaction with cancer at various stages, and how a better understanding it could lead to more effective treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc6a1c1a3bf6e0a9c1471ebde9d4748f47774edd" target='_blank'>
              The Role of Nuclear Factor-κB in Cancer Immunity and Immunoediting
              </a>
            </td>
          <td>
            S. Mukherjee, Subhadip Pati, Subhanki Dhar, Tania Sarkar, Silpita Paul, Udit Basak, S. Chakraborty, Gaurisankar Sa
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Lymphocyte antigen-plasminogen activator urokinase receptor domain-containing protein 6B (Lypd6b) is a newly identified molecule associated with neuromodulation. However, the role of Lypd6b in regulating the tumor microenvironment and its impact on CD8+ T cell-mediated antitumor immunity remain unknown. Here, we observe that Lypd6b expression is increased significantly in colorectal cancer (CRC) tumor tissues compared to normal tissues. Lypd6b is mainly expressed in CD8+ T cells in tumor tissues. Lypd6b knockout (Lypd6b−/−) mice are resistant to AOM/DSS-induced tumorigenesis. Furthermore, global deficiency or CD8+ cell deficiency of Lypd6b inhibits MC38 or CMT-93 tumor growth and promotes the infiltration of CD8+ T cells. Mechanistically, Lypd6b deficiency promotes activation and function of CD8+ T cells in anti-tumor response with increased glycolysis and reduced oxidative phosphorylation in a PI3K/mTOR/LDHA pathway-dependent manner. Notably, Lypd6b deficient CD8+ T cells have a more potent antitumor effect when combined with anti-PD1 antibody. Thus, Lypd6b as a negative regulator for T cell immunity promotes CRC development, providing a molecular target with therapeutic potential in CRC. Mechanism of CD8 T cell dysfunction in tumor microenvironment requires continuous investigation. The authors here show that Lypd6b expression is increased in CD8 T cells of colorectal cancer tissue and its absence inhibits MC38 or CMT-93 tumor growth associated with upregulated glycolysis and reduced oxidative phosphorylation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9fa839aaa68dfea04235930b1c957af2708a8f78" target='_blank'>
              Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer
              </a>
            </td>
          <td>
            Ting Liu, Fanxin Zeng, Zuyin Li, Leirong Cheng, Xuanxuan Yan, Haiqiang Chen, Qin Liu, Xue Li, Zhao Li, Jiaheng Yao, Dan Xu, Zhinan Chen, Fengchao Wang, Jun Wang, Jinhua Zhang
          </td>
          <td>2025-12-11</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Many inflammatory stimuli can induce progenitor cells in the bone marrow to produce increased numbers of myeloid cells as part of the process of emergency myelopoiesis. These events are associated with trained immunity and have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many cytokines support emergency myelopoiesis, less is known about the mechanisms that temper these events. When mice that lack the cytokine IL-27 were infected with Toxoplasma gondii, there was enhanced generation of monocyte progenitors and increased numbers of inflammatory monocytes. In the bone marrow of infected mice, there was increased production of IL-27 that localized with HSPCs, and a survey of cytokine receptor expression highlighted that HSPCs were uniquely poised to respond to IL-27. Furthermore, the use of in vitro differentiation assays and mixed bone marrow chimeras revealed that HSPCs from IL-27-deficient mice are predisposed toward the monocyte lineage. Additional studies highlighted that after infection, loss of the IL-27R resulted in reduced HSPC fitness that manifested as reduced proliferative responses and a decreased ability to reconstitute the hematopoietic system. Thus, the ability of IL-27 to act on HSPC provides a regulatory brake on differentiation to limit monocyte induction and preserve HSPC stemness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4296e880a374b1ca1dccbcbdeb368a411cccee06" target='_blank'>
              IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion
              </a>
            </td>
          <td>
            D. Aldridge, Zachary R. Lanzar, Anthony T Phan, David A. Christian, Ryan D. Pardy, Booki Min, Ross M. Kedl, Christopher A. Hunter
          </td>
          <td>2025-12-15</td>
          <td>eLife</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Macrophages are innate immune cells that extensively infiltrate and play a key role in the tumor microenvironment (TME). Tumor cell–secreted factors recruit monocytes into the TME, where they differentiate into tumor‐associated macrophages (TAMs), which can polarize into distinct phenotypes: M1 and M2. M1 TAMs promote antitumor immunity through cytokine secretion and antigen presentation, whereas M2 TAMs support tumor progression by facilitating angiogenesis, invasion, and immune escape. Despite these dual roles, the specific mechanisms governing macrophage plasticity and polarization remain insufficiently understood. This review comprehensively summarizes the origin, polarization, and functional diversity of macrophages in the TME, with emphasis on pathways that regulate TAM‐mediated immune responses. Furthermore, this article examines current TAM‐targeted therapeutic strategies, including recruitment inhibition, phenotypic reprogramming, and the development of chimeric antigen receptor macrophages (CAR‐Ms), as well as macrophage‐based drug delivery and exosome therapy. By integrating recent advances in cell engineering and immunometabolism, this review highlights the translational potential of TAM‐targeted therapies and their value in reshaping the immunosuppressive TME to enhance cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7215a076e2ef0687c2a7e70ce9deca69722be237" target='_blank'>
              The Role of Macrophages in Cancer: From Basic Research to Clinical Applications
              </a>
            </td>
          <td>
            Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng
          </td>
          <td>2025-12-19</td>
          <td>MedComm</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Fibroblasts, once considered merely passive structural components of tissues, are now recognized as dynamic regulators of the immune microenvironment. Recent advances in single-cell and spatial multi-omics have revealed their profound heterogeneity, spatial organization, and functional plasticity, positioning them as a ‘ruler’ that measures, defines, and shapes local immune responses. In both homeostasis and disease contexts—such as cancer, autoimmune disorders, and fibrosis—distinct fibroblast subpopulations exhibit specialized roles: some drive immunosuppression via PD-L1 expression, TGF-β secretion, or metabolic reprogramming; others promote inflammation or fibrosis through cytokine and chemokine secretion; while a subset supports immune resolution and tissue repair. Spatially, fibroblasts organize immune territories by forming physical and chemical barriers, orchestrating tertiary lymphoid structures, and partitioning inflammatory zones. Their bidirectional crosstalk with immune cells—including T cells, macrophages, and B cells—further fine-tunes immune activation or suppression. The dysregulation of fibroblast subsets is a hallmark of disease progression and therapy resistance. Emerging therapeutic strategies aim to ‘recalibrate’ this dysfunctional ruler through targeted depletion, phenotypic reprogramming, or disruption of pathogenic signaling. Integrating fibroblast-centric metrics into clinical practice may enable precise assessment of the immune microenvironment and personalized interventions, heralding a new era in immunotherapy and fibrotic disease management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a5b61a7cf749a3d3b53564921ffb11c2d17b261b" target='_blank'>
              Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease
              </a>
            </td>
          <td>
            Yanling Zhang, Xinyi Fang, Lian Yan, Lin Wang
          </td>
          <td>2026-01-16</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="ABSTRACT Tumor‐associated macrophages (TAMs) represent the most abundant immune cell population within the tumor microenvironment and are central drivers of malignant progression and treatment resistance. High TAMs infiltration in solid tumors consistently correlates with poor clinical outcomes, largely due to their role in establishing an immunosuppressive milieu that supports tumor growth, metastasis, and undermines the efficacy of chemotherapy, radiotherapy (RT), and immune checkpoint inhibitors. Although TAMs are well‐recognized promoters of tumor progression, the development of effective strategies to therapeutically target them remains an unmet clinical need. In this review, we examine the multifaceted mechanisms through which TAMs contribute to malignancy, including phagocytic signaling modulation, metabolic reprogramming, exosomal communication, and crosstalk with other immune cells. We also evaluate three key therapeutic strategies: blocking TAMs recruitment and survival, reprogramming TAMs toward antitumor phenotypes, and the emerging approach of chimeric antigen receptor macrophage therapy. Furthermore, we highlight the synergistic potential of integrating TAMs‐targeted strategies with conventional chemotherapy, RT, and immunotherapeutic approaches. By synthesizing current clinical evidence, this review aims to inform the rational design of next‐generation TAMs‐targeted interventions and to propose novel strategies for overcoming treatment resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f8d44c15cdc93900836129bceb89040bd162694" target='_blank'>
              Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation
              </a>
            </td>
          <td>
            Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li
          </td>
          <td>2026-01-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="There are multiple reports of elevated inflammation in patients with major depression. It is, however, unclear whether these reported perturbations in immune functions in depression affect the general functionality of the peripheral immune system. Here, using single-cell RNAsequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) extracted from blood samples collected prior to a flu vaccination administration/immunization (at baseline), we found downregulated T cell and B-cell-associated gene expression repertoire coupled with a selectively upregulated plasmablast, CD14 classical monocytes, and natural killer (NK) proliferating cell-associated gene expression in 9 depressed patients (6 females) compared to 5 healthy controls (5 females), as well as in association with depression ratings. Our cell type proportion analysis revealed shifts in immune cell populations, specifically reduced numbers of CD4+ T and CD8+ T proliferating cells, plasmablasts, and NK cells in individuals with depression compared with controls. In contrast, we found increased numbers of CD14 classical and CD16 monocytes as well as doublet cells in depressed individuals compared with controls. Although our baseline and flu vaccine challenge did not show marked differences in peripheral immune markers measured by a multiplex cytokine assay, our results suggest impaired innate and adaptive immune responses at the transcriptomic and cellular population levels in depressed patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2cf073f7c3882ea32b466937ec788669b0a8b86" target='_blank'>
              Immune System Alterations in Depression across Baseline and Flu Vaccine Challenge
              </a>
            </td>
          <td>
            D. Arasappan, Alyssa Marron, Sina Sanei, Mbemba Jabbi
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) harbors a dynamic tumor microenvironment (TME) in which macrophages are highly abundant and plastic. Under physiological conditions, macrophages switch between inflammatory and resolution/tissue-repair programs to maintain homeostasis; however, during hepatocarcinogenesis these programs are reprogrammed into tumor-associated macrophage (TAM) states that foster immune suppression, angiogenesis, and tumor progression. Purpose: To summarize macrophage heterogeneity and polarization mechanisms in HCC, and to highlight omics-informed therapeutic opportunities for targeting TAMs and improving precision immunotherapy. Research Design: This review summarizes physiological macrophage polarization and the mechanistic basis of macrophage reprogramming in the hepatocellular carcinoma immune microenvironment, integrating evidence from recent advances in single-cell sequencing, multi-omics, and spatial transcriptomics, with a focus on macrophage subset diversity, key regulatory pathways governing polarization and function, and emerging macrophage-targeted interventions and biomarkers. Results: Recent single-cell and spatial multi-omics studies reveal substantial TAM heterogeneity and plasticity in HCC. Macrophage-targeted strategies—including TAM depletion, phenotypic reprogramming, and exosome-mediated drug delivery—show encouraging preclinical efficacy. Macrophage-associated prognostic models and biomarkers may support individualized immunotherapeutic approaches. Conclusions: Macrophage polarization in HCC represents a dynamic continuum that is essential for homeostasis but is co-opted by tumors to drive immunosuppression and tissue remodeling. Advances in single-cell and spatial multi-omics are redefining TAM subsets and actionable pathways, enabling more rational macrophage-targeted therapies. However, challenges remain in standardizing TAM definitions, identifying robust predictive biomarkers, minimizing off-target effects, and optimizing combinations with immunotherapy. Integrating longitudinal multi-omics with AI-based modeling may help predict macrophage state transitions, guide patient-specific regimens, and advance precision medicine in HCC. Plain language summary Hepatocellular carcinoma is a highly aggressive cancer. Studies have found that immune cells within tumors—particularly macrophages—play a crucial role in cancer development and therapeutic response. Macrophages have two main “personalities”: the M1 type, which can kill cancer cells, and the M2 type, which supports cancer growth. They shift between these states in response to signals from the tumor microenvironment. Both liver-resident Kupffer cells and infiltrating macrophages are involved in this process. Various molecules, such as cytokines, enzymes, and exosomes, influence their polarization. This polarized state of macrophages, in turn, affects key tumor processes such as stemness, proliferation, metastasis, and angiogenesis. In recent years, scientists have been exploring drugs that specifically target macrophage polarization to suppress liver cancer, offering new directions for future therapy. Graphical Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b9c3d3369daa7c8bd747ff210bf91cca4945570" target='_blank'>
              Macrophage Polarization in the Tumor Microenvironment of Hepatocellular Carcinoma: From Mechanistic Insights to Translational Therapies
              </a>
            </td>
          <td>
            Xiaoqing Fu, Mingquan Pang, Zhixin Wang, Haijiu Wang
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>1</td>
          <td>2</td>
        </tr>

        <tr id="Gastric cancer (GC) remains a major global health burden with persistently high mortality despite therapeutic advances. Accumulating evidence highlights the pivotal role of tumor-associated macrophages (TAMs) in orchestrating gastric tumor progression through immune suppression, angiogenesis, extracellular matrix remodeling, and metastasis. Within the tumor microenvironment (TME), TAMs exhibit functional plasticity, often polarizing toward an M2-like phenotype that promotes immunosuppression and tumorigenicity. These cells actively participate in immune evasion via immune checkpoint expression and cytokine-mediated T cell inhibition, while also facilitating lymphovascular invasion and chemoresistance through exosome-mediated crosstalk. The density and phenotype of TAMs have been associated with prognosis and therapeutic response in GC. Recent studies have proposed TAMs as promising targets for therapy, with strategies focusing on depleting M2 subsets, reprogramming toward M1 phenotypes, and blocking TAM-driven oncogenic signaling. Targeted interventions, including MENK, paclitaxel, and NF-κB inhibitors, have shown potential in preclinical models. This review comprehensively discusses the mechanistic roles of TAMs in GC and evaluates emerging TAM-targeted therapeutic strategies that may enhance the efficacy of immunotherapy and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/913bc3f4af4f9d7fed06d178714e6cfa582ea213" target='_blank'>
              Tumor associated macrophages in gastric cancer dual roles in immune evasion and clinical implications for targeted therapy
              </a>
            </td>
          <td>
            Chang Wang, Xu Fan, Xiaomeng Sun, Yi Xu, Yanna Sun, Jidong Liu
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is an aggressive malignancy that is often refractory to chemotherapy and immune checkpoint inhibitors. This therapeutic resistance is driven in part by the persistence of cancer stem-like cells (CSCs) and the development of an immune-cold tumor microenvironment. However, the upstream regulators that coordinate these malignant features remain poorly defined. In this study, we identified dysadherin as a novel upstream activator of YAP that promotes both CSC plasticity and immune evasion through the FAK/YAP/TEAD2 signaling axis. Using single-cell transcriptomic analysis, in vitro assays, and multiple in vivo models including a humanized immune mouse system, we showed that dysadherin enhances the expression of pluripotency genes, such as OCT4 and upregulates PD-L1. These changes support stem-like tumor behavior and contribute to T-cell exclusion, fostering an immunosuppressive niche. Notably, genetic knockdown or peptide-based pharmacologic inhibition of dysadherin effectively restored antitumor immune activation, suppressed metastasis and improved therapeutic responsiveness. Our findings reveal a mechanistic link between dysadherin-mediated cell adhesion signaling and the transcriptional regulation of both stemness and immune escape. Collectively, these findings establish the dysadherin/YAP axis as a key driver of HCC progression and resistance, and highlight it as a compelling therapeutic target that could overcome treatment failure in advanced liver cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29884335d480102826ec8b793e157ba0b7881a1e" target='_blank'>
              Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer
              </a>
            </td>
          <td>
            T. Jang, So-El Jeon, H. Yun, Choong-Jae Lee, Da-Ye Lim, Sang Hoon Lee, Dajun Lee, Seungwon Lee, Jungmin Choi, Hyung-Sik Kim, Jeong-Seok Nam
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Background: Radiotherapy (RT) remodels the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are key mediators of TME, yet how RT reprograms TAMs toward a programmed death ligand- 1(PD-L1)⁺ immunosuppressive phenotype remains unclear. Materials and Methods: Esophageal squamous cell carcinoma (ESCC) subcutaneous xenografts in immunodeficient mice received localized RT or sham treatment. Tumor-infiltrating PD-L1⁺ TAMs were quantified via multiplex immunofluorescence and flow cytometry. Extracellular vesicles (EVs) derived from irradiated ESCC cells (IR-EVs) were isolated and characterized by nanoparticle tracking analysis and transmission electron microscopy. Functional assays included co-culture of IR-EVs-educated macrophages with autologous CD8⁺ T cells. RNA sequencing identified DYNLL1-AS1 as the most upregulated lncRNA in IR-EVs. Mechanistic studies employed RNA pull-down, mass spectrometry, RNA immunoprecipitation, and dual-luciferase reporter assays. Clinical validation utilized ESCC specimens for RNA in situ hybridization. Prognostic significance was assessed via Kaplan-Meier and Cox regression analyses. Results: RT triggered ESCC cells to secrete DYNLL1-AS1-enriched EVs, which reprogrammed macrophages into PD-L1⁺ immunosuppressive TAMs. IR-EVs-educated macrophages suppressed CD8⁺ T cell proliferation and IFN-γ/ Granzyme B secretion. Mechanistically, DYNLL1-AS1 bound SEC22B, enabling its interaction with FOXP1 to activate PD-L1 transcription via promoter binding. In vivo, EVs carrying DYNLL1-AS1 counteract anti-PD-L1 therapy by suppressing CD8+ T cell function and promoting tumor growth. In ESCC patients, high DYNLL1-AS1 expression correlated with PD-L1⁺ TAM density, poor immunotherapy response, and reduced survival. Multivariate analysis confirmed DYNLL1-AS1 as an independent prognostic factor. Conclusions: Radiation-induced DYNLL1-AS1 in ESCC EVs drives PD-L1⁺ TAMs immunosuppression via SEC22B/ FOXP1 signaling. Combining DYNLL1-AS1 inhibition with PD-L1 blockade may reverse RT-induced immunosuppression, offering a transformative strategy for ESCC radio-immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62c9c29a3e6d1b11c8904cf92b1d7f9e8f201bd1" target='_blank'>
              Extracellular vesicles derived from irradiated tumor cells foster immunosuppressive macrophages formation to promote esophageal squamous cell carcinoma immune evasion
              </a>
            </td>
          <td>
            Shanshan Jiang, Y. Pang, Yue Zhou, J. Ni, L. Chu, X. Chu, Jianghong Zhang, Yan Pan, Yida Li, R. Ye, Hongru Chen, Silai Yu, T. Guo, Chunlin Shao, Xi Yang, Zhengfei Zhu
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Decorin (DCN) predominantly produced by fibroblasts is a small leucine-rich proteoglycan with tumor-suppressive property. However, whether DCN has a role in shaping the tumor immune microenvironment remains elusive. The TCGA and GEO databases were analyzed to identify fibroblast-specific secretory proteins that are downregulated in most types of human tumors, positively correlate with CD8⁺ T cell infiltration, and associate with improved response to immune checkpoint blockade (ICB) therapy. The function of DCN in vivo was assessed using cell lines with stable DCN overexpression in both immunocompetent and immunodeficient mice. The changes in the composition and function of immune cell subpopulations in tumors were analyzed by flow cytometry analysis (FCM) and immunofluorescence staining. The role of CD8⁺ T cells in the DCN-mediated tumor suppression was further elucidated by utilizing B2m-knockout tumor cells and CD8⁺ T cell depletion assays. The in vitro co-culture system of tumor cells and T cells was applied to dissect the effects of DCN on CD8+ T lymphocyte activation and functions. Finally, the therapeutic efficacy of DCN in combination with anti-PD1 antibody was evaluated in mouse tumor model. DCN-mediated tumor suppression was present in immunocompetent mice, wherein either depletion of CD8⁺ T cells in mice or ablation of β2M in tumor cells abrogated the tumor-inhibitory effects mediated by DCN, indicating the importance of CD8⁺ T cells in the DCN-antitumor activities. DCN overexpression promoted CD8⁺ T cell infiltration into tumors and increased the production of TNF-α, IFN-γ, and perforin in infiltrating T cells, and DCN expression substantially enhanced the tumor-suppressive efficacy of anti-PD1 therapy. More importantly, integrative analyses of clinical data indicated that DCN expression is downregulated in multiple types of human tumors and positively associated with the presence of CD8⁺ T cells and their expression of cytotoxic genes. Furthermore, high DCN levels were correlated with favorable prognosis in certain types of cancer patients with ICB therapy. Our study reveals that DCN functions as a tumor-suppressive factor by enhancing T cell response, and proposes the potential of exogenous DCN as a supplement to cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d5b6eb80a5279f1cd41ac2e3910968815e0cfd4" target='_blank'>
              Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy
              </a>
            </td>
          <td>
            Ningqian Zheng, Lvzhu Xiang, Guiqin Xu, Yun Liu, Chengming Xu, Li Zhang, You Zuo, Zhiqian Ye, Yongzhong Liu, Zhaojuan Yang
          </td>
          <td>2026-01-27</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5022b23a68cf2c2cfdfb9468e2f2ae355d75f27a" target='_blank'>
              Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
              </a>
            </td>
          <td>
            Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, F. H. Zahiroh, Aris Muhammad Nurjamil, T. Wargasetia, I. M. Nainggolan, Rizal Azis, Elham Rismani, Dr. Massoud Vosough
          </td>
          <td>2026-01-01</td>
          <td>Journal of Immunology Research</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Cancer is a disease with a very high fatality rate. immunotherapy is a promising way to treating cancers, of which CTLs are important for the host immune system against tumor, directly killing tumor cells. However, the relative immunotherapy is limited by many factors that suppress the function and activity of CD8+ CTLs. This review aims to study the mechanisms by which CD8+ CTLs are suppressed in the tumor microenvironment. By collecting preclinical and clinical studies, this paper summarized the main factors that suppress CD8+ CTLs including the following factors: immune cells like regulatory T cell (Tregs), tumor-associated macrophage (TAM), myeloid-derived suppressor cells (MDSCs); metabolic factors like hypoxia, lactic acid accumulation, glucose competition, and immune checkpoints molecules (ICM) PD-1 and CTLA-4. The complex mechanisms of suppressing CD8+ CTLs in the tumor microenvironment are discussed in these findings, which may give clues to the relative treatment and help overcome these suppression effects on CD8+ CTLs in tumorigenesis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0a3c8667fb5c07636fc20ce12f9301e91ee0bab" target='_blank'>
              Suppressed Factors to CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Zeyu Zhou
          </td>
          <td>2025-12-19</td>
          <td>MedScien</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background Lipocalin-2 (Lcn2) is a sensitive early marker for acute kidney injury, delayed graft function and acute rejection of kidney transplants. We previously showed the renoprotective effect of recombinant Lcn2:Siderophore: Fe3+ (rLcn2) in a mouse kidney transplantation (KTx) model. Here, we investigate the molecular and cellular mechanisms underlying these effects. Methods Male C57BL/6 mice (10–12 weeks) received BALB/c kidney allografts, with or without rLcn2 treatment (250 µg, s.c.). To examine the immunomodulatory function of rLcn2, immune cells from graft, spleen, lymph nodes and blood were analyzed by flow cytometry at post-operative days (pod) 3 and 7. Syngeneic C57BL/6 grafts were used to investigate the impact of rLcn2 on alloimmune-independent tissue injury and inflammation through multiplex signaling assays, functional readouts, cytokine profiling and histopathological analyses. Results rLcn2 treatment markedly reduced frequencies of distinct T cell subsets, including effector memory T cells and their cytotoxic (Tc) and helper (Th) subsets across grafts, lymphoid tissues and blood by pod-7 following allogeneic KTx. In graft infiltrating CD8+ T cells, rLcn2 decreased degranulation capacity and diminished expression of interferon-γ and perforin. rLcn2 also lowered the proportion of NKG2D+ CD8+ T cells, an activating Tc subset, in spleen and blood. In contrast, its impact on innate immune cells was modest and selective, influencing only neutrophils, macrophages in lymph nodes and intermediate mature NK cells in spleen and blood. No significant effect of rLcn2 treatment was observed on alloimmune-independent tissue injury or inflammation in syngeneic kidney grafts. Conclusion rLcn2 selectively modulates T-cell activity after KTx without affecting alloimmune-independent injury pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed180d49cdbfb39ec89a170f0fe6750f292b2bde" target='_blank'>
              Lipocalin-2 modulates recipients alloimmune responses to the murine kidney transplants
              </a>
            </td>
          <td>
            A. M. Pfefferkorn, R. Fritsche-Guenther, Angelika Kusch, Hubert G. Schwelberger, Shiqian Liu, R. Klopfleisch, Yuhuan Li, R. Catar, Shaokun Liu, Felix Aigner, Johann Pratschke, Igor M. Sauer, Muhammad-Imtiaz Ashraf
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Immunity during cancer progression involves critical responses that may be harnessed to augment anti-tumor cytotoxicity. A potent arm of immunity in cancer involves cytotoxic T cells (a key CD8+ T-lymphocyte subset): Anti-tumor responses by such cells optimally involve sensitization and acquired responses to tumor antigens by antigen presenting cells. Many tumor microenvironment (TME) biophysical and functional limitations in carcinomas limit robust achievement of this ideal cellular-immunologic pathway. This is especially challenging in lung carcinoma, on which we focus mechanistically and with an eye to therapeutic translation. Localization of tumor-sensitized and activated CD8+ T cells to tumor “nests” with efficient tumor cytolysis involves many challenging steps. Amplifying and sustaining such responses is also a unique challenge. The variety of homeostatic and immunosuppressive obstacles often becomes overwhelming. Measuring the state of this response during lung cancer progression is also challenging, making it difficult to mount (and/or predict) T-cytotoxic responses in the heterogeneous and dynamic carcinoma antigen landscape. We investigate these challenges herein, while examining strategies to boost T-cytotoxic immunity in lung cancer through novel and emerging immunotherapeutic approaches. Beyond current immune checkpoint blockade approaches that are relatively non-specific with respect to antigen recognition by the T-cell receptor, we highlight ongoing and translational vaccines, cell-therapies, antigen-presenting cell boosting approaches, T-cell therapies, and biophysical considerations with an eye to overcome key barriers of this powerful arm of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d405cc42ae9819222b3a3a0b50f4e0cc2451158" target='_blank'>
              The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma
              </a>
            </td>
          <td>
            Aditya Dash, Afsheen Banisadr, Donivian Al Dikka, Scott C. Johns, Mark M. Fuster
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="The mechanisms of the chronic inflammatory response in smoking-induced chronic obstructive pulmonary disease (COPD) remain unclear, with limited understanding of T cell responses to smoke exposure in lung tissue and circulation. We characterized the alterations in T cells associated with smoke exposure using single-cell RNA sequencing, TCR sequencing, and flow cytometry-based validation. Our experiments show significant recruitment of T cells within the airways, exhibiting a multifaceted immune profile, augmented TCR clonal diversity, and a prolonged CDR3 length. Notably, smoke-induced γδ T cells, particularly clonally expanded γ6δ4 T cells with high Il17a expression, accumulate in smoke-induced airway inflammation. Despite arising in inflammation, these cells function in a protective manner: γδT17 deficiency worsens smoke-induced lung injury, whereas adoptive transfer of γδT17 cells restores tissue protection in smoke-exposed lungs over time. Here, we show γδT17 cells as a potential target for addressing smoke-induced immune dysfunctions, providing alternative avenues for early prevention and treatment of COPD. T cells have been shown to have a function in chronic lung inflammation in COPD. Here the authors characterise the single cell transcriptional profile of T cells after smoke inhalation in mouse models showing changes in TCR repertoire and Il17a expression in γδ T cells, suggesting smoke-associated γδ T cells are involved in COPD inflammation and implicating γδT17 cells as a possible target for early prevention and treatment of COPD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c72bfc4278bed289c335fdcb150aff219f94dd9e" target='_blank'>
              Comprehensive profiling of smoke-induced T cells in mice implicates clonal γδT17 cells as a hallmark of COPD
              </a>
            </td>
          <td>
            Xinyue Mei, Junxiang Wang, Yuan Wang, Li Cheng, Xiaoyu Wang, Xinyuan Liu, Ge Bai, Jiaying Zhong, Mingzhu Huang, Suyin Huang, Peiyu Huang, Jieda Cui, Yu Liu, Qianmei Wen, Ruiting Sun, Erkang Yi, Fan Wu, Xiaohui Wu, Ziqing Yuan, Q. Wan, Xiaoyang Zheng, Yujie Zuo, Jingwei Zhang, Leqing Zhu, Yumin Zhou, Zhongfang Wang, Pixin Ran
          </td>
          <td>2025-12-08</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC), the most common primary liver cancer, continues to rank among the leading causes of cancer-related death despite improvements in early detection and systemic therapies. Therapeutic advances, including immune checkpoint blockade, cancer vaccines, and adoptive cell therapies, have broadened treatment possibilities. However, their efficacy and durability are often limited by immune evasion within a metabolically challenging tumor microenvironment (TME). This review consolidates current knowledge on how metabolic reprogramming in immune cells influences HCC progression, therapy resistance, and clinical outcomes. We discuss the roles of glycolysis, oxidative phosphorylation, fatty acid oxidation, and amino acid metabolism kynurenine pathways—in regulating the differentiation and function of T cells, regulatory T cells, macrophages, dendritic cells, natural killer cells, and B cells. Environmental factors such as hypoxia, lactate accumulation, adenosine signaling, and lipid remodeling act as key TME cues that suppress antigen presentation, impair cytotoxic responses, and promote immunosuppressive myeloid phenotypes. Building on these mechanisms, current strategies focus on targeting metabolic checkpoints in immune cells, reshaping the TME, and integrating metabolic modulation with checkpoint inhibitors to enhance therapeutic efficacy. In addition, candidate biomarkers (including circulating metabolites, multi-omics profiles, and liquid-biopsy indicators of immune metabolism) offer opportunities for patient stratification and dynamic monitoring. Together, these insights provide a conceptual framework in which precise modulation of immune metabolism can potentiate existing immunotherapies and guide rational combination strategies, warranting further clinical investigation to achieve sustained benefit in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3e43a3cd7e997e6b0d1b868223afcfca36efc08" target='_blank'>
              Immune cell metabolic reprogramming in hepatocellular carcinoma: mechanisms, tumor microenvironment, and future immunotherapeutic directions
              </a>
            </td>
          <td>
            Lichen Zhou, Wenjie Zhang, Zhuoran Liu, Yaming Xie, Kangyi Jiang
          </td>
          <td>2026-01-12</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Macrophages play a key role in immunity against solid tumors. However, their development and clinical applications are limited by their difficult-to-transfect nature, low proliferative capacity, and easily changing polarization states. The combination of chimeric antigen receptor (CAR) technology with macrophages to form chimeric antigen receptor macrophages (CAR-Ms) is an emerging strategy for adoptive cell therapy. In our previous study, we confirmed that anti-CD47 CAR-Ms have potential for ovarian cancer treatment. Here, we demonstrated that the introduction of IL-21 significantly increases the tumor-suppressive effect of anti-CD47 CAR-Ms against ovarian cancer. Specifically, IL-21-modified CAR-Ms with second-generation CARs targeting CD47 showed potent tumor cell-killing activity, both in vitro and in vivo, through direct and indirect pathways (direct phagocytosis and activation of cytotoxic T lymphocytes). In addition, an IL-21 modification significantly enhanced the tumor microenvironmental regulation of immunosuppression mediated by anti-CD47 CAR-Ms in vivo, thereby improving their therapeutic efficacy in a mouse model of ovarian cancer, without any obvious adverse effects. Taken together, these results suggest that anti-CD47 CAR-Ms combined with IL-21 is a promising treatment strategy for ovarian cancer. The anti-tumor effects of a co-expression strategy of chimeric antigen receptor macrophages with IL-21 was validated in both in vitro and in vivo models of ovarian cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1287e633e565f0f44deb23e07481a37084e0b41a" target='_blank'>
              IL-21 promotes the anti-tumor effect of anti-CD47 chimeric antigen receptor macrophages in ovarian cancer
              </a>
            </td>
          <td>
            Yizhao Chen, Xiangling Zhu, Yu Chen, Zhaoyi Yang, Zhaolei Shen, Mengchen Chen, Chong Liu, Yuanyuan Zhou, Huihui Wang, Mengjuan Zhu, Jiaqi Qiu, Jinhua Huang, Xintong Han, Wei Wei, Ruilin Li, Wenming Hong, Jiajie Tu
          </td>
          <td>2025-12-23</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Kaposi’s sarcoma-associated herpesvirus (KSHV) infection is linked with the development of life-threatening malignancies in elderly and immunocompromised hosts, suggesting tight control of the infection by T cell responses. T cells against KSHV, however, are barely detectable in infected individuals, and the mechanisms underlying immune recognition of KSHV-infected cells remain poorly understood. Here, we present publicly available sequences of T cell receptors (TCRs) targeting the KSHV latency-associated nuclear antigen (LANA/ORF73). By using these TCRs transgenically expressed on T cells as identifiers for KSHV-specific cells, we show that despite their failure to recognize KSHV-infected B cells in vitro, activated effector memory differentiated LANA-specific CD4+ T cells accumulate in vivo at infection sites in the preclinical infection model of humanized mice. This suggests more efficient antigen-presentation in vivo than by KSHV-infected B cells in vitro and highlights the possible contribution of CD4+ T cells to the immunosurveillance of latently infected B cells. Karposi’s Sarcoma-associated herpesvirus (KSHV) infection is associated with malignancy in older infected humans. Here the authors characterise antigen presentation using a KSHV-specific CD4+ T cell-derived TCR in a mouse model and show that although KSHV-specific CD4+ T cells are difficult to detect in humans, antigen presentation is effective in vivo suggesting persistence and accumulation of these cells through antigen recognition.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8732f46ab8fbde7b2d707b2048fc5daf4cc8650f" target='_blank'>
              LANA-specific CD4+ effector T cells accumulate at the site of KSHV infection in humanized mice
              </a>
            </td>
          <td>
            Michelle Böni, Shitao Peng, Danusia Vanoaica, Kareem Haal, S. L. Nopper, L. Rieble, Sandra Schmid, Alma Delia Valencia-Camargo, A. Holler, Hans Stauss, Christian Münz
          </td>
          <td>2025-12-05</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Spectral flow cytometry is an advanced immunological tool that can enable comprehensive analysis of the immune system by simultaneously comparing innate and adaptive immune cells. Here, using a 40‐color antibody panel, we advance our knowledge of innate‐like cells by investigating chemokine receptors and maturation markers not usually assessed on these populations, examining age‐related effects on these immune cell subsets. We characterize phenotypic changes of peripheral blood mononuclear cells (PBMCs) in three age groups: newborns (cord blood), adults aged 20–30 years, and adults aged > 70 years. We compare the age‐related changes of innate cells, including ILCs, NK cells, monocytes, dendritic cells, and innate‐like T cells, comparing them with memory T cells. We also examine subsets of CD4−CD8− double‐negative (DN) T cells and CD3+CD161+ T cells, revealing they are phenotypically similar to known subsets of innate‐like T cells, and they also increase in frequency in an age‐related manner. The frequencies of ILC1 increased with age, ILC2 remained stable, whereas ILC3 peaked in young adults, and were higher than cord and older adults. Notably, we identify the NK cell maturation marker, CD57, as a universal marker that defines aging populations of both innate and adaptive immune cells. This study enhances our understanding of the ontogeny of human immune cells, highlighting significant age‐related changes in the frequency and phenotype of innate‐like populations of immune cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a4e3a012566e819d93d0e975e2dbb9ee039399a3" target='_blank'>
              The changing immune landscape of innate‐like T cells and other innate cells throughout life
              </a>
            </td>
          <td>
            Marziyeh Taheri, Christopher Menne, Jeremy Anderson, Louis Perriman, Shuo Li, Stuart P. Berzins, P. Licciardi, T. Ashhurst, Sedigheh Jalali, Daniel G Pellicci
          </td>
          <td>2025-12-10</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Nonclassical CD8+ T cells can compensate for classical CD8+ T cell effector responses during murine cytomegalovirus (MCMV) infection. Through a combination of motif-based discovery, predictive algorithms, AlphaFold3 structural modeling, and biological assays, we identified multiple MCMV and human cytomegalovirus (HCMV) peptides that bind to Qa-1 and HLA-E, respectively. In the mouse system, we demonstrated that these virally encoded antigens stimulate Qa-1–restricted CD8+ T cells ex vivo, which can be tracked using MCMV peptide–loaded Qa-1 tetramers. Adoptive transfer of predominantly Qa-1 tetramer+ CD8+ T cells into RAG-1–deficient mice protects them from mortality, underscoring the critical role of these cells in host defense. Single-cell RNA (scRNA)/TotalSeq and single-cell T cell receptor sequencing (scTCR-seq) reveal the expansion of unique TCR αβ clonotypes, indicating convergent antigen specificity. Together, our findings uncover a conserved and functionally important nonclassical CD8+ T cell axis mediated by Qa-1/HLA-E modulating adaptive immunity independent of classical major histocompatibility complex class I (MHC-I) pathways and present previously unidentified opportunities for vaccine development.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4168661414730197ec49ba65f203eaa1bbf0af20" target='_blank'>
              Unconventional CD8+ T cell surveillance of cytomegalovirus via Qa-1/HLA-E–restricted epitope recognition
              </a>
            </td>
          <td>
            Shanelle P. Reilly, Madison L. Smith, S. Borys, C. Fugère, Delia Demers, Michael J. Hogan, David Zemmour, L. Brossay
          </td>
          <td>2025-12-19</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e717b4466922c6801a12a8f82b0f2c866a33da" target='_blank'>
              PA28γ-containing tumor-derived exosomes promote T-cell dysfunction in head and neck squamous cell carcinoma
              </a>
            </td>
          <td>
            Ying Wang, Shiyu Zhang, Yang Yang, Yimei Wang, Yingxin Zhang, Ming Liu, Xin Zeng, Ning Ji, Silu Sun, Chunjie Li, Yuwei Zhao, Xikun Zhou, Qianming Chen, Jing Li
          </td>
          <td>2025-12-08</td>
          <td>Cellular & Molecular Immunology</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating but poorly-understood disease. ME/CFS symptoms include immune system effects alongside incapacitating fatigue and post-exertional disease exacerbation. Symptom severity can range from mild to severe and whilst symptoms can fluctuate, few people fully recover. Immunological profiles of people living with ME/CFS were analysed by flow cytometry, focusing on cytotoxic cells, to determine whether people with mild/moderate (n = 43) or severe ME/CFS (n = 53) expressed different immunological markers. Flow cytometry data were tested for normality and the two clinical groups were compared by t-test or Mann-Whitney U-test as appropriate. People with mild/moderate ME/CFS had increased expression of cytotoxic effector molecules alongside enhanced proportions of early-immunosenescence cells, determined by the CD28-CD57- phenotype, indicative of persistent viral infection. In contrast, people with severe ME/CFS had higher proportions of activated circulating lymphocytes, determined by CD69+ and CD38+ expression, and expressed more pro-inflammatory cytokines, including interferon-γ, tumour necrosis factor and interleukin-17, following stimulation in vitro, indicative of prolonged non-specific inflammation. These changes were consistent across different cell types including CD8+ T cells, mucosal associated invariant T cells and Natural Killer cells, indicating generalised altered cytotoxic responses across the innate and adaptive immune system. These immunological differences likely reflect different disease pathogenesis mechanisms occurring in the two clinical groups, opening up opportunities for the development of prognostic markers and stratified treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e6b2fa3ad265819948a6a86e70aa620144d602" target='_blank'>
              Abnormal T-Cell activation and cytotoxic T-Cell frequency discriminate symptom severity in myalgic encephalomyelitis/chronic fatigue syndrome
              </a>
            </td>
          <td>
            Ji-Sook Lee, E. Lacerda, Caroline C. Kingdon, Ella Abken, Giada Susannini, H. Dockrell, L. Nacul, J. Cliff
          </td>
          <td>2025-12-10</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. Capping protein inhibiting regulator of actin dynamics (CRACD) that promotes actin polymerization, is frequently inactivated in SCLC. However, the role of CRACD loss in SCLC is unknown. Here we show that CRACD depletion drives neuroendocrine (NE) cell plasticity and immune evasion in SCLC. Mechanistically, CRACD inactivation disrupts actin organization, leading to suppression of Yap1-NOTCH signaling and subsequent NE gene upregulation. Simultaneously, CRACD loss drives EZH2-mediated histone methylation via nuclear actin disruption, leading to repression of MHC-I genes and depletion of CD8⁺ T cells. Consequently, CRACD-downregulated tumors exhibit increased cellular heterogeneity and escape from immune surveillance. Conversely, pharmacological inhibition of EZH2 restores MHC-I expression, reactivates antitumor immunity, and suppresses tumor growth. These findings identify CRACD as a tumor suppressor that constrains cell plasticity and immune evasion, highlighting the CRACD–EZH2–MHC-I axis as a potential therapeutic vulnerability in SCLC. Small cell lung cancer (SCLC) is aggressive with limited therapeutic options. Here, authors find that loss of CRACD induces neuroendocrine plasticity and immune evasion and suggest manipulating the CRACD-EZH2-MHC-I axis as a potential therapeutic strategy for SCLC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bf325651813549672f4e19a7fc99e17df10da273" target='_blank'>
              Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer
              </a>
            </td>
          <td>
            Yoojeong Seo, Shengzhe Zhang, Jinho Jang, Kyung-Pil Ko, Kee-Beom Kim, Yuanjian Huang, Dong-Wook Kim, Bongjun Kim, Gengyi Zou, Jie Zhang, Sohee Jun, Wonhong Chu, Nicole A Kirk, Ye Eun Hwang, Y. Ban, Shilpa S. Dhar, J. Chan, Min Gyu Lee, C. Rudin, Kwon-Sik Park, Jae-Ll Park
          </td>
          <td>2025-12-06</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7c4f1d7c9259c917480b33109eb2eb505069fe2" target='_blank'>
              Gatekeepers of immunity: mechanisms and regulation of immune checkpoints and their role in immune-privileged sites
              </a>
            </td>
          <td>
            Reza Nejad Shahrokh Abadi, Zahra Shahrokh Nejad Abadi, Sara Hooshmand
          </td>
          <td>2025-12-18</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background Bystander activation has primarily focused on conventional antigen-specific T cells (TMEM) and other innate immune cell types. However, the role of virtual memory T cells (TVM) has been largely overlooked, despite their numerical superiority and highly cytotoxic phenotype. Bystander activation is particularly relevant in infections caused by intracellular pathogens. In this study, we aimed to compare the bystander activation potential of TVM cells versus TMEM cells during the early days following T. cruzi infection. Methodology/Principal Findings Our results demonstrate that TVM and TMEM cells, evaluated by flow cytometry, are present but do not undergo significant changes in frequency during the first four days post-infection (p.i.). In an in vitro co-culture system, TVM or TMEM cells pre-incubated with IL-12 and IL-18 (effector cells) were cultured with T. cruzi-infected enriched peritoneal macrophages (Tc-PM, target cells). Immunofluorescence assays revealed that both TVM and TMEM cells exhibit a highly efficient capacity to kill the parasite and induce degranulation, in contrast to naïve T cells (TN), which showed almost no cytotoxic activity. Furthermore, intracellular flow cytometry assays confirmed that both TVM and TMEM cells produce substantial amounts of IFNγ up to 4 days p.i. when stimulated in vitro with IL-12 and IL-18, whereas TN cells fail to produce this cytokine. Accordingly, TVM and TMEM cells exert their cytotoxic effects via IFNγ production, rather than NKG2D, which subsequently activates reactive oxygen species (ROS) and Nitric Oxide (NO) pathways in Tc-PM. Additionally, we demonstrate that in TVM cells, IFNγ signaling occurs through STAT1 in Tc-PM. Finally, analysis of human TVM cells within PBMCs, revealed increased expression of the functional marker granzymes in Chagas disease patients compared to healthy controls. Conclusions/Significance These results challenge the view that only TMEM cells dominate early infection control. The equivalency of TVM and TMEM cells in parasite clearance suggests TVM cells are valuable innate-like contributors, providing rapid protection. Their numerical prevalence in unprimed individuals indicates TVM cells may be an underestimated component of early immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49e47d58d53ce22ebb1eb8471770bd5352dc5158" target='_blank'>
              Bystander CD8+ conventional memory versus virtual memory T cells in the initial days post-Trypanosoma cruzi infection
              </a>
            </td>
          <td>
            M. E. Viano, R. E. Baigorrí, Gastón Bergero, M. Aoki, N. L. Lidon, Maria Guadalupe Teixeira, Melisa Rocío Herrera, C. Motran, F. Cerbán, C. Stempin, M. C. Rodriguez-Galán
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aaa50a1361ac8731da6f0c05b9a5e8ef8df006c1" target='_blank'>
              Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions
              </a>
            </td>
          <td>
            Sven Máté Treffert, Y. M. Heneka, Julie Martin, G. Andrieux, Larissa Launhardt, Eliana Stanganello, S. J. Sonnentag, Lisa-Marie Mehner, L. Munoz-Sagredo, Michelle Christ, Véronique Orian-Rousseau
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Significance This research uncovers an important role for galectin-9 (gal9) in dendritic cells (DCs) during the engagement and subsequent activation of CD4+ T cells, which is indispensable to initiate adaptive immunity. Gal9 expressed by DCs aids in the establishment of durable interactions with T cells by properly displaying activating signals (MHC-II molecules) at the contact site between both cells (immune synapses, IS). Without gal9, DCs fail to efficiently stimulate CD4+ T cells, diminishing subsequent immune responses, with consequences for antitumor immunity. This study reveals an immune-regulating mechanism mediated by galectins, which can aid in understanding disbalanced immune responses, such as cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2738e2c26c92c821c7322248e0ee4235008ae63d" target='_blank'>
              Galectin-9 binding to HLA-DR in dendritic cells controls immune synapse formation and T cell proliferation
              </a>
            </td>
          <td>
            Andrea Rodgers-Furones, Thijs Brands, Guusje van Gameren, Mirane Florencio-Zabaleta, Mayukha Bathini, Sandra Delgado, Zacharias Wijfjes, Kristina Fedorova, René Classens, Lona J Kroese, M. Verdoes, Guido van Mierlo, Jesús Jiménez-Barbero, Rik G. H. Lindeboom, A. Ardá, Annemiek B. van Spriel, L. Q. Cano
          </td>
          <td>2025-12-08</td>
          <td>Proceedings of the National Academy of Sciences of the United States of America</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) are recognized as a key mediator of immunosuppression in aging, which induce immunosenescence and increase elderly people’s susceptibility to infections, cancers, autoimmune diseases, and degenerative diseases. However, the commonly used MDSC markers overlap with those defining healthy and normal neutrophils or monocytes, which makes it challenging to distinguish MDSCs from their myeloid counterparts, and hampers deeper understanding of the pathophysiological functions of MDSCs. In this study, we compared MDSCs from aged mice to young controls using single-cell RNA sequencing. We established MDSC-specific gene signature, which revealed the general characteristics of MDSCs during aging, and thus facilitating distinguishing them from normal myeloid cells. Experimental study revealed that CD300c may serve as a specific marker for improved detection and enrichment of MDSCs in aging. CD11b+Gr1+CD300c+ cells demonstrated a robust ability of T cell suppression. The universality and applicability of MDSC-specific gene signature have also been demonstrated in human myeloid cells. We also found that MDSCs from aged individuals shared the similar developmental trajectory with their myeloid counterparts, and may develop from mature myeloid cells, both in mice and human beings, which has been reported by a limited number of studies. Overall, our work extends the understanding of MDSCs in aging process.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7343d247742e2514c816d82197f3a4e427bbbd1" target='_blank'>
              Defining the marker and developmental trajectory of myeloid-derived suppressor cells in aging by single-cell transcriptomics
              </a>
            </td>
          <td>
            Yaru Su, Ruimin Wu, Haochen Ai, Zhaoming Zhong, Lin Zou, Zihan Wang, Kewu Tu, Lingzheng Tang, Jiawen Gao, Yusheng Huang, Congrui Liao, Guanhai Zeng, Hongyang Zhang, Jian Jin, Siyuan Zhu
          </td>
          <td>2025-12-24</td>
          <td>NPJ Aging</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/28994b7df14a803a7e0314e91e0dbcfa85973adc" target='_blank'>
              Species-specific iNOS expression distinguishes epithelial and myeloid IFNγ responses in tuberculosis
              </a>
            </td>
          <td>
            Fabian Stei, Erin F. McCaffrey, Björn Zessin, Jonathan Pioch, S. Simm, B. Stubbe, Ralf Ewert, Frank Verreck, B. Schneider, A. Dorhoi, Bryan D. Bryson, Björn Corleis
          </td>
          <td>2026-01-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/41c90be54d0c8300380663bf0b722bf4b28986ad" target='_blank'>
              Divergent myelopoiesis and macrophage polarization underlie host susceptibility to chronic Chlamydia trachomatis infection
              </a>
            </td>
          <td>
            Naveen Challagundla, Shivani Yadav, Reena Agrawal Rajput
          </td>
          <td>2025-12-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet its unintended impact on chronic infections remains poorly understood. Here, we identify PD-L1 expression on CD14- CD16+ monocytes as a critical determinant for preventing early tuberculosis (TB) progression. By integrating real-world adverse event data, Mendelian randomization (MR), and transcriptomic analysis, we establish a causal and cell-specific link between PD-L1 downregulation and early TB progression. Analysis of the FAERS database revealed that the PD-L1 inhibitor durvalumab is significantly associated with TB-related adverse events (reporting odds ratio = 7.81; 95% CI: 4.43-13.78; P = 1.10×10-18). MR analysis confirmed that genetically elevated PD-L1 expression in CD14- CD16+ monocytes confers protection against early TB progression (OR = 0.918, P = 0.042), independent of confounding or reverse causality. Transcriptomic profiling revealed that PD-L1high CD14- CD16+ monocytes exhibit enhanced antigen surveillance, whereas PD-L1low cells display metabolic reprogramming associated with immune escape. Upstream regulatory analysis identified CDAN1, TCOF1, and LMO2 as transcriptional drivers of PD-L1, enriched in high-risk individuals. In silico drug prediction and molecular docking suggested several PD-L1-modulating compounds, including ruthenium, pomalidomide, zidovudine, and lycorine. Notably, several of these compounds (e.g., ruthenium complexes, pomalidomide, aziridine) have reported anti-mycobacterial effects, which supports the reliability of our screening results and their potential relevance to TB regulation. In vitro validation demonstrated that lycorine dose-dependently upregulates PD-L1 and inhibits Mycobacterium tuberculosis reactivation. Together, our findings define a mechanistic axis in CD14- CD16+ monocytes that underpins early TB control and is vulnerable to PD-L1 blockade. Collectively, these findings align with the established notion that assessing latent tuberculosis infection before initiating immune-modulating therapies is essential for minimizing reactivation risk, and propose tractable molecular targets for preventing TB reactivation in immunocompromised hosts.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f5006bad074eb74e5b4aa3f7c72db29845946bb" target='_blank'>
              CD14- CD16+ monocyte PD-L1 prevents early tuberculosis progression and constrains reactivation under immune checkpoint therapy
              </a>
            </td>
          <td>
            Wentao Wang, Chenyang Liu, Wenxaio Wu, Zhengjun Yi, Jie Shen
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Cellular and Infection Microbiology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf058c0c700be7dadc34d4d918e869fd3291a7b5" target='_blank'>
              The role of immune cell crosstalk and signaling pathways in the pathogenesis of pulmonary fibrosis
              </a>
            </td>
          <td>
            Xia Liu, Haixu Chen, Changying Guo, Yu Lin, Fei Wang, Zhi Lan
          </td>
          <td>2026-01-19</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="The tumor microenvironment (TME) is a key factor influencing carcinogenesis, disease progression, and therapeutic outcomes. Tumor-associated endothelial cells (TECs), integral components of the TME, form the structural and functional foundation of the vasculature, while also modulating tumor immune responses. TECs regulate immune cell activity and distribution through multiple molecular mechanisms, thereby influencing tumor immunity. Recent evidence highlights TEC-targeted interventions as a promising strategy to enhance immunotherapy efficacy. This review examines the mechanisms through which TECs drive tumorigenesis, progression, and metastasis, and explores the therapeutic potential of TEC-targeted approaches in cancer treatment. It also provides a systematic analysis of TECs’ impact on the immune microenvironment, assessing the potential of TEC-directed therapies to overcome chemoresistance and immunotherapy resistance, thus offering new perspectives for drug development targeting TECs. Finally, the review critically evaluates potential molecular targets within TECs and recent advancements in genetic research for cancer therapy, emphasizing key research priorities and pressing clinical challenges that require urgent focus.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cd5e2322afb5c6ffa7a0363f83b269479ee8db97" target='_blank'>
              Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches
              </a>
            </td>
          <td>
            Tianyu Zheng, Xinran Yu, Caihong Yu, Wangting Xu, Zhuoyang Fan, Yongjie Zhou, Changyu Li, Juncheng Wan, Chaoqiao Jin, Xuran Jin, Wen Zhang, Zhiping Yan, Peng Luo, Bufu Tang, Xudong Qu
          </td>
          <td>2025-12-24</td>
          <td>Biomarker Research</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Secreting a continuous, and sometimes life-long antibody supply, plasma cells are the effector arm of humoral immune system. With an incredibly diverse array of binding specificities, antibodies play critical roles in homeostasis and disease. Traditional views of plasma cells have them function at a distance, relying on circulation to ferry their antibodies to peripheral tissues. However, this review focuses on plasma cells that operate locally within tissues that lack ready access to circulating antibody, specifically, we explore plasma cells that accumulate within the central nervous system (CNS) and its borders. Through both antibody secretion and immunoregulation, plasma cells impact responses to neuroinvasive pathogens, CNS-targeting autoimmune diseases, and CNS tumors. In border sites, like the meninges and olfactory mucosa, plasma cells serve to protect against CNS pathogen invasion while also mediating pathology in autoimmunity and inflammatory diseases. In considering plasma cells in and around the CNS, we discuss their localization, function, migration, local differentiation, and persistence. Importantly, we examine where gaps remain in our knowledge of CNS plasma cells and how this work will impact the prevention and treatment of CNS infection and autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e373e7bcc14256d743cbf8cd121b0c49cd07bef" target='_blank'>
              Plasma cells in and around the central nervous system
              </a>
            </td>
          <td>
            Alexander K. Merder, E. Moseman, Doan C Nguyen, Nicole L Sullivan
          </td>
          <td>2026-01-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells. The advent of chimeric antigen receptor (CAR) technology has introduced innovative strategies for augmenting the antitumor potential of natural killer (NK) cells. Chimeric antigen receptor natural killer (CAR-NK) cells exert dual cytotoxic effects against tumor cells through CAR-mediated antigen-specific recognition in concert with the nonspecific cytolytic activity mediated by intrinsic NK receptors. This review critically evaluates the clinical progression of CAR-NK cells specifically against solid tumors, focusing on mechanisms to overcome the immunosuppressive tumor microenvironment (TME), the complexity of allogeneic manufacturing, and the latest engineering strategies for enhanced homing and persistence. Specifically, we emphasize the urgent need for robust Phase II/III clinical data and standardized Good Manufacturing Practice (GMP) protocols to realize the full potential of off-the-shelf allogeneic CAR-NK therapies. Additionally, we examine technological advancements and emerging directions addressing persistent challenges in this domain to offer theoretical underpinnings and research perspectives for the clinical deployment of CAR-NK cell therapy in solid tumor management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9835744d53df7d8a7ea69ea0d25f923b5c1aaa54" target='_blank'>
              Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment
              </a>
            </td>
          <td>
            Yu Xiang, Jiayi Dong, Lijuan Shao, Size Chen
          </td>
          <td>2025-12-19</td>
          <td>Experimental Biology and Medicine</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Endometrial carcinoma (EC), particularly high-risk molecular subtypes like p53abn and NSMP, is frequently characterized by a tumor immunosuppressive tumor microenvironment (TME) that drives progression, metastasis, and resistance to therapy. This immunosuppressive milieu is orchestrated by key cellular components, including M2-polarized tumor-associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), PD-L1-expressing tumor cells, and pro-fibrotic cancer-associated fibroblasts (CAFs), which collectively inhibit effector T cell function and promote immune exclusion/desert phenotypes. Natural products offer promising multi-targeted strategies to remodel the TME. This review comprehensively summarizes the potent immunomodulatory effects of the phytosterol β-sitosterol (BSS) and the flavonoid luteolin (Lut) specifically within the EC TME. We detail how BSS and Lut synergistically reprogram TAMs towards an M1 phenotype, inhibit Treg differentiation/function and MDSC expansion, enhance CD8+ T cell recruitment, activation, and cytotoxicity (e.g., by downregulating PD-1/TIM-3), and suppress CAF-mediated immunosuppression and fibrosis. Mechanistically, these effects are achieved through targeting critical signaling pathways (STAT3, NF-κB, PI3K/AKT, Wnt/β-catenin) and modulating key chemokines/cytokines (e.g., reducing TGF-β, IL-10, CXCL12; increasing CXCL9/10, IFN-γ). Critically, BSS and Lut demonstrate significant potential to overcome resistance to immune checkpoint inhibitors (ICIs), particularly in immune-cold EC subtypes. By remodeling the immunosuppressive TME, BSS/Lut combinations can enhance ICI efficacy, as evidenced by preclinical data showing increased tumor suppression rates and T cell infiltration. While challenges remain, including EC-specific validation, bioavailability optimization, and molecular subtype stratification, BSS and Lut represent promising natural adjuvants for combinatorial immunotherapy, offering novel strategies to improve outcomes for patients with aggressive or treatment-refractory EC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7104edd872a0f11fcab8f2569253c5f8ba5f95ef" target='_blank'>
              Remodeling the tumor microenvironment: regulatory effects of β-sitosterol and luteolin on the immunosuppressive milieu in endometrial carcinoma and implications for combinatorial immunotherapy
              </a>
            </td>
          <td>
            Guojie Ji, Pengbo Wang, Zhihong Kong, Xiangxiang Cao, Xiaowei Shi, Huigen Feng, Huanhuan Hu
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Alzheimer’s disease (AD) is a progressive neurodegenerative disorder defined by amyloid-β (Aβ) plaques, tau hyperphosphorylation, and neuroinflammation. Although earlier work emphasized brain-resident glia (microglia and astrocytes), recent studies highlight adaptive immune cells, particularly T and B lymphocytes, as modulators of AD pathology. This review synthesizes animal and human findings from 2022–2025 to provide updated insights into the multifaceted roles and therapeutic potential of adaptive immunity in AD. Infiltration of peripheral T and B cells into the brain parenchyma links peripheral immunity to central nervous system (CNS) pathology. Both infiltrating lymphocytes and resident glia show context-dependent dual effects, either exacerbating neurodegeneration or promoting neuroprotection. Therapeutic strategies under active investigation include modulation of CD4+ T cell differentiation, adoptive transfer of regulatory T cells, and next-generation active vaccines for AD. Overall, selective modulation of discrete immune subsets may enable adaptive-immunity-based treatments, a complex yet promising avenue for AD therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b57de078f4e9067551a7f587763ddb6ea70cdf6" target='_blank'>
              Adaptive Immunity and Alzheimer’s Disease: Dual Roles in Neurodegeneration and Neuroprotection with Therapeutic Implications
              </a>
            </td>
          <td>
            You Min Ahn, Min-Kyoo Shin
          </td>
          <td>2025-12-31</td>
          <td>Biomolecules & Therapeutics</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="This review systematically elucidates the core mechanisms and research advancements regarding the role of autophagy in immune evasion in Renal Cell Carcinoma (RCC). Accumulating evidence indicates that autophagy exhibits a typical “context-dependent” dual role in RCC pathogenesis: it may suppress tumorigenesis in early stages, while primarily promoting cell survival and immunosuppressive functions within the established tumor microenvironment (TME). Autophagy facilitates immune escape through multi-dimensional mechanisms, including the precise regulation of PD-L1 stability, degradation of MHC-I molecules and the antigenic peptide pool, remodeling of the metabolic microenvironment, induction of T cell exhaustion, and enhancement of immunosuppressive cell functions. Therapeutically, combining autophagy inhibitors with immune checkpoint inhibitors has demonstrated significant synergistic effects in preclinical studies, and several clinical trials have provided preliminary validation of its safety and efficacy. Future research should focus on integrating multi-omics technologies and advanced disease models to deeply elucidate the autophagy regulatory network, explore its crosstalk with other cell death pathways such as pyroptosis and ferroptosis, and promote the development of personalized treatment strategies based on precise stratification of autophagy activity, thereby offering new avenues to overcome immunotherapy resistance in RCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/62d35c020bb30a03e020fb746b92db2bcc0e8494" target='_blank'>
              Cancer Cell Survival Strategies: The Collusion between Autophagy and Immune Evasion in Renal Cell Carcinoma
              </a>
            </td>
          <td>
            Yingwen Du, Danyun Wang, Jiansen Chen, Jianxing Xie, Ming Chen, Canbin Lin
          </td>
          <td>2025-12-10</td>
          <td>Proceedings of Anticancer Research</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Tumor-associated neutrophils (TANs) exhibit highly functional heterogeneity across cancers. Although TANs promote inflammatory responses and contribute to tumor clearance, they frequently undergo context-dependent reprogramming within the tumor microenvironment (TME) into highly immunosuppressive phenotypes that facilitate cancer dissemination and immunotherapy resistance 1,2 . We contend that an underappreciated, upstream determinant of this divergence is the maturation stage of TANs 3,4 . The developmental stage of TANs determines the migration patterns and constrains the functional capacity, and the developmental stage also constrains the extent of TME-driven re-education, together shaping pro-or anti-tumor outcomes 3-5 . In this Perspective, we place maturation at the core of TAN biology and discuss current definitions for TAN developmental stages and the measurable markers that researchers and clinicians can use ( Figure 1 ). In addition, spatial and temporal transitions in TAN maturation stages and the factors that govern these transitions are elucidated. We explain how maturation status shapes TAN function and articulate the key differences between mouse and human TAN maturation systems to highlight the value of human immune system (HIS) mouse models. Based on this framework, functional biomarkers and signatures of TAN maturation are introduced and we show how to embed them into patient stratification and longitudinal monitoring. Finally, we outline immunotherapy strategies targeting TAN maturation, selecting interventions guided by maturation markers to reinforce treatment benefits for">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d662ed678180365badf4da6ebe8288f142877d8a" target='_blank'>
              From bone marrow to the tumor microenvironment: how neutrophil maturation shapes cancer immunity
              </a>
            </td>
          <td>
            Tao Shi, Yiran Cai, Hanbing Wang, Jia Wei
          </td>
          <td>2025-12-15</td>
          <td>Cancer Biology & Medicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="A recent publication by Qin et al. in Cell reported on the ﬁ rst-in-human application of anti-BCMA chimeric antigen receptor (CAR)- T cell therapy in patients with treatment-refractory progressive multiple sclerosis (MS) with a good tolerability and ef ﬁ cacy. 1 CAR-T cells rank among the breakthrough therapeutic approaches, transforming the ﬁ eld of cancer and autoimmune conditions including neuroimmunological disorders. B-cell maturation antigen (BCMA) and CD19 antigen are B-cell target antigens frequently used in CAR constructs for autoimmune diseases. 1,2 In addition to the B-cell depletion in the peripheral blood, CAR-T cells allow deep depletion of tissue-resident B cells e.g., in lymphoid tissues and hard-to-reach compartments such as the central nervous system (CNS), an effect that has not been observed with antibody-based B-cell depletion therapies. However, little is known about direct and indirect effects of CAR-T cells on microglia, even though CNS-resident microglial cells are involved as one of the key drivers and maintainers of the compartmentalized neuroin ﬂ ammation and neurodegeneration during MS progression. This is con ﬁ rmed by emerging evidence that smoldering neurodegenerative processes are hallmarked by chronic microglia-mediated neuroin ﬂ ammation with progressive axonal injury, resulting in disability progression independent of relapse activity (PIRA) and brain atrophy. 1 To date, none of the available therapies for MS are fully effective at preventing disease progression and PIRA. The emerging study by Qin et al. showed, for the ﬁ rst time, signi ﬁ cant functional improvement during a 9-month">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/aadbe175bb178ba56f15991ba7d572d20c6623b1" target='_blank'>
              Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk
              </a>
            </td>
          <td>
            F. Ismail, Hans-Peter Hartung, Nico Melzer
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Highlights What are the main findings? Neonatal hearts display a distinct post-infarction immune profile characterized by the accumulation of CD4+Foxp3+ T (T-reg) cells with reparative transcriptional programs. Reticulocalbin 3 (Rcn3) is selectively upregulated in neonatal T-reg cells and is required for functional recovery and suppression of fibrosis after myocardial infarction. What are the implications of the main findings? Neonatal T-reg cells actively contribute to cardiac repair by modulating endoplasmic reticulum stress responses and paracrine anti-fibrotic signaling. Targeting T-cell-specific pathways such as Rcn3 may represent a novel immunomodulatory strategy to enhance myocardial repair in the adult heart. Abstract The neonatal heart possesses a unique capacity for reparative healing after myocardial injury, unlike the adult heart. While immune cells, particularly T cells, regulate post-infarction inflammation, their role in age-dependent cardiac repair remains unclear. This study aimed to characterize the temporal activation of T cell subsets and their contribution to immune homeostasis and myocardial repair. Myocardial infarction was induced in mice of different ages, and T cell subsets (CD4+ T cells, CD8+ T cells, and CD4+Foxp3+ T [T-reg] cells) were analyzed using flow cytometry and RNA sequencing. Neonatal hearts exhibited CD4+ T cells, CD8+ T cells, and T-reg cells that gradually increased until seven days post-injury. Transcriptome analysis identified Rcn3 as a neonatal-specific, injury-responsive gene in T-reg cells, with minimal induction in adult and aged hearts, promoting a reparative microenvironment and exerting anti-fibrotic effects via the PI3K/Akt pathway. Under endoplasmic reticulum stress, Rcn3 activated unfolded protein response genes, and Rcn3-conditioned media reduced fibrosis-associated gene expression in adult cardiac fibroblasts. In a conditional knockout mouse model (Lck-cre; Rcn3fl/fl), Rcn3 deletion in T cells led to impaired cardiac function recovery and increased fibrosis post-injury. These findings suggest that neonatal T-reg cells play a crucial role in cardiac repair, with Rcn3 as a potential therapeutic target for enhancing immune-mediated cardiac repair and limiting pathological remodeling in the adult heart.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0089581412a45d753304f07125a1ffc0f79e817d" target='_blank'>
              Neonatal Regulatory T Cells Mediate Fibrosis and Contribute to Cardiac Repair
              </a>
            </td>
          <td>
            Tabito Kino, Sadia Mohsin, Yumi Chiba, Michiko Sugiyama, Tomoaki Ishigami
          </td>
          <td>2026-01-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by dysregulated megakaryopoiesis and expansion of neoplastic hematopoietic stem cells (HSCs). Megakaryocytes (MKs) not only regulate HSC function but also shape immune responses within the marrow niche. Using an aging murine model of MPN with MK-restricted JAK2V617F expression, we investigated the immunomodulatory roles of mutant MKs. Compared to wild-type MKs, aged mutant MKs exhibit enhanced antigen uptake and MHC I presentation, secretion of pro-inflammatory cytokines (PF4, TGFβ, IL-1β), and induction of T cell dysregulation in the marrow niche. In chimeric murine models with co-existing wild-type and JAK2V617F mutant hematopoietic cells, enhanced MK immune activity correlates with mutant cell expansion and MPN development. Single-cell RNA sequencing revealed that aging amplifies JAK2V617F MK-driven immune remodeling. Notably, aged mutant MKs showed marked upregulation of LINE-1 (long-interspersed element-1) retrotransposon transcripts alongside elevated innate immune sensors cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING), implicating retrotransposon activity in niche inflammation. In human MPN marrow, immunohistochemistry detected LINE-1-encoded protein ORF1p in MKs from 12 of 13 MPN patients, but not in orthopedic controls (n=5). These findings identify MKs as active immune regulators in MPNs, with JAK2V617F mutation and aging synergizing to reprogram MKs into inflammatory, immunemodulatory niche cells. LINE-1 activation emerges as a potential driver of chronic marrow inflammation and a targetable mechanism in clonal hematopoiesis and MPN progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/00078a7009ffc9e9c106b868442d3f41d8397509" target='_blank'>
              Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.
              </a>
            </td>
          <td>
            Xiaoxi Yang, Sandy Lee, Kyla Masarik, Tameena Ahmed, Lei Zheng, H. Zhan
          </td>
          <td>2026-01-22</td>
          <td>Haematologica</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Introduction Aging increases vulnerability of the elderly to influenza, but the mechanisms have not been fully understood. Although lethally infected aged mice are frequently used as models of influenza infection in the elderly, they are more suitable for studying mortality rather than the increased disease severity frequently observed in non-lethal infections. Therefore, understanding age-related differences under sublethal infection conditions is crucial. Methods Adult (8–12 months) and aged (22–24 months) mice were infected with a sublethal dose of H1N1 (PR8). Body weight loss, lung viral titers, pulmonary innate immune cell composition, and transcriptional levels of key inflammatory cytokines were assessed. Results Despite similar body weight loss, the aged mice showed significantly higher lung viral titers at day 8. Notably, key innate immune populations, including alveolar macrophages, neutrophils, and eosinophils, showed distinct age-related patterns. In the adult mice, alveolar macrophages negatively correlated with weight loss, whereas no protective immune factor was identified in the aged mice. Moreover, our data showed that persistent viral replication led to distinct innate immune cell composition in the adult and aged mice despite comparable transcription levels of inflammatory cytokines. The numbers and frequencies of both the neutrophils and eosinophils were significantly higher in the virus-persistent adult mice than those in the virus-persistent aged mice. Discussion Our findings reveal skewed acute immune responses to influenza in aged mice, which may partially account for their mild weight loss despite delayed viral clearance and highlight age-related impairments in early antiviral immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c351ed0e5d3df4fe77cb078ab0d2b65afface5c" target='_blank'>
              Skewed pulmonary innate immune cell composition underlies the delayed influenza clearance in aged mice
              </a>
            </td>
          <td>
            Xiaoyang Cheng, Fang Zhao, Jing Wu, Yanmin Wan, Zhaoqin Zhu, Jialin Jin
          </td>
          <td>2025-12-10</td>
          <td>Frontiers in Microbiology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d22e5bd8f8b4bed538f81ee5ec2c9337015039ea" target='_blank'>
              A vesicle-based platform for high-efficiency, high-viability CRISPR/Cas9 knockout in primary human myeloid cells
              </a>
            </td>
          <td>
            Silvia Fiori, Maira Russo, Alice Randon, Alessio Nicola Ferraro, Tiziana Julia Nadjeschda Schmidt, Elena Pinca, Rana Kamel Mohamed Ali Elnady, Ivan Castello Serrano, Paola Capasso, Abeer Mahfoud, G. Moschetti, E. Scarpa, Niklas A. Schmacke, Veit Hornung, Takanobu Tagawa, Guido Papa, M. Albanese
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Bispecific T-cell Engagers (BITEs) are a novel form of immunotherapy that overcome a deficiency of immune checkpoint inhibitors (ICI) by targeting a preidentified tumor associated antigen and redirecting a polyclonal population of effector T-cells against the tumor. High grade serous ovarian cancer is a lethal disease in the recurrent setting and has not been amenable to ICI therapy. MUC16/CA125 is overexpressed in high grade serous ovarian cancer. BITEs targeting the tumor-retained portion of MUC16/CA125 have recently been described and are in early-phase clinical trials. To identify mechanisms of resistance to BITEs, we collected serum, peripheral blood mononuclear cells, and ascites samples from patients with disease progression on MUC16-directed bispecific antibodies. Analysis of these samples showed downregulation of MUC16/CA125, elevated secretion of VEGF, and epithelial-to-mesenchymal transition in tumor cells. Interestingly, hypoxia was determined to be a driver of these changes. These findings were prospectively validated in ovarian cancer cell lines with CRISPR/Cas9 knockout of MUC16/CA125 and VEGF. Peripheral blood mononuclear cells from patients with disease progression were capable of effective cytolysis ex vivo, suggesting that resistance to therapy was primarily tumor driven. Restoration of MUC16/CA125 expression did not restore cytotoxicity in the presence of increased VEGF secretion. Combination treatment with a VEGF inhibitor rescued cytotoxicity in hypoxia-conditioned ovarian cancer cell lines with preserved target antigen expression. Collectively, these data outline a link between hypoxia and the development of resistance to BITEs and posits inhibition of VEGF inhibition as a potentially important therapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/50276863592076e01725c57fe1f33a7b17e06d98" target='_blank'>
              Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers
              </a>
            </td>
          <td>
            Mengyao Xu, S. Barakzai, Raj Kumar, Irva E Veillard, Eugene Kim, Amy Bregar, Eric Eisenhauer, Richard Penson, S. Bouberhan, Jennifer Filipi, T. Colella, Timothy S. Bond, Caroline Clark, Lawrence H Lin, Jinpeng Ruan, Cheng Wang, Xing-Lei Qin, K. Sarosiek, Bo R Rueda, Cesar Castro, David R. Spriggs, O. Yeku
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Beyond their traditional role as short-lived antimicrobial cells, neutrophils are increasingly recognized as key regulators of adaptive immunity and tumor progression. This AI-assisted integrative review investigated the neutrophil–T-cell axis, particularly the role of Galectin-9 (Gal-9), across adult T-cell leukemia/lymphoma (ATL), Sézary syndrome (SS), coronavirus disease 2019 (COVID-19), and psoriasis. Leveraging AI tools (GPT-5 and Adobe Acrobat AI Assistant) for literature synthesis (2000–2025) and expert validation, we aimed to identify common immunological mechanisms. Across all conditions, neutrophils displayed persistent activation, elevated Gal-9 expression, and modulated T-cell interactions. In ATL and SS, neutrophilia correlated with poor survival and TCR signaling dysregulation, suggesting Gal-9-mediated immune modulation. In COVID-19 and psoriasis, neutrophil-derived Gal-9-linked innate hyperactivation to T-cell exhaustion and IL-17-driven inflammation. These findings define a recurring neutrophil–Gal-9 regulatory module connecting innate and adaptive immune responses. This study underscores the feasibility of combining AI-driven literature synthesis with expert review to identify unifying immunological mechanisms and therapeutic targets across malignancy and inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6f09c2cd18cebd70f857746a605633d6065276e4" target='_blank'>
              Neutrophil–Galectin-9 Axis Linking Innate and Adaptive Immunity in ATL, Sézary Syndrome, COVID-19, and Psoriasis: An AI-Assisted Integrative Review
              </a>
            </td>
          <td>
            Toshio Hattori
          </td>
          <td>2025-12-31</td>
          <td>Reports - Clinical Practice and Surgical Cases</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple myeloma (MM) develops in the hypoxic bone marrow (BM) microenvironment, which alters tumor behavior and immune responses. While hypoxia is known to directly suppress immune function, its effect on immunotherapy-relevant antigen expression and the MM secretome remains underexplored. Here, we investigated how hypoxia affects BCMA expression and BCMA-targeted CAR T cell responses. MM cells were cultured under normoxia (21% O₂) or hypoxia (1% O₂). BCMA surface and total expression were analyzed. Anti-BCMA CAR T cells were co-cultured with normoxic or hypoxic MM cells to assess cytotoxicity and cytokine release. Conditioned media and small extracellular vesicles (sEVs) were isolated, quantified, and RNA-profiled. MM cells cultured in hypoxia showed reduced BCMA surface and total protein expression, resulting in reduced CAR-mediated signaling. Importantly, the hypoxic tumor secretome further reduced BCMA levels and significantly impaired CAR T cell killing and cytokine production, which was partially reversible by γ-secretase inhibition. To dissect the suppressive nature of the hypoxic secretome, we identified an increase in small extracellular vesicle (sEV) release under hypoxia. RNA profiling of sEVs revealed a hypoxia-induced RNA signature with potential immunomodulatory roles. This study shows that hypoxia diminishes BCMA expression and enhances secretion of immunosuppressive factors, including sEVs, thereby limiting the efficacy of BCMA CAR T cell therapy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32804a5eae759659f84b5610dc79fafee9f0e914" target='_blank'>
              Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
              </a>
            </td>
          <td>
            Chenggong Tu, A. Van der Vreken, Fien Meeus, Lauren van den Broecke, Jack Brons, K. De Veirman, K. Vanderkerken, E. De Bruyne, Karine Breckpot, E. Menu
          </td>
          <td>2026-01-08</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="CD38 is a transmembrane glycoprotein involved in NAD+ metabolism, calcium signaling, and immune cell activation. Its role in the inflammatory response has been studied extensively in innate immune cells; however, its contribution to the activation of memory T lymphocytes under inflammatory conditions is less understood. Additionally, recent studies have shown an age-related increase in the expression of the protein CD38 in various human and murine tissues. Moreover, CD8+ bystander T cells have been shown to contribute to inflammation during the aging process. Given the importance of its potential role in age-related pathologies, we examined the effect of CD38 on bystander activation of CD8+ memory T cells in aged mice following lipopolysaccharide challenge. CD38-deficient mice exhibited attenuated serum cytokine responses (IL-1β, IL-6, IFN-γ, and IL-10) and a distinct CD8+ T cell profile, characterized by a decrease in activated T cells. Wild-type mice displayed a significant expansion of CD69+TCM cells after LPS inoculation, an effect that was absent in CD38-deficient animals. LPS also promoted the expression of CD69 and CD38 in TEM/EFF subsets. Thus, our findings reveal a CD38-dependent mechanism underlying bystander activation of memory CD8+ T cells in aging. Highlighting the potential contribution of CD38 to age-related diseases, such as autoimmunity, and in the face of inflammatory conditions in aged people.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2543f635ae92595d3f140c2ea47a35fc4eab9dd" target='_blank'>
              CD38 promotes LPS-induced innate-like activation and proliferation of CD8+ T lymphocytes in aged mice
              </a>
            </td>
          <td>
            Wendolaine Santiago-Cruz, Enrique Espinosa, Jocelyn C Pérez-Lara, Héctor Romero‐Ramírez, Priyadharshini Devarajan, Fabio García-García, J. C. Rodríguez-Alba
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Aging</td>
          <td>0</td>
          <td>9</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025', '2026'],
    y: [7, 5],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>